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ABSTRACT
“Many will be disappointed to learn that pharmacoeconomic evaluations provide information, 
not answers. Although pharmacoeconomics broadens the perspective taken in evaluating drug 
therapies, the final drug therapy decision is still influenced by clinician preferences, patient 
desires, and the working and politics of the healthcare delivery system”. 1
Globally and in South Africa there is an increasing pressure on healthcare resources. These 
pressures have exponents both in the supply and demand arms of the economic equation and 
have set the scene for the development of a new discipline in healthcare. Pharmacoeconomics 
can be defined as “the description and analysis o f the cost o f drug therapy o f health care 
systems and society”. 2 Pharmacoeconomics assesses the ratio of the cost to the consequences 
of specific drug therapies using a technique called Cost Effective analysis which uses tools 
such as Cost Minimisation analysis, Cost Effective analysis and Cost Benefit analysis.
A retrospective pharmacoeconomic analysis is to be performed on two treatment groups in the 
treatment of Complicated Intra Abdominal Infections. The aim of this study is to determine 
whether the medication used in treatment for Group A is more cost effective than the 
medication used in treatment for Group B.
The purpose of this research was to compare the cost effectiveness, using a tool called cost 
minimisation, to determine which treatment group (A or B) is more cost effective in the 
treatment of intra-abdominal infections. Treatment group B is currently available on the 
South African market and is referred to as standard treatment when treating intra-abdominal 
infections. Treatment group A is a new product not yet registered for the treatment of intra­
abdominal infections.
The one hundred patients recruited for the Bayer clinical study in South Africa were included 
in the analysis and the data collected was used retrospectively to determine the cost using 
certain health economic parameters.
The results demonstrated no statistically significant difference in the clinical outcome between 
the two treatment groups, which therefore resulted in clinical equivalency. Treatment group A 
was the least cost efficient treatment group.
IV
The results clearly show that treatment for group A (CM ratio = R 1, 045, 222.09) was less 
cost efficient than the treatment for group B (CM ratio = R 877, 106.22) (efficiency = cost 
effectiveness). Therefore the treatment for group B was the most efficient (cost effective) 
treatment regimen to use when treating patients with intra abdominal infections.
It was clear that not all factors impacting on the cost could be included in this analysis. When 
looking at the final results the following aspects should be kept in mind:
• Treatment for group B consisted of generic drugs which are much cheaper
• Treatment for group A consisted of ethical products which were only recently 
registered and marketed and therefore more expensive.
• Two of the drugs in treatment for group B were eight hourly administered which 
could have led to an increase in resource cost (nursing personnel time and cost was 
not included in this analysis) and which could impact on patient compliance if the 
patient was not hospitalised till the end of the treatment.
• Treatment group A was a once a day consequential (IV and oral) therapy with the 
same drug and dosage. This could lead to a decrease in the nursing cost and an 
improved patient compliance after hospitalisation.
• This data was compiled during a clinical study. Therefore the conditions were 
more controlled, which does not necessarily reflect the real world.
• The original study was a randomised open label study. This could lead to more 
attentiveness of the investigators. Adverse events could have been more accurately 
documented when patients were randomised to treatment group A. The patients 
could have been switched to alternative antimicrobial therapy sooner in group A 
than in group B.
• This study was conducted at a government institution. Government patients are 
treated differently to patients in private institutions because their living conditions 
at home are not always acceptable for rehabilitation after major surgery. Therefore 
most of the patients were hospitalised until the treating investigator was ensured of 
a complete cure prior to discharge. This could lead to increased hospitalisation 
cost which would not necessarily be the case at private hospitals.
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Cost Minimisation Analysis - type of analysis that finds the least costly program among 
those shown or assumed to be of equal benefit.
Cost Effective Analysis - is an approach used for identifying, measuring and comparing the 
significant costs and consequences.
Effectiveness (of a drug) - The therapeutic outcome in a real world patient population 
(usually differs from efficacy determined in controlled clinical trials).
Efficiency - can be defined as achieving the maximal increment in health benefit (that is, 
improvements in the health status of a target population) for a fixed amount of resources.
“Per protocol patients” includes all patients randomised according to the inclusion- and 
exclusion- criteria, who were treated and have completed the study as described in the original 
protocol.
“Intention to treat patients” includes all patients randomised per inclusion and exclusion 
criteria and who received at least one dose of study medication. These patients did not 
complete the study due to an adverse event, treatment failure, death and / or lost to follow up.
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1.1 What is Pharmacoeconomics?
Pharmacoeconomics has been defined as “the description and analysis o f the cost o f drug 
therapy o f health care systems and society’'’ 2. Pharmacoeconomics assesses the ratio of 
the cost to the consequences of specific drug therapies using the four major types of 
pharmacoeconomic evaluation:
• Cost minimisation analysis (CMA) 3
• Cost effectiveness analysis (CEA)3
• Cost benefit analysis (CBA)3
• Cost utility analysis (CUA) 3 & 4
Pharmacoeconomic research identifies, measures and compares the cost (i.e. resources 
consumed) and consequences (clinical, economic and humanistic) of pharmaceutical 
products and services. In essence, pharmacoeconomic analyses are tools for examining the 
impact of alternative drug therapies and other medical interventions. 5
At its core, use of pharmacoeconomic principles to develop formulary medications is an 
attempt to quantify cost per outcome of different therapies. The basic criteria should be 
economic, clinical, and humanistic outcomes. The goal is to secure the lowest cost for the 
desired outcome. 5
Pharmacoeconomics is the benchmark for practical authoritative reviews of the application 
of health economics to disease management outcomes and optimum drug therapy. 6
The science of pharmacoeconomics evolved as a result of the scarcity principle in the 
healthcare environment. Its aim is to enable key decision-makers to allocate scarce 
productive resources that could have alternative uses. Various healthcare commodities can 
be produced and distributed in a more cost effective way for similar applications.
The objectives of pharmacoeconomic analyses are to improve health through better 
decision making and to determine relative values of alternative therapies.
1
Economic evaluations are becoming increasingly important foci in the delivery of 
healthcare and in particular in the choice of medical therapies.
Pharmacoeconomic data is thus a necessary component of drug development especially in 
diseases with a number of therapeutic alternatives. Individual products in a given class 
may differ in cost as well as therapeutic efficacy.
Pharmacoeconomics aims to promote the development and study of health economics as 
applied to rational drug therapy and disease management.6
For the aim of this research project the following parameters were used for 
pharmacoeconomic evaluations:
1. Type of therapy
2. Duration of therapy (IV and oral)
3. Duration of hospitalisation
4. Consumables
5. Concomitant medication




1.2 Complicated Intra-abdominal Infections
The term “intra-abdominal infection” is used to describe a broad range of infectious 
disease processes. The pathophysiology of most cases of intra-abdominal infections is a 
breach in the integrity of the gastrointestinal tract. This breach can occur due to natural 
courses or as a result of external forces like abdominal gunshot or stab wounds. 
Involvement of colonic type flora (gram negative bacilli and anaerobes) is especially 
common. The infection in the abdominal cavity may be monomicrobial or polymicrobial 
(with 2 -3 types of aerobic bacteria and up to 9 types of anaerobes) based on the number of
2
species at the infected site.7 Intra-abdominal infections occur in two broad forms:
♦ 8peritonitis and abscess formation.
The term “complicated” infection is defined per protocol as an infection requiring an 
initial operative therapeutic intervention followed by an antibiotic as a treatment. The 
treatment for complicated intra-abdominal infections should include antibacterial therapy, 
which is active against both aerobic gram negative bacilli and anaerobes since these are the 
prevailing organisms in complicated intra-abdominal infections.
A common standard treatment (ceftriaxone 2000mg IV, in combination with 
metronidazole 500mg IV, followed by co-amoxiclav 635mg oral) was used as a 
comparator in this study. Ceftriaxone is an effective and well tolerated broad-spectrum 
antibacterial with a long half-life, which permits once a day administration. Once daily, 
ceftriaxone has been associated with significantly reduced acquisition, preparation and 
administration costs.9 In addition, ceftriaxone has achieved considerable savings in 
hospitalisation costs in patients with serious bacterial infection who where able to receive 
all or part of the therapy on an outpatient basis.9 Metronidazole should be added to this 
treatment regimen because of ceftriaxone’s limited activity against anaerobic organisms. 
Metronidazole requires eight hourly administrations.
Moxifloxacin is a new fluoroquinolone which is currently in development and not yet 
registered for the treatment of complicated intra-abdominal sepsis. The aim of the original 
protocol was to establish the effectiveness of moxifloxacin in the treatment of complicated 
intra-abdominal sepsis.
Other treatment regimens for complicated intra-abdominal sepsis include: other third
generation cephalosporins (e.g. cefotaxime), quinolones (e.g. ciprofloxacin), second 
generation cephalosporins (e.g. cefuroxime), or an amoxicillin-clavulanate combination 
(Augmentin). These other agents should all be used in combination with metronidazole 
for anaerobic cover. Carbapenems e.g. imipenem (e.g. Tienam), piperacillin (Pipril), 
tazobactan (e.g. Tazocin) or fourth generation cephalosprins (e.g. cefepime -  with 
metronidazole) are normally reserved for cases with expected or proven resistance.
3
1.3 Original Study Protocol
The title of the original study protocol:10
A prospective, randomized, non-blind, multicenter trial assessing the safety and efficacy of 
sequential (intravenous/oral) BAY 12-8039 (moxifloxacin) 400 mg every 24 hr compared 
to intravenous ceftriaxone 2g every 24 hr and metronidazole 500 mg every 8 hr followed 
by oral amoxicillin/clavulanic acid tablets 625 mg every 8 hr for the treatment of patients 
with complicated Intra-abDominAl infections. (In short: The AIDA protocol.)
Trial Objectives of the original study protocol:10
To compare the safety and efficacy of sequential (intravenous/oral) moxifloxacin every 24 
hours with the combination of intravenous ceftriaxone every 24 hours and metronidazole 
every 8 hours followed by oral co-amoxiclav tablets every 8 hours for the treatment of 
adult patients with complicated intra-abdominal infections.
Inclusion Criteria10
Patients with the following:
• Hospitalised male or female patients >18 years of age
• Documented intra-abdominal infection by
A either Laparotomy reveals any of the following:
• Gross peritoneal inflammation with purulent exudate
• Intra-abdominal abscess
• Macroscopic gastrointestinal perforation
OR
B Percutaneous aspiration reveals purulent material from the abdominal cavity 
OR
C Suspected intra-abdominal infection and scheduled for a laparotomy or 
percutaneous aspiration by at least three of the following criteria:
Fever (Temperature >38.°C oral or rectal; >38.5°C core temperature) 
Leukocytosis (WBC > 12,000 cells/mm3)
Symptoms referable to the abdominal cavity (e.g., anorexia, nausea, vomiting 
or pain)
4
Tenderness (with or without rebound), absent or 
diminished bowel sounds, or abdominal wall rigidity
Radiological evidence (Abdominal Plain Films, CT, MRI or Ultrasound) of 
gastrointestinal perforation or localized collections of potentially infected 
material
• Written Informed Consent
The clinical picture must be compatible with an intra-abdominal infection. Patients must 
have one of the following infections requiring anti-infective therapy mid an operative 
procedure or percutaneous drainage:
Intra-abdominal abscess 
Bacterial peritonitis
Appendicitis with evidence of a perforation or abscess, duration of symptoms 
>24 hours
Acute perforations of the stomach or duodenum only if not operated on within 
24 hours of perforation
Traumatic perforation of the small bowel (excluding the duodenum) or large 
bowel only if not operated on within 12 hours of perforation 
Perforation unrelated to trauma of the small bowel (excluding duodenum) or 
large bowel
Intra-abdominal infections related to previous intra-abdominal surgery 
Intra-abdominal infections following penetrating and blunt trauma
The duration o f treatment o f the intra-abdominal infection is anticipated to be at least 
5 days.
Patients may receive prior anti-infective therapy under the following conditions:
Previous anti-infective therapy was given for < 24 hours.
Patients with a known intra-abdominal abscess may be enrolled into the study 
despite receiving empirical therapy for several days if pre-treatment (i.e., prior 
to study drug) cultures at the time of surgery or percutaneous drainage yield 
bacterial pathogens likely to be susceptible to both treatment regimens.
5
Exclusion Criteria: 10
Patients with the following:
• an indwelling peritoneal catheter
• pre-existing ascites who present with spontaneous bacterial peritonitis
• pancreatic, peripancreatic sepsis, or an intra-abdominal infection secondary to 
pancreatitis
• a perforated peptic ulcer or traumatic upper gastrointestinal tract (duodenal) 
perforation of < 24 hours duration
• a traumatic perforation of the small or large bowel of < 12 hours duration
• transmural necrosis of the intestine due to acute embolic, thrombotic, or obstructive 
occlusions
• acute cholecystitis with infection confined to the gallbladder
• early acute or suppurative (non perforated) appendicitis unless there is evidence of an 
abscess or peritoneal fluid containing leukocytes and micro organisms suggestive of 
regional contamination
• an infection that requires treatment with an anti-infective agent other than the study 
drugs. Patients requiring antibiotic irrigations of the abdominal cavity or surgical 
wound are not suitable for entry.
• require "open abdomen" techniques for management
• perinephric infections
• infections of the female genital tract (gynecological infections)
• multiple re-laparotomies planned
• Known hypersensitivity to any of the study drugs
• Pregnancy, nursing or in whom pregnancy cannot be excluded
• Receiving hemodialysis or peritoneal dialysis
• Severe, life-threatening disease with a life expectancy of less than 48 hours or their 
acute physiology score and chronic health evaluation (APACHE) scores are > 35
• Neutropenia (neutrophil count < 1000 cells/pl) due to malignancy or chemotherapy
• Receiving chronic treatment with known immunosuppressant therapy (including 
chronic treatment with > 15 mg/day of systemic prednisone or equivalent)
• HIV- seropositives with a CD4 count < 200 cells/pl or HIV-seropositives who are
6
receiving HAART (NOTE: HIV testing is not required for this study protocol)
• End stage hepatic cirrhosis (Child-Pugh C)
• Known congenital or sporadic syndromes of QTc prolongation or use of concomitant 
medications reported to increase the QTc interval (e.g. cisapride, Class IA and III anti- 
arrhythmic agents [amiodarone, sotalol, disopyramide, quinidine, and procainamide])
• Uncorrected hypokalemia
• Previous history of tendinopathy with quinolones
• Previously enrolled in this trial or use of any investigational drug within the previous 
30 days
• Known or suspected concomitant bacterial infection requiring additional systemic 
antibacterial treatment
• Pre-treatment with a systemic (i.e., oral or parenteral) antibacterial agent for > 24 
hours unless conditions, as outlined in Inclusion Criteria, can be met
1.3.1 Treatment Group A
1.3.1.1 Moxifloxacin 400 mg 11 12813
Moxifloxacin is a methoxy-fluoroquinolone. It has a broad spectrum and is bactericidal 
against gram positive and gram negative micro-organisms as well as gram positive and 
gram negative anaerobes.
The mean elimination half-life of this product is 12 hours (+ 1.3 hours) and steady state is 
achieved after at least 3 days with a 400 mg once daily (IV or oral) regimen.
Moxifloxacin is metabolised via glucuronide and sulphate conjugation and is eliminated 
primarily in the faeces. A very limited amount is excreted via the urine due to the 
glucoronide conjugate conversion.
1.3.2 Treatment Group B
1.3.2.1 Ceftriaxone 2000 mg9 & 14
Ceftriaxone is a third generation cephalosporin. It is a broad-spectrum cephalosporin and 
is bactericidal against gram positive and gram negative organisms (Gram positive 
organisms include: Streptococcus sp., Staphylococcus sp., Peptostreptococcus sp. and
7
Clostrium sp. and Gram negative organisms include: Haemophilus sp., Neisseria sp., 
Escherichia sp., Klebisella sp. and Enterobacter sp.). Anaerobes are only partially 
sensitive to ceftriaxone and it should therefore be used in combination with an anaerobe 
bactericidal agent, such as metronidazole.
The mean elimination half-life of this product is 6 to 9 hours. Bactericidal effects last up 
to 24 hours. Administration of this product is 2g once a day IV.
Ceftriaxone is primarily excreted unchanged in the urine by glomerular filtration. The 
remainder is excreted by the bile and is found unchanged in the faeces.
1.3.2.2 Metronidazole 500 mg 8 9& 13
Metronidazole is an anti-protozoal agent and is active against most infections involving 
anaerobic bacteria and certain parasitic infections (such as Bacteroides ffagilis, 
Selenomonas sp, Fusobacterium sp. Anaerobic gram negative cocci, Anaerobic gram 
positive cocci, Clostridium sp., Gram positive non-sporulating bacilli and Capnocytophaga 
sp.). It has the best bactericidal effect against anaerobic organisms of all drugs.
The mean elimination half-life of this product is 8 hours and should be administered 8 
hourly (three times daily)
Metronidazole is excreted primarily in the urine and the remainder is excreted via faeces.
1.3.2.3 Co-amoxiclav 625 m g9 & 15
This is a combination of amoxicillin 500mg and clavulanate 125mg. Amoxicillin is a 
broad-spectrum antibiotic but is inactivated by 6-lactamases produced by various micro­
organisms. Clavulanate is an irreversible inhibitor on B-lactamases.
Amoxicillin exerts a bactericidal action against gram positive and gram negative 
organisms. Clavulanate has no bactericidal action but it does protect amoxicillin from
8
degradation by inactivating the 13-lactamase enzyme produced by penicillin resistant strains 
of organisms.
The plasma half-life of amoxicillin is 1 -  1.5 hours and is widely distributed at varying 
concentrations in the body. Approximately 60% of amoxicillin is excreted unchanged via 
urine and a limited extent is metabolised to penicilloic acid, which is also excreted in the 
urine but this is not important for its antibacterial activity.
Clavulanic acid’s pharmacokinetics is similar to amoxicillin with a half-life of 1 hour and 
60% is excreted unchanged in the urine.
Co-amoxiclav 625mg tablets (five parts amoxicillin and one part clavulanic acid) should 
be administered orally eight hourly (three times per day).
1.4 Rationale
The goal of managed care is to deliver medical and pharmaceutical care cost-effectively. 
The consequence of healthcare’s spiralling costs is that a greater premium has been placed 
on employing available resources as efficiently and effectively as possible. With this in 
mind pharmacoeconomics may serve to identify the most cost-effective treatment 
alternatives in managed care.16
A retrospective pharmacoeconomic analysis is to be performed on two treatment groups in 
the treatment of complicated intra abdominal infections. The term “complicated” infection 
is defined per protocol as an infection requiring an initial operative therapeutic 
intervention followed by an antibiotic as a treatment. The treatment for complicated intra­
abdominal infections should include antibacterial therapy, which is active against both 
aerobic gram negative bacilli and anaerobes since these are the prevailing organisms in 
complicated intra-abdominal infections. Depending on the p-value derived from the 
eradication rate (clinical cure result) a decision will be made whether this will be a cost 
minimisation study or a cost effective study.
9
Due to the spectrum of ceftriaxone (no activity against anaerobes), metronidazole should 
be added to the treatment regimen. Together with this, metronidazole as well as the oral 
follow up drug, co-amoxiclav, have an eight hourly administration interval which could 
increase the resource cost and can negatively influence compliance, resulting in possible 
prolonged treatment.
Moxifloxacin, has a twenty four hour administration interval for both oral and IV 
treatment, which could reduce resource cost and the treatment period with an increase in 
compliance, resulting in a shorter hospital stay and thus reducing the number of disability 
days. In view of the fact that intra-abdominal infections are typically polymicrobial and 
are often treated empirically, the selected antibacterial agent must cover the likely 
spectrum of bacterial pathogens, moxifloxacin’s good tissue penetration, broad spectrum 
of activity and particularly its activity against both gram negative pathogens and anaerobic 
organisms suggest that it would be effective in the treatment of intra-abdominal infections.
The aim of this study is to determine whether the medication used in treatment for Group 
A is more cost effective than the medication used in treatment for Group B.
1.5 Objectives
This health-economic analysis is to quantify and compare the cost of healthcare 
infrastructure used in both treatment groups.
The following health economic parameters will be used:
1. Type of therapy
2. Duration of therapy (IV and oral)
3. Duration of hospitalisation
4. Consumables
5. Concomitant medication





Pharmacoeconomic data is a necessary component of drug development especially in 
diseases with a number of therapeutic alternatives. Individual products in a given class 
may differ in cost as well as therapeutic efficacy.
Direct costs for patients diagnosed with infectious diseases include the drug acquisition 
cost. Other direct medical costs include the duration of hospitalisation, professional fees, 
the cost of consumables, treatment of adverse events, and concomitant medication 
prescribed to treat adverse events and symptoms of the disease. The option to switch from 
intravenous therapy to oral therapy could lower the cost of care by potentially reducing 
both the length of stay in hospital and the number of disability days.
“Cost Effective Analysis” (CEA) is an approach used for identifying, measuring and 
comparing the significant costs and consequences. CEA also measures some non­
monetary terms. Traditionally, CEA has quantified all costs of providing a service or 
treatment in monetary terms, while measuring consequences as non-monetary health 
outcomes 2.
More recent research tends to combine Cost Beneficiary Analysis with Cost-Utility 
Analysis and CEA to create a hybrid economic evaluation. Such studies generally subtract 
cost savings induced by an intervention from the costs of the intervention itself to arrive at 
a net cost. Cost effectiveness should be used to imply value for money.
Cost-Minimisation Analysis is a type of analysis that finds the least costly program among 
those shown or assumed to be of equal benefit (clinically equivalent 17). This analytical 
technique is applied in situations where the outcomes associated with two (or more) 
alternative means of intervention are equivalent and the objective is thus to compare the 
total resource cost associated with using the different treatments '.
2. SUBJECTS AND METHODS
The original study commenced during February 2001 and continued till August 2002.
The following three end points were evaluated in the original study: efficacy, safety and 
pharmacoeconomics.10
11
The primary aim of the original study was to prove that a sequential therapy with 
group A, IV once daily (for 3 to 14 days) followed by oral treatment once daily to 
complete a total treatment period of 7 to 14 days, is not inferior to a sequential treatment 
with group B, IV (for 3 to 14 days) followed by oral treatment three times daily to 
complete a total treatment period of 7 to 14 >days of therapy. Efficacy is based on the 
clinical success rate 28-42 days after the start of therapy (test-of-cure visit {TOC}). 10
Efficacy Analysis10
The primary efficacy variable for the original study was the clinical response, determined 
by the treating investigator (clinician) at the test of cure visit (TOC) (day 28-42 after entry 
into the study). The primary efficacy analysis was performed on the valid-per-protocol 
population, which is defined as:
• Complicated intra-abdominal infection requiring surgery or percutaneous drainage 
for diagnosis and management
• No other systemic antibacterial agents administered concomitantly with the study 
drug except in cases of treatment failure
• Study drugs given for a minimum of 48 hours (in case of clinical failure) or > 5 days 
(in case of clinical cure)
• Documented compliance with > 80% of the study medication administered
• No protocol violations influencing the treatment efficacy
• Successful completion of an assessment at the TOC visit (days 28-42 after entry 
into the study)
Secondary efficacy parameters included:10
• Clinical and bacteriological response on day 3-5 or on the day of IV to PO switch if 
the day of switch is different than day 4 or 5
• Bacteriological and radiological response at the TOC visit (28-42 days after entry 
into the study)
• Clinical response at the TOC visit in patients with bacteriologically proven intra­
abdominal infection
12
• Mortality attributable to intra-abdominal infection at the time of the TOC visit (28- 
42 days after entry into the study)
• Clinical response at the TOC visit according to disease severity stratum
• Duration of hospitalization (total days)
• Duration of hospitalization post-operatively (days)
• Duration of intravenous therapy (days)
Safety Analysis10
As safety analysis, the treatment groups were compared with respect to the incidence of 
premature termination subdivided by primary reason for discontinuation, laboratory 
abnormalities, and treatment emerging adverse events.
The safety analysis also included tabulation of the type and frequency of all adverse 
events as well as events considered by the investigator to be at least possibly drug related. 
All laboratory data were analysed using descriptive statistics including identification of 
laboratory data outside normal ranges. Incidence tables were presented separately for all 
adverse events and for all adverse events occurring during IV therapy
Pharmacoeconomic evaluation10
The economic analysis will concentrate on the cost difference in resource use between the 
two treatments.
For those resources found to be quantitatively important in the pooled analysis of the 
differences between regimens, an estimate of the costs differences was done. In that case, 
costs will be estimated by multiplying the physical quantities of resource use observed by 
the unit cost of the resource.
Perspective of the Pharmacoeconomic Analysis1
The design of pharmacoeconomic analysis will depend on the perspective taken in the 
study. The perspective identifies the audience targeted in the study and will define the 
desired measure of benefits, effectiveness and cost to be included in the analysis. Several
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perspectives are possible; the most commonly used are those of the society, patient, 
provider, medical institution, regulatory body and the re-imburser.
Because the perspective determines the cost and benefits collected and recorded for a 
specific study, studies with different perspectives may not lead to the same conclusions. 
Investigating the most cost effective treatment from a medical aid (funder) perspective 
will involve only direct medical cost. The medical aid perspective was used for this 
pharmacoeconomic analysis.
2.1 Study Sample
The one hundred patients recruited for the Bayer study at Tygerberg Hospital with 
complicated intra-abdominal infections were included in this analysis. Three investigators 
(clinicians) participated in this prospective, randomised and non blind trial. The 
investigator (clinician) on call was responsible for patient inclusion, treatment and follow 
up.
Fifty patients were randomly assigned to treatment group A and they received 
moxifloxacin 400mg IV daily for a minimum of 2 days with an option to continue with 
moxifloxacin tablets administered daily. Total treatment period should not have exceeded 
15 days (including IV and oral treatment).
Fifty patients were randomly assigned to treatment group B and they received ceftriaxone 
200mg IV daily for a minimum of 3 days in combination with metronidazole 500mg IV 
(which could be stopped at any time by the treating investigator {clinician}) followed by 
co-amoxiclav 625mg tablets three times a day. Total treatment period should not have 
exceeded 15 days (including IV and oral treatment).
2.2 Treatment Allocation
Each patient was randomly allocated to either treatment group A or B. The treating clinical 
investigator was blinded until after randomisation when the blinded code was opened to 
reveal the treatment allocation. Once the blinded code was opened the treating clinical
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investigator was unblinded. Intravenous therapy commenced and was continued for a 
minimum of three days. See table 2.1 and table 2.2
Table 2.1 -  Treatment Group A
Trealtment Group A
Treatment: Strength: Route: Dosage
Interval:
Number of days of treatment:
moxifloxacin 400 mg IV 24 hours Minimum of 3 days and a 
maximum of 15 days.
moxifloxacin 400 mg Oral 24 hours Minimum of 2 days and a 
maximum of 12 days.
Table 2.2 -  Treatment Group B
Treatment Group B
Treatment: Strength: Route: Dosage
Interval:
Number of days of treatment:
ceftriaxone 2 000 mg IV 24 hours Minimum of 3 days and a 
maximum of 15 days.
metronidazole 500 mg IV 8 hours Optional and to be discontinued at 
the treating physician’s discretion.
co-amoxiclav * 625 mg Oral 8 hours Minimum of 2 days and a 
maximum of 12 days.
* 500mg amoxicillin, 125 mg clavulanate
At any time after the minimum of three days and at the discretion of the treating clinical 
investigator, the patient could be switched to oral therapy if gastro-intestinal function had 
returned. According to the study protocol (section 1.3 page 4), therapy (IV and/or IV + 
oral) should have been continued for a minimum of five days. Thereafter, the decision to 
end therapy was at the discretion of the treating clinical investigator i.e. when a patient 
was judged to be clinically cured (vital signs returned to normal).
2.3 Study Population
After the clinical study was completed, patients were categorized as per definition for 
the “per protocol patients” and the “intention to treat patients” within group A and 
group B.
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“Per protocol patients” includes all patients randomised according to the inclusion- 
and exclusion- criteria, who were treated and have completed the study as described in 
the original protocol.
“Intention to treat patients” includes all patients randomised per inclusion and 
exclusion criteria and who received at least one dose of study medication. These 
patients did not complete the study due to an adverse event, treatment failure, and death 
or lost to follow up.
For this study the intention to treat population will be used as the primary input. It will 
be supported by the per protocol population.
2.4 Pharmacoeconomics
Pharmacoeconomics is a sub division of health economics, which is based on principles 
of economics. Pharmacoeconomics mainly deals with unlimited demands of people and 
with limited ability to respond to these demands with production of drugs and services. 
It actually analysis the various treatments (alternatives) and thus highlights their pros 
and cons. The comparative account of different treatments is essential to optimise the 
patient comfort and healthcare.4
The earliest definitions of pharmacoeconomics were very narrowly focused on the 
analysis of costs of the drug therapy to healthcare systems and society. But recently a 
much broader view of pharmacoeconomics involved assessing the implications of 
projected outcomes and costs of pharmaceutical products for decision making.4
The expanded definition has the advantage of incorporating the pharmacoeconomical 
research into the process of drug development for pre-clinical studies to phase IV 
clinical studies including post marketing surveillance. Pharmacoeconomics is a tool of 
management, which should be applied to strategies and operational decisions about 
pharmaceutical development, production and consumption.4
The aim of pharmacoeconomics is to ensure the most efficient use of limited resources. 
On the whole, pharmacoeconomics should be thought of as a dynamic ongoing process,
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which communicates between research and development and marketing departments of 
the pharmaceutical industry. However, with its continued interventions, it helps in the 
metamorphosis of the structure of the industry towards and efficient use with 
sustenance.4
The ultimate aim of pharmacoeconomic evaluation is to provide a menu of choice for 
decision-making regarding the allocation of resources between different programs. To 
this end, at least two alternatives (not only the funder’s perspective) need to be 
considered at the time.4
There are four major types of pharmacoeconomic evaluation:
• Cost minimisation analysis (CMA)3
• Cost effectiveness analysis (CEA)3
• Cost benefit analysis (CBA)3
• Cost utility analysis (CUA)3 & 4
The ultimate objective of all four types of evaluation it to compare the cost and outcome 
of the alternative regimens ideally by generating a single index or cost outcome ratio.4
Pharmacoeconomics is a growing discipline, which has relevance to industrial practice 
as well. It addresses problems in healthcare which are very difficult to assess prima- 
facie and also clarifies situations which are complex by nature and thus helps in decision 
making.4
The role of pharmacoeconomics includes assessing the implications of projected 
outcomes and products to decide whether to continue or stop drug development; it also 
helps in global pricing strategy.4
Pharmaceutical companies market products in complex and diverse markets where cost 
containment is an important goal for drug purchasers. These buyers are demanding new 
types of information from companies on product performance and cost before the 
product will be added to formularies or approved for payment. Canada is considering a
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policy and Australia has enacted legislation that requires incorporation of economic 
evaluation into the regulatory process for determining drug coverage and payment.
Most European countries use economic data to help determine coverage and payment for 
new agents. In the USA, policy makers and health care purchasers are using economic 
data to develop institutional drug formularies and treatment guidelines.
Up to date, little has been written on the practical aspects of design, implementation and 
monitoring of a clinical trial that includes a pharmacoeconomic component. Many of 
these activities could be part of a model of good pharmacoeconomics practice for 
clinical studies, which would parallel current good clinical practice standards for clinical 
data collection.
Cost in Health Economics
Cost in health economics refers to the resources consumed during the provision of health 
care. 18
There are generally three types of cost:
• Direct cost3 & 18
• Indirect cost3 & 18
■ Q
• Intangible cost
Direct cost refers to those resources whose consumption is wholly attributable to the use 
of the health care intervention in question. Direct costs include resources such as
"2 Pr 1 O
physical goods, labour and time.
Indirect cost is used differently in different disciplines; however, in pharmacoeconomics 
and outcomes research it generally refers to lost productivity (paid or unpaid) resulting 
from morbidity or mortality. Both direct and indirect costs are typically presented in
3 &  18monetary terms.
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Intangible cost refers to the pain and suffering imposed by disease and its treatment and
1 8is typically more difficult to quantify in monetary terms.
The objectives of pharmacoeconomic analysis are to improve health through better 
decision making and to determine relative values of alternative therapies. 
Pharmacoeconomics is, therefore, the benchmark for practical authoritative reviews of 
the application of health economics to disease management and optimal drug therapy.
For the aim of this research project the following parameters were used for health 
economic evaluations:
1. Type of therapy - study medication the patient was randomised to - name, dose and 
duration of treatment
2. Duration of therapy -  number of days the patient was treated with IV and oral 
study medication
3. Duration of hospitalisation -  type of ward and length of stay in each ward
4. Consumables -  therapeutic adjuncts (oxygen mask, urinary catheter, nasogastric 
tubes, packed red cells, frozen plasma, central venous catheter, chest tubes etc.), 
alcohol swabs, IV lines, needles, syringes etc.
5. Concomitant medications - name, dose and duration of treatment, for treatment of 
chronic diseases, current disease and adverse events during the study period
6. Alternative antimicrobial treatment -  name, dose and duration of treatment used to 
treat any persistent or recurrent intra-abdominal infection or extra abdominal or 
non-abdominal infection during the study period.
7. Professional fees - initial visit, in hospital visits, follow up visits to the surgeon
8. Adverse events
9. Outcome -  Clinical Cure or Clinical Failure
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3. ANALYSIS
Cost Minimisation Ratio (i.e. cost per successfully treated patient)
Incremental Cost Minimisation Ratio (i.e. the amount representing the cost associated with 
each additional successful treatment, when a switch to moxifloxacin is made)
p-value (i.e. the statistical difference (comparison) between the eradication rates associated 
between group A and group B respectively.)
The above three are the pharmacoeconomic and statistical parameters that will be used and 
be described in this section.
3.1 Demographic Data
In total 100 patients were randomised in the original study protocol. Treatment group A and 
group B consisted of 50 patients each in the intention to treat population group. Treatment 
group A had 42 patients in the per protocol population and treatment group B had 43 patients 
in the per protocol population (Table 3.2).
Table 3.1 - Age
Age
Mean ± SD Median
Group A Group B Group A Group B
Per Protocol 38.1 ± 14.1 35.8 ± 13.1 36 34
Intention To Treat 38.4 ± 15.4 37.1 ± 13.9 37 34
See Appendix C 4.1 & 4.2 
See Appendix D 4.1 & 4.2
Table 3.2 - Gender
Gender





Per Protocol 32 (76%) 10 (24%) 42 (100%) 33 (77%) 10(23%) 43 (100%)
Intention To 
Treat
37 (74%) 13 (26%) 50(100%) 39 (78%) 11 (22%) 50(100%)
See Appendix C 4.1 & 4.2 
See Appendix D 4.1 & 4.2
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3.2 Nature of Surgery
Table 3.3 -  Nature of Surgery
Nature of Surgery Group A Group B Group A Group B
Per Protncol Intention to Treat
Appendectomy 17 41% 16 36% 18 i 36% 19 i 37%
Cholecystectomy 1 2% 2 5% 1 i 2% 2 ; 4%
Laparatomy 20 48% 23 52% 25 i 50% 26 i 51%
Sigmoidectomy 1 2% 2 5% 1 : 2% 2 1 4%
Incision and Drainage 0 0% 0 0% 0 i 0% 0 ; o%
Exploratory Laparoscopy 3 7% 1 2% 5 ; io% 2 ! 4%
Other 0 0% 0 0% 0 i 0% 0 i 0%
TOTAL 42 N=
eNOO 44* 100% 50 i 100% 51* i 100%
*One patient in group B had two types o f  surgeries.
See Appendix C 4.1 & 4.2 
See Appendix D 4.1 & 4.2
3.3 Outcomes
Table 3.4 -  Outcomes
Group A Group B




Patients 39 (93% ) 3 (7%) 4 2 (1 0 0 % ) 42  (98% ) 1 (2%) 43 (100% )
Intention To 
Treat Patients 44  (88% ) 6 (12% ) 50 (100% ) 43 (86% ) 7* (14% ) 50 (100% )
* One death in group B
See Appendix C 7.1 & 7.2 
See Appendix D 7.1 & 7.2
3.4 Adverse Events
Table 3.5 -  Adverse Events
GROUP A GROUP B
Per Protocol Patients 13 (31% ) 14 (33% )
Intention To Treat Patients 29  (58% ) 22 (44% )
See Appendix C 1.1 & 1.2 





3.5 Cost Summary and Cost Minimisation Ratio
To calculate the cost of each parameter the cost was applied as per May 2002 
(MIMS, May 2002 n ), private hospital rates and professional medical aid rates.
The results of this cost comparing study are summarised in table 3.6 and table 3.7.
Table 3.6 -  Cost summary -  intention to treat population
INTENTION TO TREAT POPULATION
GROUP A GROUP B
1. Clinical Cure 88% (44) 1. Clinical Cure 86% (43)
= 0.766
Number of Patients 50 2. Number of Patients 50
3. Days of Hospitalisation 482 Days of Hospitalisation 474
Days of Out Patient Care Days of Out Patient Care
5. Days of IV Treatment 246 Days of IV Treatment 249
6. Days of Oral Treatment 72 Days of Oral Treatment 46
7. Study Medication 7. Study Medication
7.1 IV -  moxifloxacin R 56,334.00 7.1 IV -  ceftriaxone R 79,597.19
7.2 Not applicable R0.00 7.2 IV -  metronidazole R 19,420.13
7.3 Oral -  moxifloxacin R 2,260.01 7.3 Oral R 1,565.71
8. Hospitalisation Costs (Including Treatment) 8.
Hospitalisation Costs 
(Including Treatment)
t.l Concomitant Medication R 62,321.00 8.1 Concomitant Medication R 42,363.55
Other Antimicrobials R 85,689.86 8.2 Other Antimicrobials R 57,034.35
8.3 Consumables R 36,535.65 8.3 Consumables R 19,488.78
8.4 Professional Fee R 155,061.20 8.4 Professional Fee R 125,338.80
Accommodation
Pooled Rate: 0.87 (the eradication rate which is estimated to be common to group A and 
group B)
See Appendix C: Intention to Treat Population group A and group B 
See Appendix D: Per Protocol Population group A and group B
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Table 3.7 -  Cost Summary -  per protocol population
PER PROTOCOL POPULATION
GROUP A GROUP B
1. Clinical Cure 93% (39) Clinical Cure 98% (42)
2. Number of Patients 42 2. Number of Patients 43
3. Days of Hospitalisation 431 3. Days of Hospitalisation 390
4. Days of Out Patient Care 0 4. Days of Out Patient Care 0
5. Days of IV Treatment 202 5. Days of IV Treatment 217
6. Days of Oral Treatment 63 6. Days of Oral Treatment 45
7. Study Medication 7. Study Medication
S7.1 IV -  moxifloxacin R 46,258.00 7.1 IV -  ceftriaxone R 69,367.83
17.2 Not applicable R 0.00 7.2 IV -  metronidazole R 16,399.22
H 3 Oral -  moxifloxacin R 1,985.14 7.3 Oral R 1,510.19
8. Hospitalisation Costs (Including Treatment) 8.
Hospitalisation Costs 
(Including Treatment)
8.1 Concomitant Medication R 24,716.00 8.1 Concomitant Medication R 13,157.51
8.2 Other Antimicrobials R 27,623.62 8.2 Other Antimicrobials R 12,709.70
js.3 Consumables R 24,296.15 8.3 Consumables R 15,133.93
Professional Fee R 122,675.00 8.4 Professional Fee R 104,098.50
1.5 Accommodation 8.5 Accommodation
■8.5.1 ICU R 48,286.40 8.5.1 ICU R 24,143.20
18.5.2 General Ward R 293,200.00 8.5.2 General Ward R 280,006.00
IrOTA L COST R 589,040.31 TOTAL COST R 536,526.08
■ (R A T IO R 618 609.34
Pooled Rate: 0.9529 (the eradication rate which is estimated to be common to group A and 
group B)
See Appendix C: Intention to Treat Population group A and group B 
See Appendix D: Per Protocol Population group A and group B
4. DISCUSSION 
4.1 General
For the purpose of this study the “Intention to Treat” population will be the one focussed 
on. Reference will be made to the “Per Protocol” population to support the data.
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“Intention to treat patients” includes all patients randomised per inclusion and exclusion criteria and 
who received at least one dose o f study medication. These patients did not complete the study due to an 
adverse event, treatment failure, and death or lost to follow up.
“Per protocol patients” includes all patients randomised according to the inclusion- and exclusion- 
criteria, who were treated and have completed the study as described in the original protocol.
Both statistical non significance and clinical equivalence were demonstrated in the two 
treatment groups regarding the clinical cure rate. For a cost effective analysis a statistical 
significant difference should be observed in the clinical outcomes. No significant 
differences were observed in the recovery rate and therefore the technique of cost 
minimisation will be used to interpret the data instead of cost effectiveness. Cost- 
Minimisation Analysis is a type of analysis that finds the least costly program among those 
shown or assumed to be of equal benefit (clinically equivalent). This analytical 
technique is applied in situations where the outcomes associated with two (or more) 
alternative means of intervention are equivalent and the objective is thus to compare the 
total resource cost associated with using the different treatments.1
For the purpose of this study the funder’s perspective was chosen. The approach of the 
funders, in this case the medical aid schemes, is based on economic principles without 
violating the viability and successful treatment of the patient. With the outcomes of this 
pharmacoeconomic study in hand, flinders may be persuaded to list a new drug in the 
treatment of intra-abdominal infections on the formulary of the medical aid scheme.
4.2 Intention to Treat Population (ITT)
4.2.1 Treatment Group A
4.2.1.1 Demographic Data -  Age and Gender (Table 3.1 and 3.2)
The study population consisted of a single diagnostic group of intra-abdominal infection 
patients in a relatively narrow age group (38.4 years with a standard deviation of 15.4). 
Treatment group A was represented by 37 males and 13 females. Male patients formed the 
majority of the patient population mainly due to the nature of their illness or injury. Many 
male patients were included in the study with either abdominal gunshot or stab wounds.
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The female patients’ intra-abdominal infections were mainly due to natural courses. 
Therefore, this population group (female) was older and had more severe cases.
4.2.1.2 Parameters per Health Economic Evaluation
4.2.1.2.1 Nature of Surgery
Patients in this group all had one type of surgery performed during their hospitalisation. 
The main surgeries performed were laparotomies (25) followed by appendectomies (18) 
and exploratory laparoscopies (5). One cholecystectomy and one sigmoidectomy were 
performed in this group of patients (table 3.3). No incision and drainage or other 
procedures were performed.
Fifty patients were randomised to treatment group A. This resulted in a cost of 
R56, 334.00 for IV medication treatment and R 2, 260.01 for oral medication treatment 
(table 3.6).
4.2.1.2.2 Duration of Therapy
In total 246 days of IV treatment and 72 days of oral treatment were administered to 
patients in treatment group A (table 3.6)
4.2.1.2.3 Duration of Hospitalisation
In total 482 days of hospitalisation was recorded for all 50 patients in treatment group A 
(table 3.6)
Per patient this can be expressed as 9.64 days hospitalisation at R 19, 149.80 per patient 
(per 1000 patients 9640 days at a cost of R 19,149, 800.00).
4.2.1.2.4 Consumables
A total amount of R 36, 535.65 was recorded to have been spent on consumables to treat 
patients in treatment group A (table 3.6)
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4.2.1.2.5 Concomitant Medication
A total amount of R 62, 321.00 was recorded to have been spent on concomitant 
medication to treat patients in treatment group A’s chronic diseases, current disease (intra­
abdominal infection) and adverse events (table 3.6).
4.2.1.2.6 Alternative Antimicrobial Therapy
In some cases it was necessary to either administer alternative antimicrobial therapy to the 
patients either prior to surgery or during surgery prior to the establishment of eligibility to 
the study and the signing of consent. Some patients received alternative antimicrobials 
because of treatment failure to study medication or relapse. This resulted in a total cost of 
R 85, 689.86 (table 3.6).
4.2.1.2.7 Professional Fee
The professional fee was established by using the medical aid rates for a surgeon seeing a 
patient for an initial visit, in hospital visits (one per day) and a follow-up visit. In total 
this amounted up to R 155, 061.20 (table 3.6)
4.2.1.2.8 Adverse Events
The adverse events documented were 29 for patients in group A (table 3.5 and 
appendix C 1.1).
4.2.1.2.9 Outcome
Clinical cure was documented for 44 out of the 50 patients in this group (88%) (table 3.6). 
Seeing that no hypothesis is tested, no p value is applicable.
4.2.1.3 Total Cost and Cost Minimisation Ratio
The total cost for patients in treatment group A was R 909, 343.22 with a CM ratio of 
R 1, 045, 222.09. This represents the average cost per successfully treated patient, where 
“success” is defined as clinical eradication.
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4.3 Intention to Treat Population (ITT)
4.3.1 Treatment Group B
4.3.1.1 Demographic Data -  Age and Gender (Table 3.1 and 3.2)
The study population consisted of a single diagnostic group of intra-abdominal infection 
patients in a relatively narrow age group (37.1 years with a standard deviation of 13.9). 
(table 3.1). Treatment group B was represented by 39 males and 11 females (table 3.2). 
Male patients formed the majority of the patient population mainly due to the nature of 
their illness or injury. Many male patients were included with either abdominal gunshot or 
stab wounds. The female patients’ intra-abdominal infections were mainly due to natural 
courses. Therefore this population group (female) was older and had more severe cases.
4.3.1.2 Parameters per Health Economic Evaluation
4.3.1.2.1 Nature of Surgery
One patient in treatment group B had two procedures, appendectomy and laparotomy. 
This was due to the nature of the injury as well as to natural courses identified by the 
treating investigator.
The main surgeries performed were laparotomies (26) followed by appendectomies (19). 
Two of each the following procedures were performed, exploratory laparoscopies, 
cholecystectomy and sigmoidectomy (table 3.3). No incision and drainage or other 
procedures were performed.
Fifty patients were randomised to treatment group B. This resulted in a cost of 
R 99, 017.32 for IV medication treatment and R 1, 565.71 for oral medication treatment 
(table 3.6).
4.3.1.2.2 Duration of Therapy
In total 249 days of IV treatment and 46 days of oral treatment were administered to 
patients in treatment group B (table 3.6)
4.3.1.2.3 Duration of Hospitalisation
In total 474 days of hospitalisation was recorded for all 50 patients in this treatment group 
(table 3.6).
27
Per patient this can be expressed as 9.48 days hospitalisation at R 13, 249.99 per patient 
(per 1000 patients 9480 days at a cost of R 13, 249, 990,00).
4.3.1.2.4 Consumables
A total amount of R 19, 488.78 was recorded to have been spent on consumables to treat 
patients in this treatment group (table 3.6)
4.3.1.2.5 Concomitant Medication
A total amount of R 42, 363.55 was recorded to have been spent on concomitant 
medication to treat patients in treatment group B’s chronic diseases, current disease and 
adverse events (table 3.6).
4.3.1.2.6 Alternative Antimicrobial Therapy
In some cases it was necessary to either administer alternative antimicrobial therapy to the 
patients either prior to surgery or during surgery prior to the establishment of eligibility to 
the study and the signing of consent. Some patients received alternative antimicrobials 
because of treatment failure to study medication or relapse. This resulted in a total cost of 
R 57, 034.35 (table 3.6).
4.3.1.2.7 Professional Fee
The professional fee was established by using the medical aid rates for a surgeon seeing a 
patient for an initial visit, in hospital visits (one per day) and a follow up visit. In total 
this was R 125, 338.80 (table 3.6)
4.3.1.2.8 Adverse Events
The adverse events documented were 22 for patients in group B (table 3.5 and 
appendix C 1.2).
4.3.1.2.9 Outcome
Clinical cure was documented for 43 out of the 50 patients in this group (86%) (table 3.6). 
Seeing that no hypothesis is tested, no p value is applicable.
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4.3.1.3 Total Cost and Cost Minimisation Ratio
The total cost for patients in treatment group B was R 763, 082.41 with a CM ratio of 
R 877, 106.22 (table 3.6). This represents the average cost per successfully treated 
patient, where “success” is defined as clinical eradication.
4.4 Per Protocol Population (PPP)
4.4.1 Treatment Group A
Forty two patients were allocated per definition to this group. An eradication rate of 93% 
was calculated and these patients were hospitalised for 431 days in total. The total cost 
was R 589, 040.31.
4.4.2 Treatment Group B
Forty three patients were classified per definition to this group. An eradication rate of 
98 % was calculated and these patients were hospitalised for 390 days. The total cost was 
R 536, 52.08.
4.5 Cost Minimisation Ratio
A pooled eradication rate was used to determine the ratio of Cost Minimisation. This was 
calculated as the weighted average of the respective eradication rates. In this trial the ITT 
population consisted of 50 patients in both treatment groups. The PP populations 
consisted of 42 patients in group A and 43 in group B. The weighted average therefore 
equals the arithmetic mean, 87% (pooled rate = 0.87).
The following formula was used to determine the CM ratio:
CM = Total Costs /  Outcome (eradication rate %)
See Table 3.6 and 3.7
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4.6 Incremental Cost Minimisation Ratio
Cost and effects must be reported as increments (these are differences between two 
alternatives) and as totals.
The CM ratio should not be used as a single figure because this can be misleading.
To prove this result the Incremental CM Ratio was also calculated.
The Incremental CM Ratio was calculated as follows:
ITT Cost Group A -  ITT Cost Group B 
ITT eradication rate Group A -  ITT eradication rate Group B
R 909, 343.22-R  763, 082.41
0.88-0.86
R7, 313, 040.00
This amount represents the cost associated with each additional successful treatment when a 
switch to moxifloxacin is made.
4.7 Statistical values
The Chi2 (X2) score with one degree of freedom was calculated and equals 0.088 with a
p value of 0.766 in the ITT population (PP population Chi2 (X2) = 1.911 and p = 0.294).
Both these values are not statistically significant and therefore equivalence in clinical 
outcomes is present in both treatment groups.




The objective of the study was to perform a health-economic analysis to quantify and 
compare the cost of healthcare infrastructure used in treatment group A and group B. 
According to the definition of a Cost Minimisation Analysis it is:
a “ type o f analysis that finds the least costly program among those shown 
or assumed to he o f equal benefit”.
The challenge in utilising pharmacoeconomic data is in the interpretation of the study 
results. 16
From the results in tables 3.6 it clearly shows that treatment for group A 
(CM ratio = R 1, 045, 222.09) was less cost efficient than the treatment for group B 
(CM ratio = R 877, 106.22) (efficiency = cost effectiveness). Therefore, the treatment for 
group B was the most efficient (cost effective) treatment regimen to use when treating 
patients with intra abdominal infections.
Although, not all factors impacting on the cost could be included in this analysis, results 
demonstrated no statistically difference in the clinical outcome in the two treatment 
groups.
The following aspects should be taken into account when examining the results of this 
study:
• Treatment for group B consisted of generic drugs which are much cheaper
• Treatment for group A consisted of ethical products which were only recently 
registered and marketed and were therefore more expensive.
• Two of the drugs in treatment for group B were eight hourly administered which 
could have led to an increase in resource cost (nursing personnel time and nursing 
personnel cost was not included in this analysis due to the original aims of the trial) 
and which could impact on patient compliance if the patient was not hospitalised 
till the end of the treatment.
• Treatment group A was a once a day consequential (IV and oral) therapy with the 
same drug and dosage. This could lead to a decrease in the nursing cost and an 
improved patient compliance after hospitalisation.
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• This data was compiled during a clinical study. Therefore the conditions were 
more controlled, which does not necessarily reflect the real world.
• The original study was a randomised open label study. This could lead to more 
attentiveness of the investigators. Adverse events could have been more accurately 
documented when patients were randomised to treatment group A. The patients 
could have been switched to alternative antimicrobial therapy sooner in treatment 
group A than B.
• This study was conducted at a government institution. Patients in government 
institutions are treated differently to patients in private institutions because their 
living conditions at home are not always favourable for rehabilitation after major 
surgery. Therefore most of the patients were hospitalised until the treating 
investigator was ensured of a complete cure prior to discharge. This will not 
necessarily be the case at private hospitals and in turn could have led to increased 
hospitalisation cost.
Treatment Group A is a new fluoroquinolone antibiotic registered in South Africa and was 
recently investigated in the treatment of intra-abdominal infections at Tygerberg Hospital. 
Due to the once a day administration and IV / oral treatments available on the South African 
market this makes it a very convenient treatment to the nursing personnel and could improve 
patient compliance when the patient is discharged from hospital. The sequential follow up 
treatment available in oral treatment could lead to a quicker switch to oral treatment and 
therefore to a sooner discharge from hospital for patients in the private hospital environment. 
Therefore, this could lead to a decrease in hospitalisation cost and could therefore be an option 
to the funder to reimburse the use of treatment group A in private hospitals.
This outcome is only applicable to the perspective of the medical aid (funder) which was 
chosen for this pharmacoeconomic analysis. If a different perspective were chosen i.e. the 
hospital perspective, a completely different outcome could be expected. This statement leads 
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Original Ethics Committee Approval by the 
University of Stellenbosch 
(Pharmaceutical Trial Advisory Committee)
DEPT. SURGERY PHONE NO. : +27 21 9337999 FeJb. 02 2001 0 1 :05PM P02jrROM :
UNIVERSITEIT VAN STEL1 JiN B O S C li 
UNIVERSITY OF STELLENBOSCH
22 January 2001 . , . . . . .
Prof b l  Warren 
Department of Surgery
Dear Prof Warren
RESEARCH PROJECT : "A PROSPECTIVE, RANDOMIZED, NON-BLIND, MULTICENTRE
TRIAL ASSESSING THE SAFETY AND EFFICACY OP  
SEQUENTIAL (INTRAVENOU5/ORAL) SAY 12-8039 
(MOXIFLOXACIN) 400 m g EVERY Mbr COMPARED TO  
INTRAVENOUS CEFTRIAXONE 2  g  EVERY 24hr AND 
METRONIDAZOLE 500 mg EVERY 8hr FOLLOWED BY ORAL 
AMOXICILLIN/CLAVULANIC ACID  TABLETS 025 m g EVERY Star 
FOR THE TREATMENT OF PATIENTS WITH COMPLICATED 
INTRA-ABDOMINAL INFECTIONS"
PROTOCOL NUMBER : BAY 12-0039
PROJECT NUMBER 2001/M 006
At a meeting o f the Pharmaceutical Trial Advisory Committee that was held on 13 November 2000 the 
above project was approved on condition that ftartbar information that was required, be submitted.
This information was supplied and the project was finally approved on 22 January 2001. Please quote the 
abovementioned project number in all ftiture correspondence.
The following documents were reviewed and approved by the Committee:
Protocol: BAY 12-8039; Im pact no. 10209; 08.09:00/Version 4 ; Controlled copy 007.
Investigator's Brochure: BAY 12-8039; Version 6; 31/12/99; International amendment 1; 18/04/00; 
International amendment 2; 09/06/2000.
Information Sheet for Patients and Informed Consent Form: P ro f BL W arren; Version 4 .0; 16 Janaury
2001.
"lnligtingablad vir PaslSme" and "Ingeligte Toeateinmingsvorm": "Prof BL Warren; Weergawe 2.0;
16 January 2001".
The study has been accepted as complying to the Ethics Standards for Clinical Research with a new 
medicine in patients, based on PDA, TCH, GCP and Declaration o f Helsinki guidelines.
A list o f  the members constituting the Pharmaceutical Trial Advisory Committee is attached.
Yours faithfully
CJ VAN TONDER
for MANAGER; RESEARCH DEVELOPMENT
UntverslteiTsknntoor University Office, Tygerbergkam pus -  "TVgerberg Campus
M  19003, T900 Tygoi-borg
(oar) a m  « mw. r«*. (oat) 091 7810, fiulAAMka/South Africa
Wits Health Consortium Ethics Committee Approval
University 
of the Witwatersrand, 
Johannesburg
Committee for Research on Human Subjects (Medical): Clinical Trials
F W A  Registered No IRB 00001233
SECRETARIAT: Suite 189, Private Bag x2600, Houghton 2041, South Africa • Tel: +27-11-717-2800 • Fax: +27-11-717-2833








Fax: 011 921 5075
Dear Miss Schmitt,
P R O TO CO L: B A Y  10209 - A  R E TR O S P E C TIV E  P H AR M ACO EN O M IC  A N A LY S IS  CO M P AR IN G  TH E  C O S T  
EFFEC TIV EN ESS O F  TW O  T R E A T M E N T S  G R O U P  IN P A TIE N TS  W ITH  C O M P L IC A TE D  IN TR A -A B D O M IN A L 
INFECTIONS.
ETHICS R E FE R E N C E  N O: 020903
1. This is to certify that the above-mentioned trial was reviewed and approved by the University of the 
Witwatersrand, Human Research Ethics Committee Medical (H R EC).
2. THIS APPRO VAL IS S U B J E C T  T O  T H E  FO LLO W IN G  PROVISOS:
* A copy of the M CC approval letter must be submitted to the Ethics Regulatory Office Secretariat before the 
study commences / the changes are implemented.
* The study is conducted according to the protocol submitted to the University of the Witwatersrand, Human 
Research Ethics Committee. Any amendments to the protocol must first be submitted to the Human Research 
Ethics Committee (Medical) for approval.
* During the study, the University of the Witwatersrand, Human Research Ethics Committee (Medical) is informed 
immediately o f :
- Any Unexpected Serious Adverse Events or Unexpected Adverse Drug Reactions, which, in the Investigator 
and/or the Sponsor's opinion are suspected to be related to the study drug. (International and Local Reports).
-  Any data received during the trial which, may cast doubt on the validity of the continuation of the study .
* The University of the Witwatersrand, Human Research Ethics Committee (Medical) is notified of any decision 
to discontinue the study and the reason stated.
* The Investigators authorised by this approval participate in this study. Additional Investigators shall be 
submitted to the University of the Witwatersrand, Human Research Ethics Committee (Medical) for approval prior 
to their participation in the study.
* In the event of an authorised Investigator ceasing to participate in the study, the University of the 
Witwatersrand, Human Research Ethics Committee (Medical) must be informed and the reason for such 
cessation given.
■ PRINCIPLES O F INFORM ED C O N S E N T:
3. The University of the Witwatersrand, Human Research Ethics Committee (Medical) requires that in all studies, 
; the Principles of Informed Consent are adhered to. This applies to volunteers as well as patients.
P R O G R ESS R EPO R TS:
4. The University of the Witwatersrand, Human Research Ethics Committee (Medical) requests that the M CC 
Progress Reports be submitted twice a year (March and September) and a report of the final results. At the 
conclusion of the study.
TH E  S U P P O R TIN G  AP P R O VAL D O C U M E N TS  A R E  A TTA C H E D :
a. Ethics Approval Form signed by the Chairperson of H R EC  -  Kindly return the copy of the Approval Form signed 
by the Principal Investigator per fax 011 711 -2833 for our records.
b. List of the members present at the H R E C  meeting held 27 S E P TEM B ER  2002.
* W E A W A IT Y O U R  R E S P O N S E S  A S  R E Q U E S TE D :
* Copy of Approval Form signed by the Principal Investigator.
The above has been noted for the Ethics Committee information and records.
KINDLY FORWARD TO THE RELEVANT INVESTIGATORS / C R A /  
SPONSOR /  STUDY CO-ORDINATORS - WHERE APPLICABLE
Regards
RENE W ILLS
For and on behalf of the Committee for Research on Human Subjects (Medical)
Attendance Register for the Ethics Meeting held on 27 September 2002 from 13:00 -15:00  
Venue: PPS Boardroom, Faculty of Health Sciences, Medical School,
jpILIATED TO THE UNIVERSITY IF THE WITWATERSRAND
liame Initials Title Discipline/s Academic Qualifications Gender Present
^agwanjee S Prof Anaesthesia MBBCh, FCA, DA (SA), FFA (SA) M Absent
Katon-Jones
Bhairperson)
P Prof Medical Practitioner BDS, MBBCh, PhD, DTM&H, DPH, 
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MASSAfr
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McLean GR Dr Philosopher and Ethicist BA (Hons) MA B Phil DPhil M Present
pokhachane M. Dr Paediatrics MBBCh, FCP (Paeds) SA, MMed F Absent
jpeputy Chairperson) (Wits)
Settle GJ Prof Surgery BSc (Hons), MBBCh, FRCS M Present
laizes A. Prof Lawyer BCom, LLB, PhD M Present
|enn C Prof Speech Pathology BA (S&HT), PhD F Present
loss E Prof Social Worker BA, MA, PhD F Absent
lehuklenk ■ U Prof Biomedical Ethics PhD M Present
r een AS
Prof Lawyer BA (Hons), BL (Hons), LLB, MPhil M Absent
Izabo CP Prof Psychiatry MBBCh, MMed, PhD M Absent
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lelaphi S Dr Paediatrics MBBCh, FCPaeds, Mmed M Present
lorster M Prof Psychiatry BA (Crim), MBBCh, MMed, F Present
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Approval of protocol entitled A retrospective pharmacoeconomic analysis comparing the cost effective­
ness of two treatment groups in patients with complicated intra-abdominal infections
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PATIENT INFORMATION LEAFLET & INFORMED CONSENT
BAYER HEALTHCARE: BAY 12-8039/10209 AIDA Study
A prospective, randomized, non-blind, multicenter trial assessing the safety and efficacy of 
sequential (intravenous/oral) BAY 12-8039 (moxifloxacin) 400 mg every 24 hr compared to 
intravenous ceftriaxone 2g every 24 hr and metronidazole 500 mg every 8 hr followed by 
oral amoxycillin/clavulanic acid tablets 625 mg every 8 hr for the treatment of patients with
_______complicated intra-abdominal infections. AIDA -  Study no.: IMPACT 10209_______
(You should keep a signed and dated copy o f the Patient Information Leaflet & Informed
Consent Form until the end o f the study)
You are being asked to participate in a research project. This document aims to give you important 
information regarding the procedures involved, the visits to your doctor, the study medication, possible side- 
effects, alternative treatments and your right to withdraw. Please take the opportunity to discuss any aspect o f  
the study and this document with the doctor. I f  you agree to participate, you will be asked to sign the attached 
Consent Form. Your participation is entirely voluntary and if you do not wish to take part, this will not 
affect the future treatment that you will receive or are entitled to in any way.
THE STUDY
This is a research study, which will compare the effects o f  a new antibiotic, moxifloxacin, with currently 
available antibiotics, ceftriaxone, metronidazole and amoxycillin/clavulanic acid, in the treatment o f  your 
condition (known as intra-abdominal infection). In total 566 patients will take part world wide and approximately 
100 patients will be recruited in South Africa. If you agree to participate, you will be allocated to one o f  the two 
treatment groups and will be treated with either moxifloxacin, or 
ceftriaxone/metronidazole/amoxycillin/clavulanic acid. The total length o f  your treatment will be between 5 and 
14 days, but you will remain in the study for 14-28 days after the treatment ends. The recruitment period for this 
trial will be approximately 18 months. Bayer provides the trial medication.
As moxifloxacin is a new antibiotic (as oral medication approved in the USA and most EU countries), it is 
important to check how well it is tolerated and the effect. Therefore, your doctor will assess your progress 
carefully during the study. You will be assessed every day while you are still in the hospital and will be asked to 
return to visit your doctor again after you have been discharged from hospital.
PROCEDURE
If you agree to participate in the study, the doctor will take a medical history, collect demographic data, vital 
signs, examine you and arrange for you to have either a x-ray, an ultrasound or any other radiographic procedure 
that is medically indicated in order to precisely diagnose your intra-abdominal infection. In addition an ECG (a 
measurement o f your heart function) will be performed. Blood and urine samples will be taken for laboratory 
testing to determine how severe you infection is. To do this, 35 milliliters (seven teaspoons) o f  blood will be 
drawn on day 1. To determine how well the medication is working against the infection 1 5 - 3 5  millilitres will 
then again be taken once between days 3-5 and or the day you start taking oral medication and again once 
between days 5 -1 4  and one last time between days 28 -  42. The volume o f blood will change between 15 -  35 
milliters depending on how well the infection respond to the medication you are taking. On the same days when 
blood is taken 50 milliliters (10 teaspoons) o f urine will be collected. Samples (drainage, fluid, tissue) from the 
infected area will be obtained to identify the bacteria which is causing the infection. This will only be done at the 
beginning o f your treatment to help the doctor.
If you are willing to take part you will have to give written consent by signing this form after which the above 
tests will be done. If these tests also indicate that you can enter the study you will be given either moxifloxacin
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or a combination o f ceftriaxone and metronidazole. If you receive the moxifloxacin you will receive the 
medication once a day directly into a vein. If you receive the combination the treatment will be three times a day 
directly into a vein. After at least three days if  you are well enough according to your doctor this medication can 
be stopped and changed to oral medication. If you receive the moxifloxacin you will have to take one tablet per 
day and if  you are on the combination treatment you will receive amoxycillin/clavulanic acid three times a day. 
You will receive oral medication for up to 11 days depending on you progress and therefore in total you will 
receive study medication for a maximum o f 14 days. The medication you will receive will be decided on 
randomly. If the treatment you are given does not cure your infection, it will be replaced by another standard 
treatment.
Full assessments will be carried out once between days 3-5 after the start o f your treatment, on the day you are 
switched from infusion to tablets (if this is different from day 4 or 5 o f treatment). This will be repeated once 
between days 5-14 and 28-42 days after your last dose o f  medicine to check that you have fully recovered from 
your infection. At all o f these visits you will be examined and have blood, urine and if appropriate, 
microbiological tests repeated. The ECG (heart function test) will be repeated after the end o f the morning 
infusion on days 1 and 3. At all visits, you will be asked about any side effects which you may have had.
It is not permitted to take part in other trials at the same time. Please inform your doctor if  you are already 
participating in another trial.
WITHDRAWAL FROM STUDY
As your participation in this study is entirely voluntary, you may withdraw from the study at any time that you 
wish even without stating your reasons. Your doctor may also withdraw you from the study should he/she 
consider that continued involvement on your part is inappropriate or may affect your well-being. If you withdraw 
from the study, this will not affect your future treatment in any way. However, if  you decide to withdraw, you will 
need to visit your doctor so that he/she can examine you and arrange further assessments if  necessary.
POTENTIAL RISKS. DISCOMFORTS. SIDE-EFFECTS
Possible side-effects o f moxifloxacin include nausea, stomach pains, diarrhoea, mild headache, rash, dizziness, 
allergic reactions and reversible changes to your liver function.





abdominal disturbances (for example cramps and diarrhoea), skin effects 
(example rash, peeling, itchiness) and allergic reactions, 
abdominal disturbances (for example cramps and 
diarrhoea), allergic reactions, weaknesses, dizziness, vomiting, nausea, 
skin rashes, darkly coloured urine, reaction to the use o f  alcohol (including 
perfume, deodorants etc.)
abdominal disturbances (for example cramps and diarrhoea), reversible effects 
to your liver such as pain and jaundice, allergic reactions, possible effects to you 
kidneys, hot flushes, skin effects (rash, peeling, itchiness), changes in tooth colour and 
fungal infections
Your ability to drive or operate machinery might be impaired, particularly in conjunction with alcohol.
New findings: You will be informed as soon as possible about any new findings which could cause you to
reconsider your decision to participate in this clinical trial.
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EXPECTED BENEFITS
Moxifloxacin is a new antibiotic which is active against a very wide variety o f bacteria which cause infection. 
Laboratory tests indicate that moxifloxacin is at least as effective as other commercially available antibiotics and 
it is expected that moxifloxacin will treat your condition successfully. The aim o f this study is to check, by 
detailed and regular testing, the safety and tolerability o f moxifloxacin. The medical knowledge gained from the 
study may benefit others in the future.
ALTERNATIVE TREATMENT
There are other antibiotics (Piperacillin, Imipenem) available in addition to those used in this study which may be 
used to treat your condition.
CONFIDENTIALITY
Your medical data and the results o f this trial will be recorded and transferred anonymously to Bayer (local and 
international) for scientific evaluation. If the results o f this trial is published your identity will remain 
confidential. Correct recording o f the measured values and clinical findings is vital for research purposes and 
therefore serves to improve drug safety. In order to ensure complete and correct transfer o f the data required for 
scientific evaluation, authorized personnel / specialists from Bayer, the local ethics committtee and regulatory 
body, auditors and the supervisory authorities in Germany and abroad who are responsible for the clinical trials 
will be granted permission by the investigator to view your personal original medical documents. Your express 
permission is required for this. By signing the attached Informed Consent Form, your are legally authorizing such 
access.
COMPENSATION
The sponsor company has taken out insurance for this study. This will compensate you for any significant 
deterioration in your health caused by the trial medication during the study. The trial is being conducted subject 
to the Association o f the British Pharmaceutical Industry (ABPI) Guidelines, rlating to compensation for injury 
arising in the course o f clinical trials. Copies o f  these guidelines are available from your study doctor, should 
they be requested.
Bayer will pay for all trial related expenses. You will not receive remuneration for taking part in this trial except 
for re-imbursement for travel expenses while meeting study commitments.
OTHER INFORMATION
(i) The local Research Ethics Committee, Pharm aceutical Trial Advisory Com mittee o f  the University o f  
Stellenbosch, has reviewed and approved the study. The conduct o f  this study will be according to ICH 
guidelines and the Declaration o f  Helsinki.
(ii) You should inform your doctor immediately if  you develop a rash or if  you experience any unexpected 
reactions.
(iii) Please inform your referring/family practitioner and your life insurer o f  your study participation.
If you are a female patient o f  childbearing potential, a urine pregnancy test must be performed prior to study 
entry. The effect o f  this drug on the unborn baby or nursing infant is not known and therefore it is important for 
you not do become pregnant or breast feed while on the trial. A reliable method o f contraception must be used 
during the study and it is recommended that female patients taking oral contraceptives use additional barrier 
contraception (e.g. condoms) or do not have sex during treatment.
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CONTACT NUMBERS
Any symptoms, adverse events or injuries occurring during the course o f the trial must be reported without delay 
the study staff, by telephone if  necessary:
Prof. Brian L Warren at 021 938 9274 / 082 557 2625 
Sr Marinda Perry at 021 938 9534 / 082 371 9291
OPPORTUNITY TO DISCUSS FURTHER QUERIES
Your doctor and his staff are available to answer any further questions arising concerning this clinical trial. They 
will also be happy to answer any questions affecting your rights as a patient and participant in this trial.
WRITTEN INFORMED CONSENT
Dr/Prof/Mr/Ms_____________________________________  _______________
(LAST AND FIRST NAME OF PATIENT BLOCK LETTERS PLEASE) RANDOM NUMBER
I agree to participate in this clinical study, which has been explained to me, and any 
questions I have asked have been answered to my satisfaction. I have been informed 
about the purpose of the trial, treatment alternatives, potential side effects, as well as 
the possibility to withdraw my participation in this study at any time, without any 
disadvantages for me in such a case.
I agree that my medical data obtained from this trial will be documented. To 
prove the accuracy of the data experts from BAYER and/or registration 
authorities may inspect the data in presence of the investigator.
I further agree that the anonymous data will be transmitted to BAYER and/or 
registration authorities to maintain patient safety in clinical trials.
I have received a signed and dated copy of the Patient Information Leaflet and 
Informed Consent for BAY 12-8039/10209 clinical trial.
Signed at Tygerberg on ___________________ __________________________
Date Patient’s signature
Signed at Tygerberg on ____
Date Investigator’s signature
BAYER South Africa / Study BAY 12-8039 / IMPACT 10209 (English - Prof BL Warren)
Patient Information Leaflet and Informed Consent / Version 4.0 /1 6  January 2001
from Protocol, Version 4.0, 08 September 2000, Outline: Version 5, 08 September 2000 Page 4 o f 4
















APPENDIX C 00 to
Adverse events treatment group A 
Adverse events treatment group B
Concomitant antimicrobial medication treatment group A 
Concomitant antimicrobial medication treatment group B
Concomitant medication treatment group A 
Concomitant medication treatment group B
Demographic data treatment group A 
Demographic data treatment group B
Hospitalisation treatment group A 
Hospitalisation treatment group B
Professional fees treatment group A 
Professional fees treatment group B
Study medication treatment group A 
Study medication treatment group B
Therapeutic adjunctions treatment group A 





ADVERSE EVENTS / TREATMENT GROUP A / ITT
ADVERSE EVENT START DATE STOP DATE
003 W ound  In fection 01 -M ar-01 08-M ar-01
005 Laparo tom y w ound  in fection 24-M ar-01 29-M ar-01
005 S ys tem ic  sep tic  in flam m ato ry  response 17-M ar-01 28-M ar-01
014 Incom p le te  sm a ll bow el obstruc tion 17-M ay-01 28 M a y 01
014 V om iting 05-Jun-01 05-Jun-01
016 C ereb ro -vascu la r acc iden t 24-M ay-01 03-Jun-01
016 P neum on ia 28-M ay-01 03-Jun-01
016 S ep ticaem ia 30-M ay-01 03-Jun-01
018 H aem op tys is 18-M ay-01 18-M ay-01
021 H yperka laem ia 11-Jun-01 15-Jun-01
021 Le ft subph ren ic  abscess 06-Jun-01 19-Jun-01
021 P ro longed  Q T  in te rva l 29-M ay-01 30-M ay-01
036 W o u n g  Sepsis 18-Aug-01 30-Aug-01
040 Laparo tom y 11-O ct-01 24-O ct-01
042 S ubphren ic  a bscess 25-O ct-01 28-O ct-01
042 V ig ina l cand idas is 06-Nov-01 08-Nov-01
047 P artia l sm a ll bow el obstuction 02-N ov-01 06-Nov-01
049 H eadache 04-N ov-01 04-Nov-01
055 A bd o m e n  and th igh  U rticaria 22-N ov-01 26-N ov-O I
068 A d u lt resp ira to ry  d is tress  synd rom e 12-Jan-02 18-Jan-02
073 Large abscess  su rg ica lly  d ra ined 08-Feb-02 08-Feb-02
073 P e lv ic  abscess 07-Feb-02 14-Feb-02
078 A tria l fib rilla tion 02-M ar-02 07-M ar-02
078 C and ida  sep ticaem ia 07-M ar-02 16-M ar-02
078 M ultip le  o rgan  d is func tion  syndrom e 26-Feb-02 15-M ar-02
078 R esp ira to ry  fa ilu re 25-Feb-02 07-M ar-02
079 E n te rocu ta neous F istu la 0 7 -M ar-02 18-M ar-02
079 M ultip le  o rgan dysfunction  syndrom e 14-M ay-02 O ngoing









001 A bd o m in a l Pa in 17-M ar-01 19-M ar-01
006 D e lirium  T re m e n s  (M en ta l C on fus ion ) 29-M ar-01 18-Apr-01
006 Lapa ro to m y w ound seps is 08-Apr-01 30-Apr-01
006 M u ltip le  in tr-abdom ina l acscesses 03-Apr-01 03-Apr-01
006 N osocom ia l P neum on ia 04-Apr-01 18-Apr-01
008 P neum ocys tic  ca rin i penum on ia 30-M ar-01 17-Apr-01
008 P neum o th o rax 15-Apr-01 15-Apr-01
013 O titis  E x te rna 22-M ay-01 ongo ing
029 G astril S tas is 13-Aug-01 17-Aug-01
048 L e ft P leura l E ffus ion 02-N ov-01 13-Nov-01
052 V e n tr icu la r 17-N ov-01 17-Nov-01
056 P artia l D eh iscence - A p p e n d e ltm y  w ound 08-D ec-01 04-Jan-02
056 T h ru m b o p le b itis 30-N ov-01 01-Dec-01
070 P eriana l abscess 17-Jan-02 17-Jan-02
087 B ronch itis 19 -A pr-02 24-A pr-02
087 D ia rrheoa 19-A pr-02 21 -A pr-02
087 W o u n d  A bscess 22-A pr-02 24 -A pr-02
089 C entra l V e n u o s  C e the te r 17 -A pr-02 23 -A pr-02
089 N asogas tric  T ube 17-A pr-02 22-A pr-02
089 O xyg e n  F acem ask 17-A pr-02 22 -A pr-02
089 U rinary  A th e te r 17-Apr-02 22 -A pr-02




CONCOMITANT ANTI MICROBIAL MEDICATION / TREATMENT GROUP A / ITT










003 Flagvl 500 mg IV 22-Feb-01 22-Feb-01 R 33.20 R 0.92
003 Gentamycin 160 mg IV 22-Feb-01 22-Feb-01 R 255.98 R 0.92
004 NA NA NA NA NA NA R 0.00 R 0.00
005 Amikacin 1 g IV 23-Mar-01 27-Mar-01 R 6.795.00 R 0.92
005 Flaovl 500 mg IV 15-Mar-01 15-Mar-01 R 33.20 R 0.92
005 Tienam 3 g IV 23-Mar-01 30-Mar-01 R 6.866.88 R 0.92
005 Zinacef 1.5 mg IV 15-Mar-01 15-Mar-01 R 82.51 R 0.92
007 NA NA NA NA NA NA R 0.00 R 0.00
009 NA NA NA NA NA NA R 0.00 R 0.00
010 Flagyl 500 mg IV 08-Apr-01 08-Apr-01 R 33.20 R 0.92
010 Zinacef 1.5 g IV 08-Apr-01 08-Apr-01 R 82.51 R 0.92
014 Kefzol 2 g IV. 06-Mav-01 06-Mav-01 R 247.84 R 0.92
016 Amikacin 500-1000 mg IV 31-Mav-01 02-Jun-01 R 4,077.00 R 0.92
016 Amoxil 750 mg PO 28-Mav-0l 30-Mav-01 R 19.93 R 0.00
016 Augmentin 3.6 mg PO 29-May-01 30-Mav-01 R 319.68 R 0.00
016 Ciprobav 200-400 mg IV 31-May-01 02-Jun-01 R 1.762.08 R 0.92
016 Flagyl 400-1200 mg PO 30-May-01 31-May-01 R 19.86 R 0.00
016 Gentamycin 240 mg IV 30-Mav-01 31-May-01 R 767.94 R 0.92
016 Rocephin 1 g IV 30-Mav-01 30-May-01 R 185.83 R 0.92
018 NA NA NA NA NA NA R 0.00 R 0.00
019 Augmentin 1.2 g IV 16-Mav-01 16-Mav-01 R 53.28 R 0.92
021 Augmentin 1.2 g IV 29-May-01 29-May-01 R 53.28 R 0.92
021 Augmentin 1.2-3.6 g IV 30-May-01 10-Jun-01 R 639.36 R 0.92
021 Flagyl 500 mg IV 29-May-01 29-May-01 R 33.20 R 0.92
021 Flagyl 500-1500 mg IV 30-May-01 04-Jun-01 R 597.60 R 0.92
021 Flagyl 2 g PR 05-Jun-01 09-Jun-01 R 250.60 R 0 .0 0
021 Gentamycin 340 mg IV 04-Jun-01 09-Jun-01 R 3,071.76 R 0.92
021 Tazocin 4.5-13.5 g IV 10-Jun-01 19-Jun-01 R 9,205.50 R 0.92
022 Flagyl 500 mg IV 30-May-01 30-May-01 R 33.20 R 0.92
022 Zinacef 1.5 g IV 30-May-01 30-May-0l R 82.51 R 0.92
025 Flagyl 500 mg IV 20-Jun-01 20-Jun-01 R 33.20 R 0.92
025 Zinacef 1.5 mg IV 20-Jun-01 20-Jun-01 R 82.51 R 0.92
028 Augmentin 2.4 g IV 03-Aug-01 03-Auq-01 R 106.56 R 0.92
028 Flagyl 1000 mg IV 03-Aug-01 03-Aug-01 R 66.40 R 0.92
030 NA NA NA NA NA NA R 0.00 R 0.00
031 Kefzol 1 g IV 23-Aug-01 23-Auq-01 R 123.92 R 0.92
036 NA NA NA NA NA NA R 0.00 R 0.00
038 NA NA NA NA NA NA R 0.00 R 0.00
040 Flagyl 500 mg IV 06-Oct-01 06-Oct-01 R 33.20 R 0.92
040 Kefzol 1 g IV 06-Oct-01 06-Oct-01 R 123.92 R 0.92
040 Zinacef 750 mg IV 06-Oct-01 06-Oct-01 R 41.26 R 0.92
042 Augmentin 1.2 g IV 18-Oct-01 18-Oct-O1 R 53.28 R 0.92
042 Ciprobay 250-500 mg PO 10-NOV-01 15-Nov-01 R 164.22 R 0.00
042 Flagyl 400-1200 mg PO 03-NOV-01 15-Nov-OI R 129.09 R 0.00
042 Flagyl 500 mg IV 18-Oct-O1 18-Oct-O1 R 33.20 R 0.92
042 Flagyl 400-1200 mg PO 28-Oct-01 01-Nov-01 R 49.65 R 0.00
042 Gentamycin 240 mq IV 19-Oct-O1 19-Oct-O1 R 383.97 R 0.92
042 Gentamycin 240 mg IV 06-Nov-OI 07-NOV-01 R 767.94 R 0.92
042 Gentamycin 240 mg IV 09-Nov-OI 09-NOV-01 R 383.97 R 0.92
042 Gentamycin 240 mg IV 28-Oct-01 04-NOV-01 R 3,071.76 R 0.92
042 Penicillin G 12-16 12-16 PO 06-Nov-01 07-NOV-01 R 66.40 R 0.00
042 Penicillin G 1 mu IV 19-Oct-O1 19-Oct-O1 R 29.94 R 0.92
042 Penicillin G 4-12 mu IV 09-NOV-01 10-NOV-01 R 66.40 R 0.92
042 Penicillin G 4-16 mu IV 29-Oct-01 04-NOV-01 R 21,502.32 R 0.92
044 Flagyl 500 mg IV 20-NOV-01 20-NOV-01 R 33.20 R 0.92
044 Zinacef 750 mg IV 20-NOV-01 21-NOV-01 R 94.90 R 0.92
045 NA NA NA NA NA NA R 0.00 R 0.00
047 Flagyl 500 mg IV 28-Oct-01 28-Oct-01 R 33.20 R 0.92
047 Zinacef 1.5 g IV 28-Oct-01 28-Oct-01 R 82.51 R 0.92
049 Augmentin 1.2 9 IV 04-NOV-01 04-NOV-01 R 53.28 R 0.92
051 Augmentin 1.2 g IV 11-Nov-01 11-NOV-01 R 53.28 R 0.92
051 Mandokef 1 g IV 11-Nov-OI 11-Nov-01 R 119.31 R 0.92
054 NA NA NA NA NA NA R 0.00 R 0.00
055 Augmentin 1.2 g IV 20-NOV-01 20-NOV-01 R 53.28 R 0.92
059 Flagyl 1000 mg IV 09-Dec-01 09-Dec-01 R 66.40 R 0.92
059 Kefzol 1 g IV 09-Dec-01 09-Dec-01 R 123.92 R 0.92
059 Zinacef 1.5 g IV 09-Dec-0i 09-Dec-01 R 82.51 R 0.92
060 Augmentin 1.2 g IV 11-Dec-01 12-Dec-01 R 106.56 R 0.92
060 Kefzol 1 g IV 12-Dec-01 12-Dec-01 R 123.92 R 0.92
061 Flagyl 1000 mg IV 15-Dec-01 15-Dec-01 R 66.40 R 0.92
061 Kefzol 1 g IV 15-Dec-01 15-Dec-01 R 123.92 R 0.92
061 Zinacef 1.5 g IV 15-Dec-01 15-Dec-01 R 82.51 R 0.92
062 NA NA NA NA NA NA R 0.00 R 0.00
066 Flagyl 500 mg IV 05-Jan-02 05-Jan-02 R 33.20 R 0.92
068 Amoxil 750 mg PO 07-Jan-02 10-Jan-02 R 26.52 R 0.00
071 Flagyl 1000 mg IV 22-Jan-02 22-Jan-02 R 66.40 R 0.92
071 Gentamycin 240 mg IV 22-Jan-02 22-Jan-02 R 383.97 R 0.92
071 Penicillin G 2 mu IV 22-Jan-02 22-Jan-02 R 29.94 R 0.92
072 NA NA NA NA NA NA R 0.00 R 0.00
073 Augmentin 1.2-3.6 mg IV 09-Feb-02 14-Feb-02 R 319.68 R 0 .9 2
073 Flagyl 500 mg IV 24-Jan-02 24-Jan-02 R 33.20 R 0.92




CONCOMITANT ANTI MICROBIAL MEDICATION / TREATMENT GROUP A / ITT










073 Gentamycin 340 mg IV 09-Feb-02 13-Feb-02 R 2,559.85 R 0.92
073 Zinacef 750 mg IV 24-Jan-02 24-Jan-02 R 41.26 R 0.92
074 NA NA NA NA NA NA R 0.00 R 0.00
075 Auqmentin 2.4 a IV 18-Feb-02 18-Feb-02 R 106.56 R 0.92
075 Flagyl 1000 mg IV 18-Feb-02 18-Feb-02 R 66.40 R 0.92
078 Kefzol 1 g IV 23-Feb-02 23-Feb-02 R 123.92 R 0.92
078 Meropenem 1-3 g IV 27-Feb-02 07-Mar-02 R 19,179.72 R 0.92
079 Cefuroxime 4.5 g IV 24-Feb-02 24-Feb-02 R 247.53 R 0.92
079 Flagyl 4 g IV 23-Feb-02 23-Feb-02 R 132.80 R 0.92
079 Flagyl 500 mg IV 24-Feb-02 24-Feb-02 R 33.20 R 0.92
079 Zinacef 1.5 mg IV 23-Feb-02 23-Feb-02 R 82.51 R 0.92
081 Augmentin 1.2 g IV 26-Feb-02 27-Feb-02 R 106.56 R 0.92
081 Augmentin 1.2 g IV 13-Mar-02 13-Mar-02 R 53.28 R 0.92
081 Augmentin 1.2-3.6 g IV 22-Mar-02 28-Mar-02 R 1,118.88 R 0.92
081 Flagyl 500 mg IV 26-Feb-02 27-Feb-02 R 66.40 R 0.92
085 Flagyl 500 mg IV 16-Mar-02 l6-Mar-02 R 33.20 R 0.92
085 Zinacef 1.5 g IV 16-Mar-02 l6-Mar-02 R 82.51 R 0.92
088 Augmentin 1.2 g IV 03-Apr-02 03-Apr-02 R 53.28 R 0.92
090 Flagyl 500-1000 mg IV 20-Apr-02 21-Apr-02 R 132.80 R 0.92
090 Zinacef 1.5-3 mg IV 20-Apr-02 21-Apr-02 R 330.04 R 0.92
091 Amfoteracin B 50 mg IV 17-Mav-02 17-May-02 R 215.46 R 0.92
091 Amikacin 1 g IV 14-May-02 14-May-02 R 1,359.00 R 0.92
091 Amikacin 1 g IV 17-Mav-02 17-May-02 R 1,359.00 R 0.92
091 Augmentin 1.2-3.6 g IV 29-Apr-02 30-Apr-02 R 310.68 R 0.92
091 Flagyl 500-1500 mg IV 29-Apr-02 30-Apr-02 R 199.20 R 0.92
091 Fluconazole 200 mg IV 15-May-02 17-May-02 R 495.42 R 0.92
091 Gentamycin 240 mg IV 09-May-02 13-May-02 R 1,919.85 R 0.92
091 Tazocin 4.5-18 g IV 09-Mav-02 15-May-02 R 8,591.80 R 0.92
091 Tienam 1.5-2 g IV 15-Mav-02 17-May-02 R 1,716.72 R 0.92
093 Augmentin 3.6 g IV 12-Mav-02 12-May-02 R 159.84 R 0.92
093 Flagyl 1500 mg IV 12-Mav-02 12-Mav-02 R 99.60 R 0.92
095 Augmentin 1.2 g IV 20-Jun-02 20-Jun-02 R 53.28 R 0.92
097 Augmentin 1.2 mg IV 25-JUI-02 25-Jul-02 R 53.28 R 0.92
097 Flagyl 500 mg IV 25-JUI-02 25-Jul-02 R 33.20 R 0.92
100 Augmentin 2.4 g IV 02-May-02 02-May-02 R 106.56 R 0.92
100 Flagyl 1000 mg IV 02-May-02 02-May-02 R 66.40 R 0.92
IIOTAL ~| R 106,995.64 R 80,24
Appendix C 2.2
RANDOM
CONCOM ITANT ANITMiCROBIAL MEDICATION / TR EA TM EN T GROUP B / ITT
NUMBER IN  H O S P ITA L D A ILY
U N IT S R O U TE
S T A R T
S T O P  DATE C O S T
C O N SU M -
M E D IC A T IO N D O S A G E D A TE A B L E S
001 Amikacin 500 mg IV 14-Feb-01 14-Feb-01 R  679 .50 R  0.92
001 Claforan 1 9 IV 14-Feb-01 14-Feb-01 R 143.15 R  0.92
002 NA NA NA NA NA NA R 0.00 R 0.00
006 Amikacin 1 9 IV 05-Apr-01 08-Apr-01 R  5 ,436 .00 R  0.92
006 Auamentin 2.4-3.6 9 IV 03-Apr-01 05-Apr-01 R  47 9 .52 R 0.92
006 Auqmentin 1.2-2.4 9 IV 15-Apr-01 17-Apr-01 R  31 9 .68 R  0.92
006 Auqmentin 3.6 mg IV 18-Apr-01 22-Apr-01 R  79 9 .20 R  0.92
006 Flagyl 500-1500 mg IV 03-Apr-01 09-Apr-01 R 697 .20 R  0.92
006 Flagyl 500 mg IV 26-Mar-01 26-Mar-01 R 33 .20 R  0.92
006 Tienam 1-2 9 IV 05-Apr-01 09-Apr-01 R 2 ,8 61 .2 0 R 0 .9 2
006 Zinacef 750 mg IV 26-Mar-01 26-Mar-01 R  4 1 .1 5 R 0.92
008 Ampicillin 2-4 9 IV 09-Apr-01 12-Apr-01 R 378 .40 R 0.92
008 Bactrim 3840 mg IV 04-Apr-01 17-Apr-01 R  7 ,9 45 .2 8 R  0.92
008 Gentamycin 240 mg IV 03-Apr-01 16-Apr-01 R  5 ,3 75 .5 8 R  0.92
008 Tazocin 4.5-13.5 9 IV 13-Apr-01 16-Apr-01 R  3 ,6 82 .2 0 R 0.92
008 Tienam 1-3 9 IV 03-Apr-01 07-Apr-01 R  4 ,2 91 .8 0 R  0.92
008 Tienam 2 9 IV 16-Apr-01 16-Apr-01 R  572 .24 R 0.92
008 Zinacef 3 mg IV 12-Apr-01 13-Apr-01 R  33 0 .04 R  0.92
011 NA NA NA NA NA NA R  0.00 R  0.00
012 NA NA NA NA NA NA R  0 .00 R 0.00
013 Flagyl 500 mg IV 30-Apr-01 30-Apr-01 R 33 .20 R  0.92
013 Zinacef 1.5 mg IV 30-Apr-01 30-Apr-01 R  82.51 R 0.92
015 NA NA NA NA NA NA R  0 .00 R  0.00
017 Augmentin 1.2 9 IV 15-May-01 15-May-01 R  53 .28 R 0.92
020 Augmentin 1.2 9 IV 22-May-01 22-May-01 R  53 .28 R 0 .92
023 Flagyl 1 9 PR 10-Jun-01 10-Jun-01 R 66 .40 R  0.00
023 Gentamycin 240 mg IV 10-Jun-01 10-Jun-01 R  383 .97 R  0.92
023 Pennicillin G 4 mu IV 10-Jun-01 10-Jun-01 R  29 .46 R  0.92
024 Augmentin 1.2 9 IV 19-Jun-01 19-Jun-01 R  53 .28 R 0 .9 2
024 Flagyl 500 mg IV 19-Jun-01 19-Jun-01 R  33 .20 R  0.92
026 Ampicillin 1 9 IV 30-Jul-01 30-Jul-01 R  23 .65 R  0.92
027 Flagyl 1000 mg IV 02-Aug-01 01-Aug-01 R  132.80 R  0.92
027 Zinacef 1.5 9 IV 02-Aug-01 02-Aug-01 R 82.51 R 0 .9 2
029 Augmentin 1.2 9 IV 09-Aug-01 09-Aug-01 R  53 .28 R 0.92
029 Flagyl 500 mg IV 09-Aug-01 09-Aug-01 R  33 .20 R  0.92
032 NA NA NA NA NA NA R  0 .00 R  0.00
033 Augmentin 1.2 9 IV 10-Sep-01 10-Sep-01 R  53 .28 R  0.92
033 Flagyl 1500 mg IV 10-Sep-01 10-Sep-01 R  99 .60 R 0.92
033 Kefzol 1 9 PO 10-Sep-01 10-Sep-01 R 123.92 R  0.00
033 Zinacef 1.5 9 IV 10-Sep-01 10-Sep-01 R 82.51 R 0.92
034 Flagyl 500 mg IV 12-Sep-01 12-Sep-01 R  33 .20 R 0.92
034 Zinacef 1.5 9 IV 12-Sep-01 12-Sep-01 R 82.51 R  0.92
035 Flagyl 500 mg IV 12-Sep-01 12-Sep-01 R  33 .20 R  0.92
035 Zinacef 750 mg IV 12-Sep-01 12-Sep-01 R 4 1 .2 6 R  0 .92
037 Augmentin 1.2 9 IV 27-Oct-01 27-Oct-01 R  53 .28 R  0.92
037 Flagyl 500 mg IV 27-Oct-01 27-Oct-01 R 33 .20 R 0.92
037 Zinacef 750 mg IV 27-Oct-01 27-Oct-01 R 41 .26 R 0.92
039 NA NA NA NA NA NA R  0 .00 R  0 .00
041 Flagyl 1000 mg IV 10-Oct-01 10-Oct-01 R  66 .40 R  0.92
041 Zinacef 1.5 9 IV 10-Oct-01 10-Oct-01 R 82.51 R  0.92
043 NA NA NA NA NA NA R 0.00 R  0.00
046 Augmentin 1.2 9 IV 23-Oct-01 23-Oct-01 R  53 .28 R  0 .92
046 Cefepime 2-4 9 IV 29-Oct-01 04-Nov-01 R  1 ,5 75 .0 0 R 0.92
046 Gentamycin 240 mg IV 29-Oct-01 03-NOV-01 R 2 ,3 03 .8 2 R 0.92
046 Mandokef 1 9 IV 22-Oct-01 22-Oct-01 R 119.31 R  0.92
048 Tazocin 13.5 9 IV 05-Nov-01 14-Nov-01 R 9 ,2 05 .5 0 R  0.92
050 Auqmentin 1.2 9 IV 07-Nov-01 07-Nov-01 R  53 .28 R  0.92
052 Flagyl 500 mg IV 17-Nov-01 17-Nov-01 R 33 .20 R 0.92
052 Mandokef 1 9 IV 17-Nov-01 17-Nov-01 R  119.31 R  0.92
053 NA NA NA NA NA NA R  0 .00 R 0.00
056 Augmentin 1.2 9 IV 27-Nov-01 27-Nov-OI R 53 .28 R  0.92
056 Augmentin 1.2 9 IV 27-Nov-OI 27-Nov-01 R  53 .28 R  0.92
056 Flagyl 500 mg IV 27-Nov-01 27-Nov-01 R 33 .20 R 0.92
056 Flagyl 500 mg IV 27-Nov-OI 27-Nov-01 R  33 .20 R  0.92
057 Flagyl 500 mg IV 03-Dec-01 03-Dec-01 R 33 .20 R  0.92
057 Flagyl 500 mg IV 03-Dec-01 03-Dec-01 R 33 .20 R 0.92
057 Kefzol 1 9 IV 03-Dec-01 03-Dec-01 R 123.92 R 0 .9 2
057 Kefzol 1 g IV 03-Dec-01 03-Dec-01 R  123.92 R  0.92
058 NA NA NA NA NA NA R 0.00 R 0.00
058 NA NA NA NA NA NA R  0 .00 R 0.00
063 Flagyl 500 mg IV 16-Dec-01 16-Dec-01 R 33 .20 R  0 .92
063 Kefzol 1 9 IV 17-Dec-01 17-Dec-01 R  123 .92 R  0 .92
063 Zinacef 1.5 9 IV 16-Dec-01 16-Dec-01 R  82.51 R 0 .92
064 Kefzol 1 9 IV 17-Dec-01 17-Dec-01 R 123.92 R  0 .92
065 NA NA NA NA NA NA R  0 .00 R  0.00
067 Flagyl 500 mg IV 05-Jan-02 05-Jan-02 R  33 .20 R 0.92




CONCOM ITANT ANITMICROBIAL MEDICATION / TR EA TM EN T GROUP B / ITT
IN  H O S P IT A L  
M E D IC A T IO N
D A ILY
D O S A G E
U N ITS R O U TE
S TA R T
D A TE
S TO P  DATE C O S T
C O N S U M ­
A B LE S
069 Flagyl 500 mg IV 12-Jan-02 12-Jan-02 R  33 .20 R  0.92
069 Zinacef 1.5 9 IV 12-Jan-02 12-Jan-02 R 82.51 R  0.92
070 Auqmentin 1.2 9 IV 14-Jan-02 14-Jan-02 R  53 .28 R  0.92
076 Ampicillin 1 9 IV 19-Feb-02 19-Feb-02 R  23 .65 R 0.92
076 Flagyl 1000 mg IV 19-Feb-02 19-Feb-02 R  66 .40 R  0.92
076 Gentamycin 240 mg IV 19-Feb-02 19-Feb-02 R  383 .97 R  0.92
076 Kefzol 1 9 IV 19-Feb-02 19-Feb-02 R 123 .92 R 0.92
077 Flagyl 50 mg IV 20-Feb-02 20-Feb-02 R  33 .20 R  0.92
077 Kefzol 1 9 IV 20-Feb-02 20-Feb-02 R  123 .92 R  0.92
080 Auqmentin 1.2 9 IV 24-Feb-02 24-Feb-02 R  53 .28 R  0.92
080 Flagyl 500 mg IV 24-Feb-02 24-Feb-02 R  33 .20 R  0.92
080 Kefzol 1 9 IV 24-Feb-02 24-Feb-02 R 1 ,323 .23 R  0.92
082 Auqmentin 1.2 9 IV 07-Mar-02 07-Mar-02 R  53 .28 R  0.92
083 Auqmentin 3.6 mg PO 25-Mar-02 29-Mar-02 R  79 9 .20 R  0.00
083 Flagyl 500 mg IV 10-Mar-02 10-Mar-02 R  33 .20 R  0.92
083 Kefzol 1 9 IV 10-Mar-02 10-Mar-02 R  1 ,323 .23 R  0.92
086 Flagyl 500-1000 mg IV 17-Mar-02 18-Mar-02 R 132.80 R 0 .92
086 Zinacef 1.5-3.0 9 IV 17-Mar-02 18-Mar-02 R  33 0 .04 R 0 .92
087 Auqmentin 1.2-4.8 9 IV 22-Apr-02 24-Apr-02 R  63 9 .36 R 0.92
087 Auqmentin 1.2 9 IV 29-Mar-02 30-Mar-02 R  106.56 R 0 .92
089 Auqmentin 1.2 9 IV 17-Apr-02 17-Apr-02 R  53 .28 R 0 .92
089 Betadine 1 applic TOP 18-Apr-02 18-Apr-02 R 45 .37 R  0.00
092 Auqmentin 1.2 9 IV 08-May-02 08-Mav-02 R 53 .28 R 0.92
092 Flagyl 500 mg IV 08-Mav-02 08-May-02 R 33 .20 R 0.92
094 Auqmentin 1.2 9 IV 08-Jun-02 09-Jun-02 R  106.56 R 0 .92
094 Flagyl 500 mg IV 08-Jun-02 09-Jun-02 R 66 .40 R 0.92
096 Auqmentin 1.2 9 IV 09-Jul-02 09-Jul-02 R  53 .28 R  0.92
096 Flagyl 500 mg IV 09-Jul-02 09-Jul-02 R  33 .20 R  0.92
098 Flagyl 500 mg IV 11-Aug-02 11-Aug-02 R  33 .20 R 0 .92
098 Kefzol 1 9 IV 11-Aug-02 11-Aug-02 R  123 .92 R  0.92
099 Amoxicillin 1500 mg PO 04-Sep-02 09-Sep-02 R 89 .46 R  0.00
099 Flagyl 500 mg IV 11-Aug-02 11-Aug-02 R  33 .20 R 0 .92
099 Zinacef 1.5 a _________ IV 11-Aug-02 11-Aug-02 R  82.51 R 0.92
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003 D oloro l Forte 1 0 1 6 -2 0 3 2 m g PO R 0.00 27-Feb-01 01-M ar-01 R 11.28
003 D oloro l Forte 1016 mg PO R 0.00 08-M ar-01 12-M ar-01 R 9.40
003 M axalon 10 mg IM R 21.36 23-Feb-01 24-Feb-01 R 6.88
003 P ethed ine 1 5 0 -3 0 0 mg IM R 53.40 23-Feb-01 27-Feb-01 R 119.92
004 D o lo ro l Forte 2032 mg PO R 0.00 26-Feb-01 26-Feb-01 R 3.76
004 D oxyfene 2 tabs PO R 0.00 28-Feb-01 28-Feb-01 R 7.19
004 M orph ine 20-30 mg IM R 53.40 23-Feb-01 27-Feb-01 R 106.31
005 A drena line 10-15 m g IV R 0.92 20-M ar-01 25-M ar-01 R 410.19
005 A m inophy lin 250-1500 mg IV R 0.92 23-M ar-01 28-M ar-01 R 875.71
005 D oloro l Forte 2032 mg PO R 0.00 30-M ar-01 30-M ar-01 R 3.76
005 D orm icum 200-250 mg IV R 19.39 17-M ar-01 26-M ar-01 R 8,212.56
005 H eparin 15000 iu SC R 138.84 16-M ar-01 28-M ar-01 R 272.61
005 Lasix 10-15 mg IV R 0.92 20-M ar-01 27-M ar-01 R 89.44
005 M orph ine 10-20 mg IM R 138.84 15-M ar-01 27-M ar-01 R 113.40
005 Panado 30-120 ml PO R 0.00 19-Mar-01 26-M ar-01 R 17.64
005 S e repax 10 mg PO R 0.00 20-M ar-01 20-M ar-01 R 0.71
005 U lsan ic 4 g PO R 0.00 15-M ar-01 28-M ar-01 R 159.51
005 V a lium 10 mg PO R 0.00 30-M ar-01 31 -M ar-01 R 23.45
007 M orph ine 10-30 mg IM R 53.40 26-M ar-01 30-M ar-01 R 106.31
009 M orph ine 20-40 mg IM R 42.72 07-Apr-01 10-Apr-01 R 113.40
010 A troven t 0.5-1.5 mg INH R 0.00 11-Apr-01 13-Apr-01 R 95.75
010 B ero tec 1.25-3.75 mg INH R 0.00 11-Apr-01 13-Apr-01 R 50.35
010 M orph ine 10-20 mg IM R 42 .72 09-Apr-01 12-Apr-01 R 56.70
014 D oloro l Forte 1016-2032 mg PO R 0.00 09-M ay-01 12-May-01 R 15.04
014 M orph ine 10-20 m g IM R 42.72 07-M ay-01 10-M ay-01 R 56.70
014 P ethed ine 0-50 mg IM R 64 .08 2 1 -M ay-01 26-M av-01 R 44.30
016 A teno lo l 25 mg PO R 0.00 17-May-01 23-M ay-01 R 44.33
016 A troven t 3 INH R 0.00 29-M ay-01 01-Jun-01 R 255.36
016 B ero tec 3.75 mg INH R 0 .00 29-M ay-01 01-Jun-01 R 67.08
016 D oloro l Forte 3048 mg PO R 0.00 21 -M ay-01 23-M ay-01 R 16.92
016 D oxyfene 2-6 tabs PO R 0.00 29-M ay-01 31 -May-01 R 64.62
016 G lucophage  fo rte 1700 mg PO R 0.00 22-M ay-01 23-M ay-01 R 4.78














016 H eparin 5000-15000 iu SC R 85.44 14-M ay-01 2 1 -M ay-01 R 167.76
016 Indocid 100-200 mg PR R 0.00 18-M ay-01 20-M ay-01 R 73.80
016 Insulin 0-15 iu SC R 96.12 13-M ay-01 21-M ay-01 R 1,167.05
016 Lasix 60 mg PO R 0.00 29-M ay-01 02-Jun-01 R 39.22
016 Lasix 40 mg PO R 0.00 16-M ay-01 23-M ay-01 R 30.49
016 M axa lon 10 mg IV R 19.39 13-May-01 13-M ay-01 R 6.88
016 P ethed ine 50-100 mg IM R 64 .08 12-May-01 17-May-01 R 44.30
016 R en itec 20 m g IV R 0.92 20-M av-01 23-M ay-01 R 30.53
016 T ryp tano l 25 mg PO R 0.00 29-M ay-01 29-M ay-01 R 0.49
016 V o lta ren  supos ito ry 50 m g PR R 0.00 15-M ay-01 15-M ay-01 R 16.17
018 M orph ine 10-30 m g IM R 74.76 15-May-01 2 1 -M ay-01 R 148.83
018 N eostigm ine 2.5 m g IV R 0.92 15-May-01 15-M ay-01 R 6.54
018 N im bex 8 m g IV R 19.39 15-M ay-01 15-M ay-01 R 198.78
018 P ethed ine 50 mg IM R 32.04 15-M ay-01 17-M ay-01 R 22.14
018 R obinu l 0.6 mg IV R 0.92 15-M ay-01 15-May-01 R 220.59
018 T e ta n u s  toxo id 0.5 m l IM R 3.56 13-M ay-01 13-M ay-01 R 35.68
019 D oloro l Forte 1016-2032 mg PO R 0.00 19-May-01 22-M ay-01 R 15.04
019 M orph ine 20-30 m g IV R 19.39 17-M ay-01 18-M ay-01 R 42.52
021 Bru fen 400-1200 mg PO R 0.00 30-M ay-01 09-Jun-01 R 34.31
021 D oloro l Forte 1016 mg PO R 0 .00 11-Jun-01 14-Jun-01 R 7.52
021 D oxyfene 1 tabs PO R 0.00 15-Jun-01 15-Jun-01 R 3.59
021 H eparin 2000 iu SC R 117.48 30-M ay-01 09-Jun-01 R 30.80
021 K exe la te 60 9 PO R 0.00 12-Jun-01 15-Jun-01 R 521.55
021 Las ix 20 mg IV R 19.39 04-Jun-01 04-Jun-01 R 2.61
021 M orph ine 10 mg IM R 3.56 29-M ay-01 29-M ay-01 R 7.09
021 P ethed ine 75 mg IM R 3.56 04-Jun-01 04-Jun-01 R 14.03
021 P ethed ine 50 mg IM R 3.56 14-Jun-01 14-Jun-01 R 7.38
021 Phenargan 25 mg IM R 3.56 14-Jun-01 14-Jun-01 R 0.84
021 V o lta ren 75 mg IM R 32.04 15-Jun-01 17-Jun-01 R 23.56
021 V o lta ren 75 mg IM R 3 .56 04-Jun-01 04-Jun-01 R 7.85
022 A troven t 0 .25-1 .25 m g INH R 0.00 30-M ay-01 03-Jun-01 R 132.98
022 M orph ine 10-40 mg IM R 53.40 30-M ay-01 03-Jun-01 R 141.75
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022 P ethed ine 75 mg IM R 3.56 30-M ay-01 30-M ay-01 R 14.03
022 T e tanus  toxo id 0.5 ml IM R 3.56 30-M ay-01 30-M ay-01 R 35.68
022 V a lium 10 mg PO R 0.00 03-Jun-01 03-Jun-01 R 11.72
022 V a lium 20 mg IM R 3.56 03-Jun-01 03-Jun-01 R 23.45
022 V ento lin 5-25 mg INH R 0.00 30-M ay-01 03-Jun-01 R 76.61
025 M axa lon 10 mg IM R 3.56 21-Jun-01 21-Jun-01 R 6.99
025 M axalon 10 mg IM R 3.56 23-Jun-01 23-Jun-01 R 6.88
025 M orph ine 20-40 mg IV R 19.39 20-Jun-01 25-Jun-01 R 170.10
028 Brufen 1200 mg PO R 0.00 07-Aug-01 16-Aug-01 R 31.19
028 D oloro l Forte 2032 mg PO R 0.00 07-Aug-01 12-Aug-01 R 22.56
028 M orph ine 10 mg IM R 32.04 03-Aug-01 05-Aug-01 R 21.27
028 S tem etil 12.5 mg IM R 3.56 05-Aug-01 05-Aug-01 R 9.19
030 H eparin 10000 iu SC R 64 .08 15-Aug-01 20-Aug-01 R 83.88
030 Losec 20 mg PO R 0.00 21 -Aug-01 continu ing R 393.77
030 M orph ine 10-20 mg IM R 3.56 15-Aug-01 15-Aug-01 R 14.18
030 P ethed ine 75 mg IM R 3.56 15-Aug-01 15-Aug-01 R 14.03
030 S tem etil 12.5 mg IM R 3.56 17-Aug-01 17-Aug-01 R 9.19
030 T a g a m e t 400-800 mg IV R 19.39 15-Aug-01 20-Aug-01 R 88.92
031 Lam ictin 400 9 PO R 0.00 23-Aug-01 30-Aug-01 R 103.84
031 M orph ine 10-30 mg IM R 53 .40 23-Aug-01 27-Aug-01 R 106.35
031 S tem etil 12.5 m g IM R 3.56 24-Aug-01 24-Aug-01 R 9.19
036 A m ytryp tiline 25 mg PO R 0.00 13-Sep-01 26-Sep-01 R 15.49
036 Isord il 0.5 m g SL R 0.00 17-Sep-01 26-Sep-01 R 7.18
036 Lasix 5-10 mg IV R 19.39 15-Sep-01 18-Sep-01 R 22.36
036 Losec 200 mg PO R 0 .00 17-Sep-01 18-Oct-O1 R 449.92
036 M orph ine 10-50 mg IM R 85.44 14-Sep-01 21-Sep-01 R 283.60
036 S tem etil 25 mg IM R 3.56 14-Sep-01 14-Sep-01 R 212.70
036 S tem etil 12.5 mg IM R 21 .36 22-Sep-01 23-Sep-01 R 18.38
038 M orph ine 10-30 mg IM R 21.36 28-O ct-01 29-O ct-01 R 42.54
040 A tro ve n t 0.25-1 mg INH R 0 .00 10-O ct-01 15-Oct-O1 R 127.66
040 B ero tec 1.25-6.25 mg INH R 0.00 10-Oct-01 15-O ct-01 R 167.82
040 M orph ine 20-40 mg IM R 53.40 06-O ct-01 10-Oct-01 R 141.80




CONCOMITANT MEDICATION / TREATMENT GROUP A / ITT








042 A troven t 0.5-1.5 mg INH R 0.00 19-Oct-O1 10-Nov-01 R 734.16
042 B ero tec 1.25-3.75 mg INH R 0.00 19-Oct-O1 10-Nov-01 R 385.71
042 C anestan  C ream U N K U N K PV R 0.00 06-Nov-01 08-Nov-01 R 167.22
042 D oloro l Forte 1016 m g PO R 0.00 29-O ct-01 29-O ct-01 R 1.88
042 D oloro l Forte 1016 mg PO R 0.00 31-O ct-01 31 -Oct-01 R 1.88
042 D o lo ro l Forte 1016-4064 m g PO R 0.00 03-Nov-01 15-Nov-01 R 97.76
042 H eparin 5000-20000 iu SC R 74 .76 31 -O ct-01 06-Nov-01 R 195.72
042 Isord il 5 mg SL R 0.00 30-O ct-01 30-O ct-01 R 0.72
042 Lasix 20-40 mg PO R 0.00 23-Oct-Q1 16-Nov-01 R 95.29
042 M axa lon 10 mg IM R 3.56 27-O ct-01 27-O ct-01 R 6.88
042 M axa lon 10-20 mg IM R 42.72 31-O ct-01 03-N ov-01 R 55.01
042 M axalon 10 mg IM R 21.36 05-Nov-01 06-Nov-01 R 6.88
042 M axa lon 20-30 mg PO R 0.00 09-Nov-01 10-Nov-01 R 9.54
042 M axalon 20 mg PO R 0.00 12-Nov-01 13-Nov-01 R 6.36
042 M axalon 10 mg PO R 0.00 15-Nov-O I 15-Nov-01 R 1.59
042 M orph ine 10-40 mg IM R 117.48 01-Nov-01 11-Nov-01 R 311.96
042 M orph ine 10-20 mg IM R 74.76 19-Oct-O1 25-O ct-01 R 99.26
042 M orph ine 20 mg SC R 32.04 28-O ct-01 30-O ct-01 R 42.54
042 P ethed ine 50-100 mg IM R 42 .72 27-O ct-01 30-O ct-01 R 31.98
042 S enoko t 4 tabs PO R 0.00 13-Nov-01 13-Nov-01 R 1.76
044 M orph ine 15-60 mg IM R 53.40 21 -Nov-01 25-N ov-01 R 212.70
045 D oloro l Forte 3048 mg PO R 0.00 24-O ct-01 25 O c t 01 R 11.28
045 M orph ine 20-30 mg IV R 19.39 21 -O ct-01 23-O ct-01 R 63.81
047 D oxyfene 4 tabs PO R 0.00 31-O ct-01 03-Nov-01 R 57.49
047 M orph ine 20-50 mg IV R 19.39 28-O ct-01 30-O ct-01 R 106.35
049 A m ilo re tic 55 m g PO R 0.00 04-Nov-01 08-N ov-01 R 33.50
049 D oloro l Forte 2032 mg PO R 0.00 07-Nov-01 07-Nov-01 R 3.76
049 P rem arin 0.625 mg PO R 0.00 04-Nov-01 08-N ov-01 R 71.81
051 A troven t 0 .75-2 .25 mg INH R 0.00 12-Nov-01 19-Nov-01 R 382.99
051 B ero tec 2.5-7 .5 mg INH R 0.00 12-Nov-01 19-Nov-01 R 179.01
051 D oloro l fo rte 1016-3048 mg PO R 0.00 17-Nov-01 20-N ov-01 R 22.56
051 Losec 20 mg PO R 0.00 16-Nov-01 continu ing R 393.77














054 D oloro l Forte 1016-2032 mg PO R 0.00 22-N ov-01 24-N ov-O I R 11.28
054 M orph ine 10 mg IM R 32.04 19-Nov-01 2 1 -Nov-01 R 21.27
055 D oloro l Forte 1016 mg PO R 0.00 24-Nov-01 26-Nov-01 R 5.64
055 Losec 20 mg PO R 0.00 22-N ov-O I continu ing R 393.77
055 M orph ine 10-40 mg IM R 32.04 10-Dec-01 12-Dec-01 R 85.08
055 P ethed ine 150-200 mg IM R 32.04 20-Nov-01 22-N ov-01 R 47.97
055 P henargan 10-30 mg PO R 0.00 22-N ov-01 26-N ov-O I R 7.10
055 S tem etil 12.5 mg IM R 3.56 14-Dec-01 14-Dec-01 R 9.19
055 T a g a m e t 400 -1200 mg PO R 0.00 20-N ov-01 22-Nov-01 R 66.66
055 V a lium 10-20 mg PO R 0.00 11-Dec-01 13-Dec-01 R 70.35
059 D oloro l Forte 1016 mg PO R 0.00 14-Dec-01 14-Dec-01 R 1.88
059 M orph ine 10-40 mg IM R 32 .04 10-Dec-01 12-Dec-01 R 85.08
059 S tem etil 12.5 mg IM R 3.56 14-Dec-01 14-Dec-01 R 9.19
059 V a lium 10-20 mg PO R 0.00 11-D ec-01 13-Dec-01 R 70.35
060 A troven t 0.25-1 mg INH R 0.00 11-Dec-01 16-Dec-01 R 127.66
060 B ero tec 1.25-5 mg INH R 0.00 11-Dec-01 16-Dec-01 R 134.26
060 Pethed ine 100-300 mg IM R 74.76 10-Dec-01 16-Dec-01 R 167.89
061 A tro ve n t 0.25-1 mg INH R 0.00 17-Dec-01 21-D ec-01 R 106.38
061 B ero tec 1.25-5 mg INH R 0.00 17-Dec-01 2 1 -Dec-01 R 111.88
061 D oloro l 3 9 PO R 0.00 21 -Dec-01 2 1 -Dec-01 R 2.76
061 D u lco lax 10 mg PR R 0.00 21-D ec-01 21 -Dec-01 R 4.14
061 M orph ine 20-30 mg IM R 53.40 15-Dec-01 19-Dec-01 R 106.35
062 M orph ine 10-50 mg IM R 32.04 17-Dec-01 19-Dec-01 R 106.35
062 Panado 1000-2000 mg PO R 0.00 20-D ec-01 21 -Dec-01 R 4.28
062 S erepax 10 mg PO R 0.00 19-Dec-01 20-D ec-01 R 1.42
066 D oloro l Forte 1016-2032 mg PO R 0.00 06-Jan-02 09-Jan-02 R 15.04
066 M orph ine 20 mg IM R 3.56 06-Jan-02 06-Jan-02 R 14.18
068 A troven t 0 .25-3 mg INH R 0.00 15-Jan-02 21 -Jan-02 R 446.82
068 B ero tec 1.25-7.5 mg INH R 0.00 15-Jan-02 2 1 -Jan-02 R 234.95
068 D oloro l Forte 2032-4064 mg PO R 0.00 21 -Jan-02 23-Jan -02 R 22.56
068 D orm icum 9 mg IV R 0.92 12-Jan-02 12-Jan-02 R 53.63
068 H eparin 5000-15000 iu SC R 96.12 12-Jan-02 20-Jan-02 R 188.73
068 Lasix 5-10 mg IV R 0.92 15-Jan-02 16-Jan-02 R 11.18
CONCOMITANT MEDICATION / TREATMENT GROUP A / ITT
RANDOM





DATE STOP DATE COST
068 M orph ine 10-30 mg IM R 21.36 11-Jan-02 12-Jan-02 R 42.54
068 M orph ine 10-50 mg IV R 19.39 12-Jan-02 17-Jan-02 R 212.70
068 M orph ine 10-20 mg IM R 21.36 18-Jan-02 19-Jan-02 R 28.36
068 Panado 30-60 ml PO R 0.00 12-Jan-02 16-Jan-02 R 17.64
068 Panado 30 ml PO R 0 .00 19-Jan-02 19-Jan-02 R 17.64
068 U lsan ic 4 g PO R 0.00 12-Jan-02 18-Jan-02 R 74.44
071 A troven t 1.5-2.5 mg INH R 0.00 23-Jan-02 28-Jan-02 R 319.15
071 B ero tec 3.75-6 .25 mg INH R 0.00 23-Jan-02 28-Jan-02 R 167.82
071 D oloro l Forte 1016-2032 mg PO R 0.00 25-Jan -02 29-Jan-02 R 18.80
071 Losec 20 mg PO R 0.00 25-Jan-02 continu ing R 393.77
071 M orph ine 10-30 mg IM R 32.04 22-Jan-02 24-Jan -02 R 63.81
071 N eostigm ine 0.5 mg IV R 0.92 22-Jan-02 22-Jan -02 R 3.09
071 N im bex 12 mg IV R 0.92 22-Jan-02 22-Jan-02 R 298.17
071 P henylephrine 250 mg IV R 0.92 22-Jan -02 22-Jan -02 R 993.58
071 R obinul 2.5 mg IV R 0.92 22-Jan-02 22-Jan-02 R 882.36
071 T a g a m e t 800 mg IV R 19.39 24-Jan-02 25-Jan -02 R 29.64
072 D oloro l Forte 1016-2032 mg PO R 0.00 25-Jan-02 10-Feb-02 R 63.92
072 M orph ine 20-30 mg IM R 21 .36 23-Jan-02 24-Jan-02 R 42.54
073 A troven t 0.5-2 m g INH R 0.00 01-Feb-02 04-Feb-02 R 170.22
073 B ero tec 1.25-5 m g INH R 0.00 01-Feb-02 04-Feb-02 R 89.50
073 D oloro l Forte 1016 mg PO R 0.00 13-Feb-02 15-Feb-02 R 5.64
073 M axalon 10-20 mg IM R 53.40 08-Feb-02 12-Feb-02 R 68.76
073 M orph ine 10-50 m g IM R 64 .08 08-Feb-02 13-Feb-02 R 212.70
073 P ethed ine 75-300 m g IM R 85.44 23-Jan-02 30-Jan-02 R 191.88
073 Pethed ine 75 mg IM R 3.56 08-Feb-02 08-Feb-02 R 14.03
074 D oloro l 3 9 PO R 0.00 03-Feb-02 06-Feb-02 R 10.96
074 M axa lon 10 mg IM R 3.56 30-Jan-02 30-Jan-02 R 6.88
074 M orph ine 10-30 mg IM R 42 .72 29-Jan-02 01 -Feb-02 R 85.08
074 V o lta ren 75-150 m g IM R 21.36 30 -Jan-02 31-Jan-02 R 31.42
075 D oloro l Forte 1016-2032 mg PO R 0.00 25-Feb-02 03-M ar-02 R 26.32
075 Losec 20 mg PO R 0.00 22-Feb-02 con tinu ing R 393.77
075 M orph ine 10-30 mg IM R 53.40 18-Feb-02 22-Feb-02 R 106.35
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075 T a g a m e t 800-1200 m g IM R 53.40 18-Feb-02 22-Feb-02 R 111.15
078 A ctrap id 5-10 iu IV R 0 .92 28-Feb-02 01 -M ar-02 R 233.41
078 A d rena line 2-30 m g IV R 0.92 25-Feb-02 10-M ar-02 R 1,367.32
078 A m ioda rone 150-300 m g IV R 0.92 02-M ar-02 07-M ar-02 R 143.09
078 A m ioda rone 200 mg IV R 0.92 08-M ar-02 13-M ar-02 R 81.77
078 A troven t 1-3 m g INH R 0 .00 26-Feb-02 26-F eb-02 R 63.83
078 A tro ve n t 1-3 mg INH R 0.00 11-M ar-02 12-M ar-02 R 127.68
078 B ero tec 2.5-7 .5 mg INH R 0.00 26-Feb-02 26-Feb-02 R 33.56
078 B ero tec 2 .5 -7 .5 mg INH R 0.00 11-M ar-02 12-M ar-02 R 67.08
078 D igoxin 0.75 mg IV R 19.39 27-Feb-02 27-Feb-02 R 14.48
078 D igoxin 0 .125-0 .5 mg PO R 0.00 13-M ar-02 15-M ar-02 R 4.50
078 D igoxin 0 .125-0 .5 mg PO R 0.00 13-M ar-02 15-M ar-02 R 1.80
078 D itropan 5-15 mg PO R 0.00 07-M ar-02 12-M ar-02 R 73.38
078 D obutrex 300-600 mg IV R 0.92 01-M ar-02 11-M ar-02 R 11,525.00
078 D obutrex 20-25 mg IV R 0.92 26-Feb-02 27-Feb-02 R 12.00
078 D obu trex 100-500 mg IV R 0.92 13-M ar-02 15 -M ar-02 R 2,881.26
078 H eparin 5000-10000 iu SC R 42 .72 25-Feb-02 28-Feb-02 R 55.92
078 H eparin 5000-15000 iu SC R 64.08 28-Feb-02 03-M ar-02 R 125.82
078 H eparin 10000-15000 iu SC R 96.12 04-M ar-02 12-M ar-02 R 188.73
078 Intropin 100-400 mg IV R 0.92 27-Feb-02 06-M ar-02 R 1,100.05
078 K exe la te 20-90 g PO R 0.00 27-Feb-02 02-M ar-02 R 782.32
078 Lasix 10-1500 mg IV R 0.92 26 -Feb-02 09-M ar-02 R 3,161.11
078 Lasix 20 mg IV R 0.92 11-M ar-02 12 -M ar-02 R 22.36
078 Losec 20 mg PO R 0.00 27 -Feb-02 12-M ar-02 R 393.77
078 M orph ine 10-30 mg IM R 32.04 23 -Feb-02 25-Feb-02 R 63.81
078 M orph ine 2-30 m g IV R 0.92 25-Feb-02 28-Feb-02 R 85.08
078 Panado 30 ml PO R 0 .00 02-M ar-02 02-M ar-02 R 15.47
078 R en itec 20 mg PO R 0.00 12-M ar-02 12-M ar-02 R 213.72
078 R en itec 20 mg PO R 0.00 12-M ar-02 12-M ar-02 R 213.72
078 S prino lactine 50 mg PO R 0.00 08-M ar-02 12-M ar-02 R 25.73
078 S tem etil 12.5 m g IM R 3.56 24-Feb-02 24-F eb-02 R 9.19
078 T h iam ine 100 mg IV R 0.92 14-M ar-02 12-M ar-02 R41.33
078 U lsan ic 1-4 9 PO R 0.00 26-Feb-02 02-M ar-02 R 53.17
Appendix C 3.1
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078 V ita m in e  B C om p lex 1 ml IV R 0.92 14-M ar-02 12-M ar-02 R 24.20
079 D oloro l Forte 1016-4064 mg PO R 0.00 08-M ar-02 23-M ar-02 R 45.12
079 Lasix 20-40 mg IV R 19.39 24-Feb-02 25-F eb-02 R 44.72
079 M orph ine 30 mg IM R 3.56 24-Feb-02 24-Feb-02 R 21.27
079 M orph ine 20 m g IM R 3.56 26-Feb-02 26-Feb-02 R 14.18
081 A troven t 1.5-2 mg INH R 0.00 14-M ar-02 19-M ar-02 R 255.32
081 B ero tec 1.25-5 mg IM R 74.76 26-Feb-02 04-M ar-02 R 156.63
081 B ero tec 3.76-5 mg INH R 0.00 14-M ar-02 19 -M ar-02 R 134.26
081 Brufen 200 mg PO R 0 .00 05-M ar-02 12-M ar-02 R 4.16
081 D o lo ro l Forte 1016-2032 m g PO R 0.00 05-M ar-02 12-M ar-02 R 30.08
081 D oloro l Forte 1016 mg PO R 0.00 26-M ar-02 30-M ar-03 R 9.40
081 H eparin 5000-10000 iu SC R 74.76 20-M ar-02 26-M ar-02 R 97.86
081 H eparin 5000 iu SC R 3.56 20-M ar-02 20 -M ar-02 R 6.99
081 M axalon 10 mg IM R 3.56 20-M ar-02 20-M ar-02 R 6.88
081 M axa lon 10 m g IV R 0.92 20-M ar-02 20-M ar-02 R 6.99
081 M orph ine 40 mg IV R 19.39 20-M ar-02 20-M ar-02 R 28.36
081 M orph ine 10-20 mg IM R 42 .72 27-Feb-02 02-M ar-02 R 56.72
081 M orph ine 10-40 m g IM R 138.84 13-M ar-02 25 -M ar-02 R 368.68
081 N eostigm ine 2.5 mg IV R 0.92 20-M ar-02 20-M ar-02 R 6.54
081 P ethed ine 100 mg IM R 3.56 20-M ar-02 20-M ar-02 R 7.99
081 R obinu l 0.8 mg IV R 0.92 20-M ar-02 20 -M ar-02 R 294.12
081 S tem etil 12.5 mg IM R 21 .36 15-M ar-02 16-M ar-02 R 18.38
081 S tem etil 12.5 m g IM R 3.56 20-M ar-02 20-M ar-02 R 9.19
081 V ento lin 200 ug INH R 0.00 1990 ongoing R 46.26
085 D oloro l Forte 1016-2032 m g PO R 0.00 20-M ar-02 21 -M ar-02 R 7.52
085 M orph ine 30-40 mg IV R 19.39 18-M ar-02 19-M ar-02 R 56.72
088 D oloro l Forte 1016 mg PO R 0 .00 07-A pr-02 11-A pr-02 R 9.40
088 P ethed ine 50-100 m g IV R 19.39 03-A pr-02 05 -A pr-02 R 23.98
090 D oloro l Forte 1016-3048 mg PO R 0.00 23-A pr-02 02-M ay-02 R 56.40
090 M orph ine 20-30 m g IM R 21.36 21 -A pr-02 22-A pr-02 R 42.54
090 S tem etil 12.5 mg IM R 3.56 21 -A pr-02 2 1 -A pr-02 R 9.19
091 A cebu to lo l 1 mg IV R 0.92 17-M ay-02 17-M ay-02 R 47.30




CONCOMITANT MEDICATION / TREATMENT GROUP A / ITT






DATE STOP DATE COST
091 A drena line 20-50 mg IV R 19.39 10-M ay-02 12-M ay-02 R 683.66
091 A drena line 40-100 mg IV R 0.92 14-M ay-02 18-M ay-02 R 2,278.86
091 A tro ve n t 0 .25-1 .25 mg INH R 0.00 06-M ay-02 17-M ay-02 R 319.15
091 B ero tec 1.25-7.5 mg INH R 0.00 06-M ay-02 17-M ay-02 R 402.77
091 D obutrex 200 mg IV R 0.92 17-M ay-02 17-M ay-02 R 384.17
091 D oloro l Forte 1016-3048 mg PO R 0.00 07-M ay-02 09-M ay-02 R 16.92
091 D orm icum 4 mg IV R 0.92 09-M ay-02 09-M ay-02 R 26.81
091 D orm icum 2-50 mg IV R 0.92 13-M ay-02 14-M ay-02 R 328.50
091 D ura tears 02-Jan drops EYE R 0.00 16-M ay-02 17-M ay-02 R 46.16
091 H eparin 5000-10000 iu SC R 64 .08 12-M ay-02 17-M ay-02 R 83.88
091 Lasix 10-20 mg PO R 0.00 09-M ay-02 11-M ay-02 R 7.84
091 Lasix 40-500 mg IV R 0.92 14-M ay-02 17-M ay-02 R 351.23
091 Lorazepan 2 mg IV R 0.92 11-M ay-02 11-M ay-02 R 2.40
091 Losec 20 mg PO R 0.00 03-M ay-02 09-M ay-02 R 112.50
091 Losec 20 mg PO R 0.00 11-M ay-02 17-M ay-02 R 98.44
091 M orph ine 10-20 mg IM R 53.40 01-M ay-02 05-M ay-02 R 70.90
091 M orph ine 2-20 mg IV R 0.92 09-M ay-02 16-M ay-02 R 113.44
091 Panado 30-120 ml PO R 0.00 10-M ay-02 17-M ay-02 R 17.64
091 Pavulon 12.5 mg IV R 0.92 17-M ay-02 17-M ay-02 R 92.07
091 P en ie le fe rine 10-40 mg IV R 0 .9 2 17-M ay-02 18-M ay-02 R 397.43
091 P ropofo l 12 ml IV R 0.92 14-M ay-02 14-M ay-02 R 174.43
091 S e repax 10 mg PO R 0.00 05-M ay-02 07-M ay-02 R 2.12
091 S erepax 10 mg PO R 0.00 09-M ay-02 14-M ay-02 R 4.25
091 S o lu -co rte f 100 mg IV R 0.92 17-M ay-02 17-M ay-02 R 31.82
091 U lsan ic 1 9 PO R 0.00 09-M ay-02 11-M ay-02 R 7.98
091 U lsan ic 1 9 PO R 0.00 15-M ay-02 17-M ay-02 R 7.98
093 D oloro l Forte 2032 mg PO R 0.00 14-M ay-02 14-M ay-02 R 3.76
093 M orph ine 20 mg IV R 19.39 12-M ay-02 13-M ay-02 R 28.36
093 Pethed ine 100 mg IM R 21.36 11-M ay-02 12-M ay-02 R 15.99
093 V o lta ren 75 mg IM R 10.68 13-M ay-02 13-M ay-02 R 7.85
095 D oloro l Forte 1016-4064 mg PO R 0.00 25-Jun-02 30-Jun-02 R 45.12
095 D oloro l Forte 1016-4064 mg PO R 0 .00 10-Jul-02 12-Jul-02 R 10.82




CONCOMITANT MEDICATION / TREATMENT GROUP A / ITT







095 M axa lon 10 m g PO R 0.00 24-Jun-02 24-Jun -02 R 1.59
095 M orph ine 10-40 mg IM R 53.40 20-Jun-02 24-Jun-02 R 141.80
095 P ethed ine 50 m g IM R 32.04 07-Ju l-02 09-Ju l-02 R 22.15
095 S tem etil 25 mg IM R 7.12 22-Jun -02 22-Jun-02 R 18.38
095 S tem etil 12.5 m g IM R 3.56 24-Jun-02 24-Jun-02 R 9.19
097 M orph ine 30-40 m g IV R 0.92 25-Ju l-02 26 -Ju l-02 R 56.72
097 T ag a m e t 200-800 mg IV R 19.39 25-Ju l-02 29-Ju l-02 R 74.10
100 A tro ve n t 0.5-2.5 m g INH R 0.00 04-M ay-02 12-M ay-02 R 478.73
100 B ero tec 1.25-6.25 mg INH R 0.00 04-M ay-02 12-M ay-02 R 251.73
100 D oloro l Forte 1016-3048 mg IV R 19.39 04-M ay-02 05-M ay-02 R 11.28
100 D oloro l Forte 1016-2032 m g IV R 0.92 09-M ay-02 12-M ay-02 R 15.04
100 H eparin 5000-10000 iu SC R 106.80 02-M ay-02 11-M ay-02 R 139.80
100 M orph ine 10-40 mg IM R 72.45 02-M ay-02 08-M ay-02 R 198.52
| TO TA L | R 4,495.72 R 62,278.43




CONCOMITANT MEDICATION / TREATMENT GROUP B / ITT
IN HOSPITAL MEDICATION DAILY
DOSAGE UNITS ROUTE
CONSUM-ABLES START DATE STOP DATE COST
001 A kine ton 4 g PO R 0.00 10-M ar-01 ongo ing R 128.79
001 B ayer A sp irin 2 g PO R 0.00 16-M ar-01 18-M ar-01 R 25.99
001 D orm icum 7.5 m g IV R 0.92 16-Feb-01 16-Feb-01 R 40.22
001 M axa lon 10 m g IV R 19.39 17-Feb-01 21-Feb-01 R 6.88
001 M orph ine 10 m g IM R 96.12 16-Feb-01 24-Feb-01 R 63.81
001 Servatrin 37.5 m g PO R 0.00 unk ongoing R 54.40
002 D oloro l 2000 m g PO R 0.00 23-Feb-01 23-Feb-01 R 0.91
002 M orph ine 10-40 m g IM R 53.40 20-Feb-01 24-Feb-01 R 141.80
006 A tro ve n t 0.25-1 .5 m g INH R 0.00 05-Apr-01 29-Apr-01 R 797.89
006 B ero tec 1.25-7.5 m g INH R 0.00 05-Apr-01 29-Apr-01 R 839.10
006 Brufen 400 mg PO R 0.00 22-Apr-01 29-Apr-01 R 28.07
006 D oloro l Forte 1016-3048 m g PO R 0.00 15-Apr-01 29-Apr-01 R 84.44
006 Fybogel 3.5-7 g PO R 0.00 22-Apr-01 28-Apr-01 R 32.24
006 H eparin 5000-10000 iu SC R 64 .08 05-Apr-01 10-Apr-01 R 83.88
006 M orph ine 20 mg IM R 32.04 03-Apr-01 05-Apr-01 R 42.54
006 Panado 30-120 m l PO R 0.00 05-Apr-01 08-Apr-01 R 17.64
006 P eth id ine 75-300 mg IM R 53.40 26-M ar-01 30-M ar-01 R 119.92
006 S tem etil 12.5 mg IM R 3.56 04-Apr-01 04-Apr-01 R 9.19
006 V a lium 10-30 mg PO R 0.00 30-M ar-01 02 -Apr-01 R 140.69
006 V o lta ren 75 mg IM R 32.04 27-M ar-01 29-M ar-01 R 23.56
008 A d rena line 5-15 mg IV R 0.92 04-Apr-01 17-Apr-01 R 68.37
008 A troven t 2 mg INH R 0.00 29-M ar-01 17-Apr-01 R 851.08
008 B ero tec 5 mg INH R 0.00 29-M ar-01 17-Apr-01 R 447.52
008 D obutrex 250 mg IV R 0.92 29-M ar-01 06-Apr-01 R 4,321.89
008 D orm icum 200-250 mg IV R 19.39 31-M ar-01 17-Apr-01 R 14,782.61
008 H eparin 5 - 25000 iu SC R 96.12 29-M ar-01 06-Apr-01 R 311.31
008 Insu lin 5-15 iu IV R 0.92 07-Apr-01 17-Apr-01 R 2,567.51
008 Lasix 20-40 mg IV R 0.92 01 -M ar-01 12-Apr-01 R 983.94
008 M axa lon 20 mg IV R 0.92 30-M ar-01 30-M ar-01 R 13.76
008 M orph ine 5-10 mg IV R 0.92 31-M ar-01 17-Apr-01 R 127.62




CONCOMITANT MEDICATION / TREATMENT GROUP B / ITT
IN HOSPITAL MEDICATION DAILY
DOSAGE UNITS
ROUTE CONSUM-ABLES START DATE STOP DATE COST
008 Pavulon 8-20 m g IV R 0.92 16-Apr-01 17-Apr-01 R 263.04
008 P eth id ine 150 m g IM R 10.68 28-M ar-01 28-M ar-01 R 15.38
008 P redn isone 40 m g PO R 0.00 07-Apr-01 12-Apr-01 R 105.17
008 S olu  C o rte f 100-300 m g INH R 0.00 29-M ar-01 06-Apr-01 R 859.07
011 D o lo ro l Forte 1016-2032 m g PO R 0.00 18-Apr-01 19-Apr-01 R 7.51
011 M orph ine 10-30 m g IM R 42.72 11-Apr-01 14-Apr-01 R 113.44
012 P anado 1-3 9 PO R 0.00 16-Apr-01 19-Apr-01 R 12.83
012 P eth id ine 75-200 m g IM R 32.04 15-Apr-01 17-Apr-01 R 47.97
013 A tro ve n t 0 .5 -0 .75 mg INH R 0.00 01-M ay-01 07-M ay-01 R 111.70
013 B ero tec 2 .5-3 .75 m g INH R 0.00 01 -M ay-01 07-M ay-01 R 117.47
013 F lam azine 1 app lic TO P R 0.00 02-M ay-01 09-M ay-01 R 89.90
013 M orph ine 20-40 m g IM R 21.36 01 -M ay-01 02-M ay-01 R 56.72
013 T h iam ine 100 m g IM R 42.72 04-M ay-01 07-M ay-01 R 82.66
013 V a lium 10 m g PO R 0.00 04-M ay-01 05-M ay-01 R 23.45
015 P eth id ine 150-200 mg IM R 64.08 09-M ay-01 14-M ay-01 R 95.94
017 B ru fen 600 m g PO R 0.00 20-M ay-01 27-M ay-01 R 16.02
017 D oloro l Forte 1016 mg PO R 0.00 16-M ay-01 20-M ay-01 R 9.40
017 D o lo ro l Forte 3048 m g PO R 0.00 21 -M ay-01 27-M ay-01 R 39.48
017 M orph ine 10-30 mg IM R 42.72 15-M ay-01 18-M ay-01 R 85.08
017 P eth id ine 75 m g IM R 10.68 15-M ay-01 15-M ay-01 R 14.03
017 S tem etil 12.5 mg IM R 7.12 16-M ay-01 17-M ay-01 R 18.38
020 D o lo ro l Forte 1016 m g PO R 0.00 21 -M ay-01 2 1 -M ay-01 R 1.88
020 M orph ine 10-30 mg IM R 64.08 22-M ay-01 27-M ay-01 R 127.62
020 M orph ine 10 m g IV R 19.39 27-M ay-01 27-M ay-01 R 7.09
020 P eth id ine 50-100 mg IV R 0.92 20-M ay-01 21-M ay-01 R 15.99
020 T e ta n u s  Toxo id 0.5 m l IM R 3.56 20-M ay-01 20-M ay-01 R 35.68
023 H eparin 4000 iu SC R 32.04 11-Jun-01 13-Jun-01 R 16.80
023 M orph ine 20 m g IM R 3.56 11-Jun-01 11-Jun-01 R 14.18
023 P eth id ine 50 mg IM R 3.56 10-Jun-01 10-Jun-01 R 7.38
024 A troven t 0.25 m g INH R 0.00 23-Jun-01 25-Jun-01 R 15.96
024 B ero tec 1.25 mg INH R 0.00 23-Jun-01 25-Jun-01 R 16.78
CONCOMITANT MEDICATION / TREATMENT GROUP B / ITT
RANDOM
NUMBER IN HOSPITAL MEDICATION DAILY
DOSAGE UNITS
ROUTE CONSUM-ABLES START DATE STOP DATE COST
024 D o lo ro l Forte 1016 mg PO R 0.00 25-Jun-01 25-Jun-Q1 R 1.88
024 H eparin 5000-10000 iu SC R 32.04 19-Jun-01 21-Jun-01 R 41.94
024 M orph ine 10-30 mg IM R 74.76 19-Jun-01 25-Jun-01 R 148.89
024 S tem etil 12.5 m g IM R 3.56 23-Jun-01 23-Jun-01 R 9.19
026 M orph ine 20-50 mg IM R 53.40 01 -Jul-01 05-Jul-01 R 212.70
026 P eth id ine 75 mg IM R 3.56 30-Jul-01 30-Jul-01 R 14.03
027 Losec 20 m g PO R 0.00 06-Aug-01 06-Aug-01 R 14.06
027 M orph ine 10 mg IM R 53.40 02-Aug-01 06-Aug-01 R 42.54
027 S tem etil 12.5 mg IM R 3.56 06-Aug-01 06-Aug-01 R 9.19
027 T a g a m e t 800-600 m g IV R 19.39 03-Aug-01 06-Aug-01 R 49.32
029 H eparin 5000-10000 iu SC R 74.76 10-Aug-01 16-Aug-01 R 97.86
029 M orph ine 10-30 mg IM R 53.40 10-Aug-01 14-Aug-01 R 106.35
029 S tem etil 12.5 mg IV R 19.39 12-Aug-01 18-Aug-01 R 64.33
032 Losec 20 mg PO R 0.00 27-Aug-01 con tinue ing R 393.77
032 P eth id ine 75-400 mg IM R 85.44 23-Aug-01 30-Aug-01 R 255.83
032 S tem etil 12.5-25 mg IM R 7.12 26-Aug-01 27-Aug-01 R 36.76
033 D o lo ro l 1-3 9 PO R 0.00 14-Sep-01 15-Sep-01 R 5.52
033 M orph ine 30-60 mg IM R 42.72 10-Sep-01 13-Sep-01 R 170.16
033 S tem etil 12.5 mg IM R 3.56 10-Sep-01 10-Sep-01 R 9.19
033 T e ta n u s  T oxo id 0.5 ml SC R 3.56 09-Sep-01 09-Sep-01 R 5.68
033 T h iam ine 200 m g PO R 0.00 13-Sep-01 14-Sep-01 R 0.90
033 V itC 1000 mg PO R 0.00 13-Sep-01 14-Sep-01 R 0.81
034 M orph ine 10-40 mg IM R 32.04 12-Sep-01 14-Sep-01 R 85.08
035 A troven t 0 .25-0 .75 mg INH R 0.00 14-Sep-01 24-Sep-01 R 159.58
035 B ero tec 1.25-3.75 mg INH R 0.00 14-Sep-01 24-Sep-01 R 184.60
035 D isprin 150 mg PO R 0.00 19-Sep-01 26-Sep-01 R 1.12
035 D oxyfene 2-4 tab le ts PO R 0.00 19-Sep-01 21 -Sep-01 R 43.08
035 F lee t Enem a 1 bottle PR R 0.00 18-Sep-01 20-Sep-01 R 15.05
035 H eparin 5000-15000 iu SC R 85.44 13-Sep-01 20-Sep-01 R 167.76
035 M axa lon 20 m g PO R 0.00 18-Sep-01 20-Sep-01 R 3.18




CONCOMITANT MEDICATION / TREATMENT GROUP B / ITT
IN HOSPITAL MEDICATION DAILY
DOSAGE UNITS ROUTE CONSUM-ABLES START DATE STOP DATE COST
035 Z es to re tic 1 tab le ts PO R 0.00 NA NA R 123.82
037 D o lo ro l Forte 1016-2032 mg PO R 0.00 01-O ct-01 03-O ct-01 R 5.64
037 M orph ine 30 m g IM R 3.56 27-Sep-01 27-Sep-01 R 21.27
037 M orph ine 10 mg IM R 3.56 29-O ct-01 29-O ct-01 R 7.09
039 M orph ine 30 mg IM R 32.04 01-O ct-01 03-O ct-01 R 63.81
039 S tem etil 12.5 mg IM R 3.56 02-O ct-01 02-O ct-01 R 9.19
041 D o lo ro l Forte 1016-3048 mg PO R 0.00 18-Oct-O1 30-O ct-01 R 73.32
041 D oxyfene 4 caps PO R 0.00 18-Oct-Q1 22-O ct-01 R 71.80
041 H eparin 5000-15000 iu SC R 74.76 12-Oct-O1 18-Oct-O1 R 125.82
041 P eth id ine 150-200 mg IM R 53.40 10-Oct-01 14-Oct-01 R 79.95
043 M orph ine 10-30 mg IM R 64 .08 19-Oct-O1 24-O ct-01 R 127.62
046 C anesten  C ream 1-3 NA PV R 0.00 01 -Nov-01 05-N ov-01 R 167.22
046 D orm icum 100-140 m g IV R 0.92 23-O ct-01 25-O ct-01 R 1,478.26
046 H eparin 10000-15000 iu SC R 117.48 24-O ct-01 03-Nov-01 R 230.67
046 M axa lon 10-30 mg IM R 32.04 28-O ct-01 30-O ct-01 R 61.89
046 M axa lon 10 mg IM R 3.56 02-Nov-01 02-Nov-01 R 6.99
046 M orph ine 5-70 mg IV R 19.39 23-O ct-01 31-O ct-01 R 446.67
046 M orph ine 10-30 m g IM R 32.04 31-O ct-01 02-Nov-01 R 63.81
046 S e rapax 20 mg PO R 0.00 29-O ct-01 30-O ct-01 R 2.83
046 U lsan ic 1-4 9 PO R 0.00 25-O ct-01 0 1 -Nov-01 R 85.07
046 V o lta ren 150 mg IM R 21.36 29-O ct-01 30-O ct-01 R 31.42
046 V o lta ren 75 mg IM R 3.56 03-NOV-01 03-N ov-01 R 7.85
048 A tro ve n t 0.5-2.5 m g INH R 0.00 30-O ct-01 05-Nov-01 R 372.35
048 B ero tec 1.25-6.25 mg INH R 0.00 30-O ct-01 05-Nov-01 R 195.79
048 M orph ine 10-30 mg IM R 64.08 29-O ct-01 03-N ov-01 R 127.62
050 D epo  P ruvera 1 am p IM R 3.56 R 21.01
050 D o lo ro l Forte 1016 mg PO R 0.00 10-Nov-01 12-Nov-01 R 5.64
050 Indocid 100-300 m g PR R 0.00 08-N ov-01 11-Nov-01 R 147.59
050 M axa lon 10 mg IM R 3.56 09-Nov-01 09-Nov-01 R 6.88
050 M orph ine 7.5-30 mg IM R 21.36 08-Nov-01 09-N ov-01 R 42.54




CONCOMITANT MEDICATION / TREATMENT GROUP B / ITT
IN HOSPITAL MEDICATION DAILY
DOSAGE
UNITS ROUTE CONSUM-ABLES START DATE STOP DATE COST
052 A trop ine 3 mg IV R 0.92 17-Nov-01 17-Nov-01 R 16.67
052 C a lc ium  G lusona te 10 ml IV R 0.92 17-Nov-01 17-Nov-01 R 9.14
052 L ignoca ine 80 m g IV R 0.92 17-Nov-01 17-N ov-O I R 37.67
052 M orph ine 20 mg IM R 3.56 17-Nov-01 17-Nov-01 R 14.18
053 D oloro l Forte 1016-2032 mg PO R 0.00 21 -Nov-01 23-N ov-01 R 11.28
053 M orph ine 20 m g IM R 3.56 19-N ov-O I 19-Nov-01 R 14.18
056 Bru fen 600 mg PO R 0.00 01-D ec-01 08-D ec-01 R 16.02
056 D oloro l Forte 3048 m g PO R 0.00 01-D ec-01 18-Dec-01 R 101.52
056 V o lta ren 75 m g IM R 32.04 27-N ov-O I 29-N ov-01 R 23.56
056 V o lta ren 75 m g IM R 32.04 27-N ov-01 29-N ov-01 R 23.56
057 M orph ine 10-30 m g IM R 32.04 03-D ec-01 05-D ec-01 R 63.81
058 D oloro l Forte 1016 m g PO R 0.00 10-Dec-01 11-Dec-01 R 3.76
058 D o lo ro l Forte 1016 m g PO R 0.00 15-Dec-01 15-Dec-01 R 1.88
058 D o lo ro l Forte 1016 m g PO R 0.00 10-Dec-01 11-Dec-01 R 3.76
058 M orph ine 20-30 m g IM R 32.04 09-D ec-01 10-Dec-01 R 42.54
058 M orph ine 20-30 m g IV R 0.92 09-D ec-01 10-D ec-02 R 42.54
058 S tem etil 12.5-25 m g IM R 32.04 11-D ec-01 13-Dec-01 R 55.14
058 S tem etil 12.5-25 m g IM R 32.04 11-D ec-01 13-Dec-01 R 55.14
063 M orph ine 20-40 m g IM R 53.40 17-Dec-01 21-Dec-01 R 141.80
063 M orph ine 10 m g IM R 3.56 23-D ec-01 23-D ec-01 R 7.09
063 V o lta ren 75 m g IM R 74.76 17-Dec-01 23-D ec-01 R 54.98
064 D oloro l Forte 2032 m g PO R 0.00 21 -D ec-01 21-Dec-01 R 3.76
064 M orph ine 10-40 m g IM R 53.40 17-Dec-01 21-Dec-01 R 141.80
065 D o lo ro l Forte 2032-3048 m g PO R 0.00 07-Jan-02 11-Jan-02 R 28.20
065 M orph ine 30-40 m g IM R 53.40 02-Jan-02 06-Jan-02 R 170.16
067 P eth id ine 75-150 m g IM R 32.04 05-Jan -02 07-Jan-02 R 46.14
069 A tro ve n t 0.25-1 m g INH R 0.00 14-Jan-02 18-Jan-02 R 106.38
069 B ero tec 1.25-5 mg INH R 0.00 14-Jan-02 18-Jan-02 R 111.88
069 M axa lon 10-20 mg IM R 21.36 13-Jan-02 14-Jan-02 R 27.51
069 M orph ine 10-30 m g IM R 42.72 13-Jan-02 16-Jan-02 R 85.08
070 A tro ve n t 0.5-2 ma________ INH R 0.00 16-Jan-02 18-Jan-02 R 127.66
Appendix C 3.2
CONCOMITANT MEDICATION / TREATMENT GROUP B / ITT
RANDOM
NUMBER IN HOSPITAL MEDICATION DAILY
DOSAGE UNITS
ROUTE CONSUM-ABLES START DATE STOP DATE COST
070 B ero tec 2.5-5 mg INH R 0.00 16-Jan-02 18-Jan-02 R 67.13
070 D o lo ro l Forte 1016 m g PO R 0.00 18-Jan-02 18-Jan-02 R 1.88
070 H eparin 5000-10000 iu SC R 42.72 15-Jan-02 18-Jan-02 R 55.92
070 Losec 20 m g PO R 0.00 19-Jan-02 continu ing R 393.77
070 M orph ine 20 mg IM R 3.56 15-Jan-02 15-Jan-02 R 14.18
070 M orph ine 10 mg IM R 3.56 18-Jan-02 18-Jan-02 R 7.09
070 P eth id ine 125-200 mg IM R 21.36 14-Jan-02 15-Jan-02 R 31.98
070 T a g a m e t 400 -1200 mg IV R 19.39 15-Jan-02 18-Jan-02 R 200.07
070 Theophy lin 400 mg PO R 0.00 19-Jan-02 02-Feb-02 R 45.85
076 B uscopan 20-60 mg IM R 32.04 20-Feb-02 22-Feb-02 R 141.73
076 B uscopan 20 mg IM R 21.36 25-Feb-02 26-Feb-02 R 31.50
076 D oloro l Forte 1016-3048 mg PO R 0.00 24-Feb-02 29 Feb 02 R 33.84
076 M axa lon 10 mg IV R 0.92 20-Feb-02 20-Feb-02 R 6.88
076 M orph ine 10 mg IM R 3.56 2 1 -Feb-02 2 1 -Feb-02 R 7.09
076 P eth id ine 50 mg IM R 21.36 19-Feb-02 20-Feb-02 R 14.77
077 A lphagan 2 drops EYE R 0.00 20 -F eb-02 continu ing R 130.12
077 B etagan 2 drops EYE R 0.00 20-Feb-02 con tinu ing R 116.33
077 D o lo ro l Forte 1016 mg PO R 0.00 25 -F eb-02 01 -M ar-02 R 9.40
077 M orph ine 7.5-20 mg IM R 32.04 20-Feb-02 22-F eb-02 R 42.54
077 S e rapax 10 mg PO R 0.00 23 -Feb-02 24-Feb-02 R 0.71
080 M axa lon 10 mg IM R 3.56 24-Feb-02 24-F eb-02 R 6.88
080 M orph ine 10-20 mg IM R 42.72 24 -Feb-02 27-Feb-02 R 56.72
080 P eth id ine 75 mg IM R 3.56 24-Feb-02 24-F eb-02 R 14.03
082 D oloro l Forte 1016-3048 mg PO R 0.00 07-M ar-02 11-M ar-02 R 28.20
082 D o lo ro l Forte 1016-3048 mg PO R 0.00 11-M ar-02 15-M ar-02 R 28.20
082 P eth id ine 50 mg IV R 0.92 07-M ar-02 07-M ar-02 R 7.38
082 P e th id ine 200 mg IM R 21.36 07-M ar-02 08-M ar-02 R 31.98
083 D o lo ro l Forte 1016-3048 mg PO R 0.00 13-M ar-02 15-M ar-02 R 16.92
083 D o lo ro l Forte 1046-2032 mg PO R 0.00 17-M ar-02 18-M ar-02 R 7.52
083 D o lo ro l Forte 1016 mg PO R 0.00 22-M ar-02 22-M ar-02 R 1.88




CONCOMITANT MEDICATION / TREATMENT GROUP B / ITT
IN HOSPITAL MEDICATION DAILY
DOSAGE
UNITS ROUTE CONSUM-ABLES START DATE STOP DATE COST
083 M orph ine 7.5-20 m g IM R 42.72 10-M ar-02 13-M ar-02 R 56.72
083 P eth id ine 50 m g IM R 3.56 17-M ar-02 17-M ar-02 R 7.38
083 S tem etil 12.5 m g IM R 3.56 11-M ar-02 11-M ar-02 R 9.19
086 D o lo ro l Forte 1016-2032 m g PO R 0.00 20 -M ar-02 23-M ar-02 R 15.04
086 M orph ine 30 m g IM R 32.04 17-M ar-02 19-M ar-02 R 63.81
087 A tro ve n t 0.5-1 m g INH R 0.00 23 -A pr-02 24 -A pr-02 R 42.55
087 B ero tec 1.25-2.5 m g INH R 0.00 23-A pr-02 24-A pr-02 R 22.38
087 B uscopan 20 m g IM R 3.56 19 -A pr-02 19-Apr-02 R 15.75
087 D o lo ro l Forte 4064 m g PO R 0.00 03-A pr-02 08 -A pr-02 R 45.12
087 M orph ine 10 m g IM R 3.56 30-M ar-02 30-M ar-02 R 7.09
089 A tro ve n t 0.5-2 m g INH R 0.00 20-A pr-02 22-A pr-02 R 127.66
089 B ero tec 1.25-5 mg INH R 0.00 20 -A pr-02 22-A pr-02 R 67.13
089 D o lo ro l Forte 1016 mg PO R 0.00 25 -A pr-02 29-A pr-02 R 9.40
089 M orph ine 10-30 mg IM R 53.40 17-Apr-02 21 -A pr-02 R 106.35
092 D o lo ro l Forte 1016-3048 mg PO R 0.00 14-M ay-02 2 1 -M ay-02 R 45.12
092 P eth id ine 75-300 mg IM R 64 .08 08-M ay-02 13-M ay-02 R 143.91
094 D o lo ro l Forte 1016-2032 mg PO R 0.00 15-Jun-02 28-Jun -02 R 48.88
094 H eparin 5000-15000 iu SC R 74.76 09-Jun -02 15-Jun-02 R 146.79
094 Losec 20 mg PO R 0.00 14-Jun-02 continu ing R 393.77
094 M orph ine 10-40 mg IM R 64 .08 09-Jun-02 14-Jun-02 R 170.16
096 A tro ve n t 1-1.5 mg INH R 0.00 09-Ju l-02 11 -Ju l-02 R 95.75
096 B ero tec 2 .5 -3 .75 mg INH R 0.00 09-Ju l-02 11 -Ju l-02 R 50.35
096 D o lo ro l Forte 3048-4064 mg PO R 0.00 12-Ju l-02 19-Ju l-02 R 60.16
096 P eth id ine 75-150 mg IM R 53.40 08-Ju l-02 12-Ju l-02 R 76.89
098 A n ta b u se  im p lan t unk unk SC R 3.56 Ju ly 2002 O ngo ing R 4.14
098 D F118 30-90 mg PO R 0.00 13-A ug-02 13-Aug-02 R 9.11
098 D o lo ro l Forte 3048 mg PO R 0.00 17-Aug-02 27-A ug-02 R 62.04
098 D u lco lax 10 mg PR R  0.00 18-A ug-02 18-Aug-02 R 170.16
098 Fybogel 3.5 9 PO R 0.00 22-A ug-02 O ngo ing R 69.10
098 M orph ine 30-40 mg IM R 42 .72 10-A ug-02 13-Aug-02 R 113.44




CONCOMITANT MEDICATION / TREATMENT GROUP B / ITT
IN HOSPITAL MEDICATION DAILY
DOSAGE
UNITS ROUTE CONSUM-ABLES START DATE STOP DATE COST
098 S tem etil 12.5 mg IM R 3.56 11-A ug-02 11-A ug-02 R 9.19
099 A tro ve n t 0.5-2 mg INH R 0.00 13-Aug-02 18-A ug-02 R 8.01
099 B ero tec 1.25-5 m g INH R 0.00 13-A ug-02 18-A ug-02 R 255.32
099 Bru fen 600 m g PO R 0.00 04-S ep-02 07-S ep-02 R 15.99
099 H eparin 10000-15000 iu SC R 53.40 12-A uq-02 16-Aug-02 R 134.26
099 M orph ine 10-40 mg IM R 64.08 11-A ug-02 16-Aug-02 R 9.19
099 P eth id ine 50-100 mg IM R 21.36 11-S ep-02 12-Sep-02 R 15.99
099 S tem etil 12.5 mg IM R 3.56 12-Aug-02 12-Aug-02 R 104.85
R 42,363.55| TO TA L | R 3,573.20








GENDER NATURE OF SURGERY
FEMALE MALE A P P E N D E C T O M Y C H O L E C Y S T E C O M Y L A P A R A T O M Y S IG M O ID E C T O M Y IN C IS IO N  A N D  
D R A IN A G E
E X P L O R A T O R Y
L A P A R O S C O P Y
O T H E R
005 15-May-61 41 1 1
016 14-Jun-26 76 1 1
021 10-Jan-77 24 1 1
040 10-Mar-71 18 1 1
047 03-Nov-65 37 1 1
073 19-Sep-73 30 1 1
078 23-Mar-33 69 1 1
085 31-Dec-82 20 1 1
003 11-Dec-65 37 1 1
004 03-Nov-38 64 1 1
007 14-Dec-79 23 1 1
009 12-Feb-75 27 1 1
010 15-Aug-82 20 1 1
014 26-Apr-62 40 1 1
018 13-Apr-80 22 1 1
019 14-Feb-40 62 1 1
021
022 06-Feb-52 50 1 1
025 01-Jan-38 64 1 1
028 17-Dec-65 37 1 1
030 12-Feb-60 42 1 1
031 16-Aug-80 22 1 1
036 13-Mar-33 69 1 1
038 28-Jan-81 21 1 1
042 05-Mar-67 35 1 1
044 01-Nov-78 24 1 1
045 20-Nov-81 21 1 1
049 07-Jul-30 72 1 1
051 27-Nov-71 31 1 1
054 11-Oct-74 28 1 1
055 07-Aug-55 45 1 1
059 29-Jul-64 38 1 1
060 29-Jan-60 42 1 1
061 21-Dec-80 22 1 1
062 18-Jul-62 40 1 1
066 14-Jul-57 45 1 1
068 16-Apr-72 30 1 1
071 17-Sep-50 51 1 1








GENDER NATURE OF SURGERY
FEMALE MALE A P P E N D E C T O M Y C H O L E C Y S T E C O M Y L A P A R A T O M Y S IG M O ID E C T O M Y IN C IS IO N  A N D  
D R A IN A G E
E X P L O R A T O R Y
L A P A R O S C O P Y
O T H E R
074 6-Sep-76 26 1 1
075 21-May-59 43 1 1
079 1-Jan-60 41 1 1
081 18-Mar-59 43 1 1
084 30-Nov-65 35 1 1
088 8-Jul-74 28 1 1
090 16-Apr-66 34 1 1
091 29-Dec-50 51 1 1
093 28-Aug-52 50 1 1
095 3-Nov-78 24 1 1
097 6-Jun-74 28 1 1
100 12-Oct-52 50 1 1
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GENDER NATURE OF SURGERY
FEMALE MALE A P P E N D E C T O M Y C H O L E C Y S T E C O M Y L A P A R A T O M Y S IG M O ID E C T O M Y IN C IS IO N  A N D  
D R A IN A G E
E X P L O R A T O R Y
L A P A R O S C O P Y
O T H E R
006 17-Nov-56 46 1 1
008 05-Aug-69 33 1 1
048 22-Jun-62 40 1 1
052 17-Feb-52 50 1 1
067 27-Jun-67 35 1 1
077 19-Nov-22 80 1 1
080 10-Mar-70 32 1 1
001 12-Jul-30 71 1 1
002 03-Jul-78 24 1 1
011 15-May-58 44 1 1
012 07-Jan-77 25 1 1
013 28-Dec-58 44 1 1
015 01-Aug-64 38 1 1
017 11-Nov-82 30 1 1
020 15-Jul-70 32 1 1
023 31-Dec-54 48 1 1
024 31-Mar-52 50 1 1
026 24-Mar-72 30 1 1
027 15-Nov-68 34 1 1
029 08-Oct-63 39 1 1
032 30-Apr-59 43 1 1
033 29-Sep-68 34 1 1
034 192/12/16 40 1 1
035 05-Mar-23 79 1 1
037 21-Sep-79 23 1 1
039 15-Feb-65 37 1 1
041 27-Jan-63 39 1 1
043 13-Mar-83 19 1 1
046 02-Mar-81 21 1 1
050 02-Mar-74 28 1 1
053 21-Jul-59 43 1 1
056 14-Oct-73 29 1 1
057 19-Dec-81 21 1 1
058 28-Jul-53 49 1 1
063 1-Jan-81 21 1 1
064 21-Jan-81 21 1 1
065 24-Oct-68 34 1 1
069 23-Mar-74 28 1 1
070 28-Jan-62 40 1 1
076 31-Jul-79 22 1 1
Appendix C 4.2
------------------V i1----------------- DEMOG (TGROUP B / ITT
RANDOM
NUMBER DATE OF AGE
GENDER NATURE OF SURGERY
BIRTH
FEMALE MALE A P P E N D E C T O M Y C H O L E C Y S T E C O M Y L A P A R A T O M Y S IG M O ID E C T O M Y IN C IS IO N  A N D  
D R A IN A G E
E X P L O R A T O R Y
L A P A R O S C O P Y
O T H E R
082 1-Jan-76 25 1 1
083 5-Apr-57 45 1 1
086 8-Apr-51 51 1 1
087 26-Jul-68 34 1 1 1
089 4-Aug-78 23 1 1
092 14-Mar-80 22 1 1
094 6-Apr-46 56 1 1
096 5-Jan-72 30 1 1
098 23-Sep-64 38 1 1
099 3-Apr-68 34 1 1






















003 20-Feb-01 08-M ar-01 0 R 0.00 17 R 12,461 .00 R 12,461.00
004 22-Feb-01 01 -Mar-01 0 R 0.00 8 R 5 ,864.00 R 5,864.00
004 28-M ar-01 02-Apr-01 0 R 0.00 3 R 2 ,199 .00 R 2,199.00
005 15-Mar-01 28-M ar-01 14 R 42 ,250 .60 0 R 0.00 R 42,250.60
005 28-M ar-01 02 -Apr-01 0 R 0.00 3 R 2 ,199 .00 R 2,199.00
007 26-M ar-01 05-Apr-01 0 R 0.00 11 R 8 ,063 .00 R 8.063.00
009 07-Apr-01 12-Apr-01 0 R 0.00 6 R 4 ,398 .00 R 4,398.00
010 09-Apr-01 10-Apr-01 0 R 0.00 6 R 4 ,398 .00 R 4,398.00
014 06-M av-01 14-May-01 0 R 0.00 9 R 6 ,597 .00 R 6,597.00
014 21-M av-01 28-M ay-01 0 R 0.00 8 R 5 ,864.00 R 5,864.00
016 12-Mav-01 21 -May-01 0 R 0.00 10 R 7 ,330 .00 R 7,330.00
016 24-M ay-01 03-Jun-01 0 R 0.00 11 R 8 ,063.00 R 8,063.00
018 15-May-01 22-M ay-01 0 R 0.00 8 R 5 ,864 .00 R 5,864.00
019 15-May-01 24-M ay-01 0 R 0.00 8 R 5 ,864 .00 R 5,864.00
021 28-M ay-01 20-Jun-01 0 R 0.00 24 R 17,592.00 R 17,592.00
022 30-M ay-01 03-Jun-01 0 R 0.00 5 R 3 ,665 .00 R 3,665.00
025 19-Jun-01 28-Jun-01 0 R 0.00 10 R 7 ,330 .00 R 7,330.00
028 03-Aug-01 07-Aug-01 0 R 0.00 5 R 3 ,665.00 R 3,665.00
030 14-Aug-01 2 1 -Aug-01 0 R 0.00 8 R 5 ,864 .00 R 5,864.00
031 23-Aug-01 30-Aug-01 0 R 0.00 8 R 5 ,864 .00 R 5,864.00
036 13-Sep-01 26-Sep-01 0 R 0.00 14 R 10,262.00 R 10,262.00
038 28-Sep-01 01 -Oct-01 0 R 0.00 4 R 2 ,932 .00 R 2,932.00
040 06-Oct-01 25-O ct-01 0 R 0.00 20 R 14,660 .00 R 14,660.00
042 18-Oct-O1 20-Nov-01 0 R 0.00 34 R 24 ,922 .00 R 24,922.00
044 20-O ct-01 26-Oct-01 0 R 0.00 7 R 5 ,131.00 R 5,131.00
045 20-O ct-01 26-O ct-01 0 R 0.00 7 R 5 ,131 .00 R 5,131.00
047 28-O ct-01 08-N ov-O I 0 R 0.00 12 R 8 ,796 .00 R 8,796.00
049 04-Nov-01 08-Nov-01 0 R 0.00 5 R 3 ,665.00 R 3,665.00
051 11-Nov-01 2 1 -Nov-01 0 R 0.00 11 R 8 ,063 .00 R 8,063.00
054 18-Nov-01 24-Nov-01 0 R 0.00 7 R 5 ,131 .00 R 5.131.00
055 19-Nov-01 26-Nov-01 0 R 0.00 8 R 5 ,864.00 R 5,864.00
055 05-Dec-01 05-Dec-01 0 R 0.00 1 R 733 .00 R 733.00






















060 10-Dec-01 17-Dec-01 0 R 0.00 8 R 5 ,864 .00 R 5.864.00
061 15-Dec-01 21 -Dec-01 0 R 0.00 7 R 5 ,131.00 R 5,131.00
062 16-Dec-01 21-Dec-01 0 R 0.00 6 R 4 ,398 .00 R 4,398.00
066 04-Jan-02 10-Jan-02 0 R 0.00 7 R 5 ,131.00 R 5,131.00
068 10-Jan-02 11-Jan-02 0 R 0.00 2 R 1,466.00 R 1,466.00
068 12-Jan-02 17-Jan-02 6 R 18,107.40 0 R 0 .00 R 18,107.40
068 18-Jan-02 2 1 -Jan-02 0 R 0.00 4 R 2 ,932 .00 R 2,932.00
071 22-Jan-02 29-Jan-02 0 R 0.00 8 R 5 ,864.00 R 5,864.00
072 2 2 -Jan-02 28-Jan-02 0 R 0.00 7 R 5 ,131 .00 R 5,131.00
073 23-Jan-02 04-Feb-02 0 R 0.00 13 R 9 ,529.00 R 9,529.00
073 07-Feb-02 15-Feb-02 0 R 0.00 9 R 6 ,597 .00 R 6,597.00
074 29-Jan-02 04-Feb-02 0 R 0.00 7 R 5 ,131.00 R 5,131.00
075 17-Feb-02 26-Feb-02 0 R 0.00 10 R 7 ,330 .00 R 7,330.00
078 22-Feb-02 24-Feb-02 0 R 0.00 3 R 2 ,199 .00 R 2,199.00
078 25-Feb-02 12-M ar-02 15 R 45 ,268 .50 0 R 0.00 R 45,268.50
079 23-Feb-02 03-M ar-02 0 R 0.00 9 R 6 ,597 .00 R 6,597.00
081 26-Feb-02 05-M ar-02 0 R 0.00 8 R 5 ,864.00 R 5,864.00
084 12-M ar-02 26-M ar-02 0 R 0.00 14 R 10,262.00 R 10,262.00
085 16-M ar-02 22-M ar-02 0 R 0.00 7 R 5 ,131.00 R 5,131.00
088 02-Apr-02 07-Apr-02 0 R 0.00 6 R 4 ,398 .00 R 4,398.00
090 20-A pr-02 25-A pr-02 0 R 0.00 6 R 4 ,398 .00 R 4,398.00
091 29-A pr-02 08-M ay-02 0 R 0.00 10 R 7 ,330.00 R 7,330.00
091 09-M ay-02 18-M ay-03 10 R 30,179 .00 0 R 0.00 R 30,179.00
093 11-M ay-02 16-M ay-02 0 R 0.00 6 R 4 ,398 .00 R 4,398.00
095 20-Jun-02 25-Jun-02 0 R 0.00 6 R 4 ,398 .00 R 4,398.00
095 06-Ju l-02 10-Jul-02 0 R 0.00 5 R 3 ,665 .00 R 3,665.00
097 24-Ju l-02 30-Ju l-02 0 R 0.00 7 R 5 ,131.00 R 5,131.00
100 02-M ay-02 12-M ay-02 0 R 0.00 11 R 8 ,063 .00 R 8,063.00






















001 30-Jan-01 27-Feb-01 0 R 0.00 29 R 21 ,257 .00 R 21 ,257 .00
001 18-M ar-01 20-M ar-01 0 R 0.00 3 R 2 ,199 .00 R 2 ,199 .00
002 20-Feb-01 24-Feb-01 0 R 0.00 5 R 3,665.00 R 3 ,665.00
006 26-M ar-01 03-Apr-01 3 R 9 ,053.70 0 R 0.00 R 9 ,053.70
006 04-Apr-01 09-Apr-01 0 R 0.00 10 R 7 ,330.00 R 7 ,330.00
006 10-Apr-01 23-Apr-01 0 R 0.00 14 R 10,262.00 R 10,262.00
008 29-M ar-01 17-Apr-01 20 R 60 ,358 .00 0 R 0.00 R 60 ,358 .00
011 10-Apr-01 19-Apr-01 0 R 0.00 10 R 7,330.00 R 7 ,330.00
012 14-Apr-01 19-Apr-01 0 R 0.00 6 R 4 ,398 .00 R 4 ,398 .00
013 30-Apr-01 09-M ay-01 0 R 0.00 10 R 7 ,330.00 R 7 ,330.00
015 08-M ay-01 16-M ay-01 0 R 0.00 9 R 6 ,597 .00 R 6 ,597 .00
017 14-M ay-01 20-M ay-01 0 R 0.00 7 R 5,131.00 R 5 ,131.00
020 20-M ay-01 29-M ay-01 0 R 0.00 10 R 7 ,330.00 R 7 ,330 .00
023 10-Jun-01 15-Jun-01 0 R 0.00 6 R 4 ,398 .00 R 4 ,398 .00
024 19-Jun-01 27-Jun-01 0 R 0.00 9 R 6 ,597.00 R 6 ,597 .00
026 30-Jun-01 07-Jul-01 0 R 0.00 8 R 5 ,864.00 R 5 ,864.00
027 02-Aug-01 08-A ug-08 0 R 0.00 8 R 5,864.00 R 5 ,864.00
029 09-Aug-01 20-Aug-01 0 R 0.00 12 R 8 ,796.00 R 8 ,796.00
032 23-Aug-01 30-Aug-01 0 R 0.00 8 R 5 ,864.00 R 5 ,864.00
033 09-Sep-01 15-Sep-01 0 R 0 .00 7 R 5 ,131.00 R 5 ,131 .00
034 12-Sep-01 18-Sep-01 0 R 0.00 7 R 5,131.00 R 5 ,131.00
035 12-Sep-01 26-S ep-02 0 R 0.00 15 R 10,995.00 R 10,995.00
037 26-Sep-01 01-O ct-01 0 R 0.00 6 R 4 ,398 .00 R 4 ,398 .00
039 30-Sep-01 07-O ct-01 0 R 0.00 8 R 5 ,864.00 R 5 ,864.00
041 10-O ct-01 23-O ct-01 0 R 0 .00 14 R 10,262.00 R 10,262 .00
043 18-Oct-O1 24-O ct-01 0 R 0.00 3 R 2 ,199 .00 R 2 ,199.00
046 23-O ct-01 30-O ct-01 8 R 24 ,143 .20 0 R 0.00 R 24 ,143 .20
046 31 -O ct-01 06-Nov-01 0 R 0.00 7 R 5,131.00 R 5 ,131.00
048 29-O ct-01 14-Nov-01 0 R 0.00 17 R 12,461.00 R 12,461.00
050 07-N ov-01 12-Nov-01 0 R 0.00 12 R 8,796.00 R 8 ,796 .00
052 16-Nov-01 17-Nov-01 0 R 0.00 2 R 1,466.00 R 1,466.00
053 18-Nov-01 24-Nov-01 0 R 0.00 7 R 5,131.00 R 5 ,131 .00
056 26-N ov-01 01-D ec-01 0 R 0.00 6 R 4 ,398 .00 R 4 ,398 .00
057 02-D ec-01 09-Dec-01 0 R 0.00 8 R 5 ,864 .00 R 5 ,864.00
058 08-D ec-01 15-Dec-01 0 R 0.00 8 R 5,864.00 R 5 ,864 .00
w p p B n a n r t r s . z
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TO TA L COST
063 16-Dec-01 26-D ec-01 0 R 0.00 11 R 8 ,063.00 R 8 ,063 .00
064 17-Dec-01 22-D ec-01 0 R 0.00 6 R 4 ,398 .00 R 4 ,398 .00
065 02-Jan-01 07-Jan-02 0 R 0.00 6 R 4 ,398 .00 R 4 ,398 .00
067 05-Jan-02 08-Jan-02 0 R 0.00 4 R 2 ,932 .00 R 2 ,932 .00
069 12-Jan-02 18-Jan-02 0 R 0.00 7 R 5 ,131.00 R 5 ,131 .00
070 14-Jan-02 19-Jan-02 0 R 0.00 6 R 4 ,398 .00 R 4 ,398 .00
076 18-Feb-02 26-Feb-02 0 R 0.00 9 R 6 ,597.00 R 6 ,597 .00
077 19-Feb-02 25-Feb-02 0 R 0.00 7 R 5 ,131.00 R 5 ,131.00
080 23-Feb-02 01 -M ar-02 0 R 0.00 7 R 5 ,131.00 R 5 ,131 .00
082 06-M ar-02 11-M ar-02 0 R 0.00 6 R 4 ,398 .00 R 4 ,398 .00
083 09-M ar-02 15-M ar-02 0 R 0.00 7 R 5 ,131.00 R 5 ,131.00
083 16-M ar-02 25-M ar-02 0 R 0.00 10 R 7,330.00 R 7 ,330.00
086 17-M ar-02 23-M ar-02 0 R 0.00 7 R 5,131.00 R 5 ,131.00
087 29-M ar-02 03-A pr-02 0 R 0.00 6 R 4 ,398 .00 R 4 ,398 .00
087 22-A pr-02 24-A pr-02 0 R 0.00 3 R 2 ,199 .00 R 2 ,199 .00
089 16-A pr-02 25-A pr-02 0 R 0.00 9 R 6 ,597 .00 R 6 ,597 .00
092 08-M ay-02 14-M ay-02 0 R 0.00 7 R 5,131.00 R 5 ,131.00
094 08-Jun-02 15-Jun-02 0 R 0.00 8 R 5 ,864.00 R 5 ,864.00
096 08-Ju l-02 14-Jul-02 0 R 0.00 7 R 5 ,131.00 R 5 ,131.00
098 10-A ug-02 19-A ug-02 0 R 0.00 10 R 7 ,330.00 R 7 ,330.00
099 10-A ug-02 18-Aug-02 0 R 0.00 9 R 6 ,597.00 R 6 ,597 .00
TOTALS 31 R 93,554.90 443 R 324,719.00 R 418,273.90
Appendix C 6.1
PROFESSIONAL FEE / TREATMENT GROUP A / ITT
In it ia l V is it H o s p ita l V is i t F in a l V is i t T O T A L  C O S T
003 R 841 .20 R 2 ,383 .40 R 210 .30 R 3 ,434.90
004 R 841 .20 R 1 ,121.60 R 210 .30 R 2 ,173 .10
004 R 841 .20 R 420 .60 R 210 .30 R 1,472.10
005 R 841.20 R 1 ,962.80 R 210 .30 R 3,014.30
005 R 841 .20 R 420 .60 R 210 .30 R 1,472.10
007 R 841.20 R 1 ,542.20 R 210 .30 R 2 ,593 .70
009 R 841 .20 R 841 .20 R 210 .30 R 1,892.70
010 R 841.20 R 841 .20 R 210 .30 R 1,892.70
014 R 841 .20 R 1 ,261.80 R 210 .30 R 2 ,313 .30
014 R 841.20 R 1,121.60 R 210 .30 R 2 ,173 .10
016 R 841 .20 R 1 ,402.00 R 210 .30 R 2 ,453 .50
016 R 841 .20 R 1,542.20 R 210 .30 R 2 ,593 .70
018 R 841 .20 R 1 ,121 .60 R 210 .30 R 2 ,173.10
019 R 841 .20 R 1,121.60 R 210 .30 R 2 ,173 .10
021 R 841 .20 R 3 ,364 .80 R 210 .30 R 4 ,416 .30
022 R 841.20 R 701.00 R 210 .30 R 1,752.50
025 R 841 .20 R 1 ,402.00 R 210 .30 R 2 ,453 .50
028 R 841.20 R 701 .00 R 210 .30 R 1,752.50
030 R 841 .20 R 1,121.60 R 210 .30 R 2 ,173 .10
031 R 841.20 R 1,121.60 R 210 .30 R 2 ,173 .10
036 R 841 .20 R 1,962.80 R 210 .30 R 3,014.30
038 R 841.20 R 560.80 R 210 .30 R 1,612.30
040 R 841 .20 R 2 ,804 .00 R 210 .30 R 3 ,855.50
042 R 841 .20 R 4 ,766 .80 R 210 .30 R 5 ,818.30
044 R 841 .20 R 981 .40 R 210 .30 R 2 ,032 .90
045 R 841.20 R 981.40 R 210 .30 R 2 ,032 .90
047 R 841 .20 R 1 ,682.40 R 210 .30 R 2 ,733 .90
049 R 841.20 R 701 .00 R 210 .30 R 1,752.50
051 R 841 .20 R 1 ,542.20 R 210 .30 R 2 ,593 .70
054 R 841.20 R 981 .40 R 210 .30 R 2 ,032 .90
055 R 841 .20 R 1 ,121.60 R 210 .30 R 2 ,173 .10
055 R 841 .20 R 140.20 R 210 .30 R 1 ,191.70
059 R 841.20 R 841.20 R 210 .30 R 1,892.70
060 R 841 .20 R 1 ,121.60 R 210 .30 R 2 ,173 .10
061 R 841.20 R 981 .40 R 210 .30 R 2 ,032 .90
062 R 841 .20 R 841 .20 R 210 .30 R 1,892.70
066 R 841 .20 R 981 .40 R 210 .30 R 2 ,032 .90
068 R 841.20 R 280 .40 R 210 .30 R 1,331.90
068 R 841 .20 R 0 .00 R 210 .30 R 1,051.50
068 R 841.20 R 560 .80 R 210 .30 R 1,612.30
071 R 841.20 R 1 ,121.60 R 210 .30 R 2 , 173.10
072 R 841 .20 R 981 .40 R 210 .30 R 2 ,032 .90
073 R 841.20 R 1,822.60 R 210 .30 R 2 ,874 .10
073 R 841 .20 R 1,261.80 R 210 .30 R 2 ,313 .30
074 R 841.20 R 981 .40 R 210 .30 R 2 ,032 .90
075 R 841.20 R 1,402.00 R 210 .30 R 2 ,453 .50
078 R 841.20 R 420 .60 R 210 .30 R 1,472.10
078 R 841.20 R 2 ,103 .00 R 210 .30 R 3,154.50
079 R 841 .20 R 1 ,261.80 R 210 .30 R 2 ,313 .30
081 R 841.20 R 1 ,121.60 R 210 .30 R 2 ,173.10
R 841 .20 R 0.00 R 210 .30 R 1,051.50
081 R 841.20 R 1 ,121.60 R 210 .30 R 2 ,173 .10
084 R 841.20 R 1,962.80 R 210 .30 R 3,014.30
R 841.20 R 0.00 R 210 .30 R 1 ,051.50
R 841.20 R 0 .00 R 210 .30 R 1,051.50
R 841 .20 R 0 .00 R 210 .30 R 1,051.50
R 841.20 R 0 .00 R 210 .30 R 1,051.50
R 841.20 R 0 .00 R 210 .30 R 1,051.50
Appendix C 6.1
PROFESSIONAL FEE / TREATMENT GROUP A / ITT
Initial Visit Hospital Visit Final Visit TO TA L COST
R 841 .20 R 0 .00 R 210 .30 R 1,051.50
R 841 .20 R 0 .00 R 210 .30 R 1,051.50
R 841 .20 R 0 .00 R 210 .30 R 1,051.50
R 841.20 R 0 .00 R 210 .30 R 1,051.50
R 841.20 R 0 .00 R 210 .30 R 1,051.50
084 R 841.20 R 1 ,962.80 R 210 .30 R 3 ,014 .30
085 R 841.20 R 981 .40 R 210 .30 R 2 ,032 .90
088 R 841.20 R 841 .20 R 210 .30 R 1 ,892.70
090 R 841.20 R 841 .20 R 210 .30 R 1 ,892.70
091 R 841 .20 R 1 ,402.00 R 210 .30 R 2 ,453 .50
091 R 841 .20 R 1 ,402.00 R 210 .30 R 2 ,453 .50
093 R 841 .20 R 841 .20 R 210 .30 R 1 ,892.70
095 R 841 .20 R 841 .20 R 210 .30 R 1,892.70
095 R 841 .20 R 701 .00 R 210 .30 R 1,752.50
097 R 841 .20 R 981 .40 R 210 .30 R 2 ,032 .90
100 R 841 .20 R 1 ,542.20 R 210 .30 R 2 ,593 .70




PROFESSIONAL FEE / TREATMENT GROUP B / ITT
Initial Visit Hospital Visit Final Visit TO TA L COST
001 R 841 .20 R 4 ,06 5 .8 0 R 210 .30 R 5 ,117.30
001 R 841 .20 R 420 .60 R 210 .30 R 1,472.10
002 R 841 .20 R 701 .00 R 210 .30 R 1,752.50
006 R 841 .20 R 420 .60 R 210 .30 R 1,472.10
006 R 841 .20 R 1 ,402 .00 R 210 .30 R 2 ,453.50
006 R 841 .20 R 1,962.80 R 210 .30 R 3 ,014.30
008 R 841 .20 R 2 ,804 .0 0 R 210 .30 R 3 ,855.50
011 R 841 .20 R 1,402.00 R 210 .30 R 2 ,453 .50
012 R 841.20 R 841 .20 R 210 .30 R 1,892.70
013 R 841 .20 R 1 ,402.00 R 210 .30 R 2 ,453 .50
015 R 841 .20 R 1 ,261.80 R 210 .30 R 2 ,313.30
017 R 841 .20 R 981 .40 R 210 .30 R 2 ,032 .90
020 R 841 .20 R 1 ,402.00 R 210 .30 R 2 ,453 .50
023 R 841 .20 R 841 .20 R 210 .30 R 1,892.70
024 R 841 .20 R 1 ,261.80 R 210 .30 R 2 ,313 .30
026 R 841 .20 R 1 ,121.60 R 210 .30 R 2 ,173 .10
027 R 841.20 R 1 ,121.60 R 210 .30 R 2 ,173 .10
029 R 841 .20 R 1 ,682.40 R 210 .30 R 2 ,733 .90
032 R 841.20 R 1 ,121.60 R 210 .30 R 2 ,173 .10
033 R 841 .20 R 981 .40 R 210.30 R 2 ,032 .90
034 R 841 .20 R 981 .40 R 210 .30 R 2 ,032 .90
035 R 841 .20 R 2 ,103 .00 R 210 .30 R 3 ,154 .50
037 R 841 .20 R 841 .20 R 210 .30 R 1,892.70
039 R 841 .20 R 1 ,121.60 R 210 .30 R 2 ,173 .10
041 R 841 .20 R 1 ,962.80 R 210 .30 R 3 ,014.30
043 R 841 .20 R 420 .60 R 210 .30 R 1,472.10
046 R 841 .20 R 1 ,121.60 R 210 .30 R 2 ,173 .10
046 R 841 .20 R 981 .40 R 210 .30 R 2 ,032 .90
048 R 841.20 R 2 ,383 .40 R 210 .30 R 3 ,434.90
050 R 841 .20 R 1 ,682.40 R 210 .30 R 2 ,733 .90
052 R 841.20 R 280 .40 R 210 .30 R 1,331.90
053 R 841 .20 R 981 .40 R 210 .30 R 2 ,032 .90
056 R 841.20 R 841 .20 R 210 .30 R 1,892.70
057 R 841 .20 R 1 ,121.60 R 210 .30 R 2 ,173 .10
058 R 841.20 R 1 ,121.60 R 210 .30 R 2 ,173 .10
063 R 841 .20 R 1 ,542.20 R 210 .30 R 2 ,593 .70
064 R 841 .20 R 841 .20 R 210 .30 R 1,892.70
065 R 841 .20 R 841 .20 R 210 .30 R 1,892.70
067 R 841.20 R 560.80 R 210 .30 R 1,612.30
069 R 841 .20 R 981 .40 R 210 .30 R 2 ,032 .90
070 R 841.20 R 841 .20 R 210 .30 R 1,892.70
076 R 841 .20 R 1 ,261.80 R 210 .30 R 2 ,313 .30
077 R 841.20 R 981 .40 R 210 .30 R 2 ,032 .90
080 R 841 .20 R 981 .40 R 210 .30 R 2 ,032 .90
082 R 841.20 R 841 .20 R 210 .30 R 1,892.70
083 R 841 .20 R 981 .40 R 210 .30 R 2 ,032 .90
083 R 841.20 R 1 ,402.00 R 210 .30 R 2 ,453 .50
086 R 841 .20 R 981 .40 R 210 .30 R 2 ,032 .90
087 R 841.20 R 841 .20 R 210 .30 R 1,892.70
087 R 841.20 R 420 .6 0 R 210.30 R 1,472.10
089 R 841 .20 R 1 ,261.80 R 210 .30 R 2 ,313 .30
092 R 841 .20 R 981 .40 R 210 .30 R 2 ,032 .90
094 R 841 .20 R 1 ,121.60 R 210 .30 R 2 ,173 .10
096 R 841.20 R 981 .40 R 210 .30 R 2 ,032 .90
098 R 841 .20 R 1 ,402.00 R 210 .30 R 2 ,453 .50
099 R 841 .20 R 1 ,261.80 R 210 .30 R 2 ,313 .30
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CEFTRIAXONE TREATMENT METRONIDAZOLE TREATMENT CO-AMOXICLAVTABLETS

































001 16-Feb-01 23-F e b -0 1 8 R 2.557.34 16-Feb-01 18-Feb-01 6 R 199.18 N A N A 0 0 R 0.06 R 2.756.52 C ure R 109.04
0 0 2 20-Feb-01 24-F e b -0 1 5 R 1.598.34 20-Feb-01 23-Feb-01 9 R 298.77 N A N A 0 0 R 0.06 R 1.897.11 C u re R 109.04
006 26-M ar-01 02 -A o r-0 1 8 R 2.557.34 26-M ar-01 0 2 -A pr-01 23 R 763.53 N A N A 0 0 R0.0C R 3.320.87 F a ilu re R 109.04
008 29 -M a r-0 1 0 2 -A or-01 5 R 1.598.34 29-M ar-01 0 3 -A or-01 14 R 464.76 N A N A 0 0 R0.0C R 2.063.0S F a ilu re R 109.04
011 14-ADr-01 15-A pr-01 5 R 1.598.34 14-Aor-01 16-ADr-01 15 R 497.96 16-Apr-01 19-A pr-01 9 0 R 99.94 R 2.196.23 C ure R 109.04
0 1 2 15-A nr-01 18-A br-01 4 R 1.278.67 15-A or-01 18-A pr-01 10 R 331.97 18-Aor-01 20-A pr-01 6 0 R 66.62 R 1.677.26 C ure R 109.04
0 1 3 0 1-M av-01 0 7-M av-01 7 R 2.237.67 01-M av-01 07-M av-01 21 R 697.13 N A N A 0 0 R 0.06 R 2.934.80 C u re R 109.04
015 09«M av-01 14-M av-01 6 R1.918.0C 0 9-M av-01 14-M av-01 15 R 497.96 14-M av-01 16-M av-01 5 0 R 55.52 R 2.471.48 C u re R 109.04
017 15-M av-01 2 0-M av-01 6 R1.918.0C 15-M av-01 2 0-M av-01 14 R 464.76 N A N A 0 0 R0.0C R 2.382.76 C ure R 109.04
0 2 0 22-M av-01 2 7 -M a v-0 1 6 R 1.918.0C 27-M av-01 2 8-M av-01 4 R 132.76 27-M av-01 2 8 -M a v -0 l 4 0 R 44.42 R 2.095.21 C ure R 109.04
0 2 3 11-Jun -01 1 3-Jun -01 3 R 959.0C 11-Jun-01 13-Jun-01 6 R 199.16 13-Jun-01 14-Jun-01 5 0 R 55.52 R 1 .213.70 C u re R 109.04
024 19-Jun-01 2 5 -Ju n -0 1 7 R 2.237.67 19-Jun-01 26 -Ju n -0 1 19 R 630.74 N A N A 0 0 R 0.06 R 2.868.41 C u re R 109.04
026 30-Jun -01 05-Ju l-01 6 R 1.918.00 01-Ju l-01 06 -Ju l-01 15 R 497.96 06-Ju l-01 0 7 -Ju l-O l 4 0 R 44.42 R 2.460.37 C u re R 109.04
0 2 7 0 2 -A ua-01 0 6 -A ua-01 5 R 1.598.34 02-A uo-01 0 6 -A u a -0 1 11 R 365.16 N A N A 0 0 RO.OC R 1.963.50 C u re R 109.04
0 2 9 10-A ua-01 17-AUQ-01 8 R 2.557.34 10-Auq-01 17-A ua-01 21 R 697.13 N A N A 0 0 R0.0C R 3.254.47 C ure R 109.04
0 3 2 2 3 -A uq-01 28 -A u q -0 1 6 R 1.918.od 23-AUQ-01 2 5 -A ua-01 7 R 232.36 29-A uo-01 30-AUO-01 3 0 R 33.31 R 2.183.70 C ure R 109.04
0 3 3 10-S ep-01 15-S6D-01 4 R 1.278.67 10-S ep-01 13-S eo-01 9 R 298.77 14-S ep-01 15-S ep-01 4 0 R 44.42 R 1.621.86 C u re R 109.04
034 12-SeD-01 15-S eo-01 4 R 1.278.67 13-S ep-01 16-S eD -02 8 R 265.57 16-Sep-01 18-SeD-01 6 0 R 66.63 R 1.610.87 C u re R 109.04
035 13-A ua-01 17 -A uq-01 5 R 1.598.34 N A N A 0 R0.0C 18-Auq-01 20-A uo-01 3 0 R 33.31 R 1.631.65 C ure R 109.04
037 27-S eD -01 3 0 -S ep-01 4 R 1,278.67 27-S6D -01 30-S 6D -01 11 R 365.16 01-S ep-01 01-S6P-01 0 R 11.10l R 1,654.94 C ure R 109.04
0 3 9 O1-Oct-O1 0 1 -O c t-0 1 4 R 1.278.67 0 1 -O ct-01 05 -O ct-01 12 R 398.36 05-O ct-01 0 6 -O c t-01 5 0 R 55.52 R 1.732.58 C u re R 109.04
041 10-O ct-01 16 -O ct-01 7 R 2.237.67 11 -O ct-01 16 O c  01 18 R 597.54 17-Oct-O1 19-Oct-O1 5 0 R 55.52 R 2.890.74 C u re R 109.04
043 19-Oct-O1 2 3-O ct-01 5 R 1.598.34 19-O ct-01 23 -O c t-01 10 R 331.97 2 3 -O d -0 1 2 6-O c t-01 4 0 R 44.42 R 1.974.75 C ure R 109.04
046 2 3-O ct-01 2 9 -O c t-01 7 R 2.237.67 2 4-O ct-01 2 9 -O c t-O I 17 R 564.36 N A N A 0 0 R 0.00l R 2.802.02 F a ilu re R 109.04
048 30-O ct-01 04-NOV-01 6 R 1.918.0C 30-O ct-01 0 5 -N o v-0 1 19 R 630.74 N A N A 0 0 R 0.00 R 2.548.74 F a ilu re R 109.04
050 08 -N o v-0 1 1 2 -N ov-01 5 R 1.598.34 08-NOV-01 11-NOV-01 11 R 365.16 N A N A 0 0 R 0.00 R 1.963.50 C u re R 109.04
052 17-N ov-01 1 7 -N ov-01 1 R 319.67 17-N ov-01 17-NOV-01 R 33.2C N A N A 0 0 R 0.00 R 352.86 D e a th R 109.04
053 19-NOV-01 2 2 -N o v -O I 4 R 1.278.67 19-N ov-O I 2 2 -N ov-01 9 R 298.77] 2 3 -N o v -D I 23-NOV-01 0 R 11.1C R 1.588.55 C ure R 109.04
056 2 7 -N o v -O l 2 9 -N o v -O I 3 R 959.00 27-N ov-01 30-NOV-01 9 R 298.77 30-NOV-01 0 1 -D ec-01 4 0 R 44.42 R 1.302.18 C ure R 109.04
057 0 3 -D ec-01 0 7 -D ec-01 5 R 1.598.34 0 3 -D ec-01 0 7 -D ec-01 12 R 398.36 N A N A 0 0 R 0.00 R 1.996.70 C u re R 109.04
058 0 9 -D ec-01 14-D ec-01 6 R 1.918.00 09-D ec-01 14-D ec-01 16 R 531.15 N A N A 0 0 R 0.00 R 2.449.1! C u re R 109.04
063 17-D ec-01 25 -D e c-0 1 9 R 2.877.01 17-D ec-01 2 5 -D ec-01 22 R 730.32 N A N A 0 0 R 0.00 R 3.607.34 C ure R 109.04
064 18-D ec-01 2 0 -D ec-01 3 R 959.00 18-D ec-01 21-D6C-01 8 R 265.57 2 1 -D ec-01 2 2 -D ec-01 3 0 R 33.31 R 1.257.89 C ure R 109.04
065 0 2 -Ja n -0 2 0 5 -Ja n -0 2 4 R 1.278.67 N /A N /A 0 R 0.00 0 6 -Ja n -0 2 0 7 -Ja n -0 2 3 0 R 33.31 R 1.311.98 C u re R 109.04
067 0 5 -Ja n -0 2 0 7 -Ja n -0 2 3 R 959.00 0 5 -Ja n -0 2 0 8 -Ja n -0 2 8 R 265.57 0 8 -Ja n -0 2 0 8 -Ja n -0 2 0 R 11.10 R 1.235.68 In d e te rm in a te R 109.04
069 13 -Ja n -0 2 1 6 -Ja n -0 2 4 R 1.278.67 1 3-Jan -02 1 7 -Ja n -0 2 11 R 365.16 17-Jan -02 18-Ja n -0 2 5 0 R 55.52 R 1.699.36 C u re R 109.04
070 1 4-Ja n -0 2 1 8-Ja n -0 2 5 R 1.598.34 14-Ja n -0 2 18-Ja n -0 2 12 R 398.36 18-Ja n -0 2 19 -Ja n -0 2 4 0 R 44.42 R 2.041.12! C ure R 109.04
076 19-F e b -0 2 2 2 -F e b -0 2 4 R 1.278.67 19-Feb-02 2 2 -F e b -0 2 10 R 331.97 2 2 -F e b -0 2 2 6 -F e b -0 2 11 0 R 122.15 R 1.732.79 C ure R 109.04
077 20 -F e b -0 2 2 4 -F e b -0 2 5 R 1.598.34 2 0 -F e b -0 2 2 4 -F e b -0 2 14 R 464.76 N A N A 0 0 R 0.00 R 2.063.09 In d e te rm in a te R 109.04
0 8 0 2 4 -F e b -0 2 2 7 -F e b -0 2 4 R 1.278.67 2 4 -F e b -0 2 2 8 -F e b -0 2 12 R 398.36 2 8 -F e b -0 2 0 1 -M a r-0 2 4 0 R 44.42 R 1.721.46 C u re R 109.04
0 8 2 0 7 -M a r-0 2 0 9 -M a r-0 2 3 R 959.00 0 7 -M ar-0 2 0 9 -M a r-0 2 9 R 298.77 10-M ar-02 11-M a r-0 2 4 0 R 44.42 R 1.302.16 C u re R 109.04
083 1O -M ar-02 14 -M a r-0 2 5 R 1.598.34 10 -M a r-0 2 14 -M a r-0 2 12 R 398.36 14-M ar-02 15 -M a r-0 2 4 0 R 44.42 R 2.041.12 C ure R 109.04
086 18 -M ar-02 2 0 -  M a r-0 2 3 R 959.00 18-M ar-02 2 1 -M a r-0 2 9 R 298.77 2 1 -M a r-0 2 2 3 -M a r-0 2 6 0 R 66.63 R 1.324.40 C ure R 109.04
087 29 -M a r-0 2 0 2 -A o r-0 2 4 R 1.278.67 30 -M a r-0 2 0 2 -A p r-0 2 9 R 298.77 02-A o r-0 2 0 2 -A p r-0 2 0 R 11.10 R 1.588.55 C ure R 109.04
089 1 6-A pr-02 2 5 -A p r-0 2 6 R 1.918.00 1 7-A pr-02 2 3 -A p r-0 2 16 R 531.15 2 3-A p r-0 2 2 5 -A p r-0 2 6 0 R 66.63 R 2.515.78 C u re R 109.04
092 0 9 -M a v-0 2 1 2 -M a v-0 2 4 R 1.278.67 0 9 -M a v -0 2 1 3-M av-02 12 R 398.36 13-M av-02 1 4 -M a v-0 2 3 0 R 33.31 R 1.710.34 C u re R 109.04
094 0 9 -Ju n -0 2 1 3 -Ju n -0 2 5 R 1.598.34 0 9 -Ju n -0 2 1 3 -Ju n -0 2 12 R 398.36 13 -Jun -02 15 -Ju n -0 2 6 0 R 66.63 R 2.063.32 C ure R 109.04
096 0 9 -J u l-0 2 1 1 -Ju l-0 2 3 R 959.00 0 9 -Ju i-0 2 12 -Ju l-0 2 8 R 265.57 1 2 -Ju l-0 2 1 4 -Ju l-0 2 6 0 R 66.63 R 1.291.20 C ure R 109.04
098 1 1 -A ua-02 1 5 -A u q -0 2 5 R 1.598.34 1 1-AUQ-02 16 -A u q -0 2 15 R 497.95 N A N A 0 0 R 0.00 R 2.096.29 C ure R 109.04
099 1 1 -A u a -0 2 15-AUQ-02 5 R 1.598.34 1 1 -A uo-02 16 -A u q -0 2 14 R 464.76 1 6 -A u q -0 2 18 -A u q -0 2 5 0 R 55.52 R 2.118.61 C u re R 109.04
I TOTALS I I 249 I R79.597.18l I 581 I R 19,420.131 I 141 I 0 1 R 1.565.711 R 100,583.031 I R 5,452.00




THERAPEUTIC ADJUNCTIONS / TREATMENT GROUP A / ITT
THERAPEUTIC
ADJUNCTIONS
UNITS STARTDATE STOP DATE COST
003 N asogas tric  T ube 1 22-Feb-01 23-Feb-01 R 16.30
003 U rinary  C a the te r 1 22-Feb-01 23-Feb-01 R 23.46
004 N asogastric  T ube 1 23-Feb-01 25-Feb-01 R 16.30
004 U rinary  C a the te r 1 23-Feb-01 25-Feb-01 R 23.46
005 C entra l V enous  C a th e te r 1 15-M ar-01 25-M ar-01 871.13
005 C hes t P hys io the rapy 1 15-M ar-01 28-M ar-01 R 1,913.10
005 N asogastric  T ube 1 15-M ar-01 16-M ar-01 R 16.30
005 O xygen  F ace  M ask 1 17-M ar-01 26-M ar-01 R 50.00
005 O xygen  F ace  M ask 1 15-M ar-01 17-M ar-01 R 50.00
005 O xygen  F ace  M ask 1 23-M ar-01 28-M ar-01 R 50.00
005 U rina ry  C a the te r 1 15-M ar-01 28-M ar-01 R 23.46
007 U rina ry  C a the te r 1 26-M ar-01 04-Apr-01 R 23.46
009 C hest P hys io the rapy 1 07-Apr-01 09-Apr-01 R 409.95
009 N asogas tric  T ube 1 06-Apr-01 07-Apr-01 R 16.30
009 U rina ry  C a the te r 1 06-Apr-01 08-Arp-01 R 23.46
010 C hest P hys io the rapy 1 10-Apr-01 12-Apr-01 R 409.95
010 N asogas tric  T ube 1 09-Apr-01 09-Apr-01 R 16.30
010 U rina ry  C a the te r 1 08-Apr-01  09-Apr-01 R 23.46
014 N asogas tric  T  ube 1 06-M ay-01 07-M ay-01 R 16.30
014 U rina ry  C a the te r 1 06-M ay-01 07-M av-01 R 23.46
016 C en tra l V enous C a the te r 1 13-M ay-01 20-M ay-01 871.13
016 O xygen  F ace  M ask 1 13 M a y  01 13-M ay-01 R 50.00
016 urina ry  ca th e te r 1 13-M ay-01 19-M ay-01 R 23.46
018 U rina ry  C a the te r 1 15-M ay-01 17-M ay-01 R 23.46
019 N asogastric  T ube 1 16-M ay-01 18-M ay-01 R 16.30
019 O xygen  F ace  M ask 1 16-M ay-01 17-M ay-01 R 50.00
019 U rinary  ca th e te r 1 16-M ay-01 18-M ay-01 R 23.46
021 U rina ry  C a the te r 1 29-M  ay-01 01-Jun-01 R 23.46
022 NA 0 NA NA R 0.00
025 N asogastric  T ube 1 19-Jun-01 21-Jun-01 R 16.30
025 U rinary  C a th e te r 1 20-Jun-01 21-Jun-01 R 23.46
028 U rina ry  C a the te r 1 03-Aug-01 04-Aug-01 R 23.46
030 N asogastric  T ube 1 14-Aug-01 17-Aug-01 R 16.30
030 U rina ry  C a the te r 1 14-Aug-01 16-Aug-01 R 23.46
031 U rinary  C a the te r 1 23-Aug-01 24-Aug-01 R 23.46
036 N asogastric  Tube 1 13-Aug-01 17-Aug-01 R 16.30
036 O xyg e n  F ace  M ask 1 14-Aug-01 16-Aug-01 R 50.00
036 U rina ry  C a the te r 1 13-Aug-01 16-Aug-01 R 23.46
038 NA 0 NA NA R 0.00
040 C hest tubes 1 03-O ct-01 15-Oct-O1 R 87.52
040 P acked  Red ce lls 4 06-O ct-01 NA R 2,100.00
040 U rina ry  C a the te r 1 06-O ct-01 09-O ct-01 R 23.46
042 N asogas tric  T ube 1 19-Oct-O1 22-O ct-01 R 16.30
042 P acked  R ed ce lls 2 19-Oct-O1 19-Oct-O1 R 1,050.00
042 U rina ry  C a the te r 1 19-Oct-O1 22-O ct-01 R 23.46
042 U rinary  C a the te r 1 28-O ct-01 03-N ov-01 R 23.46
044 N asogas tric  T ube 1 2 1 -N ov-01 22-N ov-01 R 16.30
044 U rina ry  ca th e te r 1 21 -N ov-01 22-N ov-O I R 23.46
045 U rinary  C a the te r 1 2 1 -N ov-01 22-N ov-O I R 23.46
047 N asogas tric  T ube 1 30-O ct-01 31-O ct-01 R 16.30
047 N asogastric  T ube 1 03-NOV-01 05-NOV-01 R 16.30
047 U rina ry  C a the te r 1 30-O ct-01 30-O ct-01 R 23.46
049 N A 0 N A NA R 0.00
051 C en tra l V enous  C a the te r 1 12-N ov-O I 13-N ov-O I 871.13










051 O xygen  Face  M ask 1 12-N ov-01 12-Nov-01 R 50.00
051 U rinary  C a the te r 1 11-N ov-01 13-Nov-01 R 23.46
054 N asogastric  T ube 1 19-N ov-01 22-N ov-O I R 16.30
054 P acked  Red ce lls 4 19-Nov-01 19-Nov-01 R 2,100.00
054 U rina ry  C a the te r 1 19-Nov-01 20-N ov-01 R 23.46
055 N asogastric  T ube 1 20-N ov-01 20-N ov-O I R 16.30
055 U rina ry  C a the te r 1 20-N ov-01 2 1 -Nov-01 R 23.46
059 O xygen  F ace  M ask 1 09-D ec-01 10-Dec-01 R 50.00
059 U rinary  C a the te r 1 09-D ec-01 10-Dec-01 R 23.46
060 N asogastric  T ube 1 12-Dec-01 12-Dec-01 R 16.30
060 U rina ry  C a the te r 1 12-Dec-01 12-Dec-01 R 23.46
061 C hest T ubes 1 15-Dec-01 18-Dec-01 R 87.52
061 N asogastric  T ube 1 15-Dec-01 16-Dec-01 R 16.30
061 O xygen  Face M ask 1 15-Dec-01 16-Dec-01 R 50.00
061 U rina ry  C a the te r 1 15-Dec-01 17-Dec-01 R 23.46
062 C en tra l V enous  C a th e te r 1 16-Dec-01 17-Dec-01 871.13
062 U rina ry  C a the te r 1 16-Dec-01 18-Dec-01 R 23.46
066 N A 0 N A NA R 0.00
068 N asogastric  tube 1 11-Jan-02 16-Jan-02 R 16.30
068 O xygen  Face M ask 1 12-Jan-02 16-Jan-02 R 50.00
068 O xygen  Face m ask 1 12-Jan-02 12-Jan-02 R 50.00
068 O xygen  F ace  m ask 1 16-Jan-02 19-Jan-02 R 50.00
068 U rina ry  C a the te r 1 11-Jan-02 19-Jan-02 R 23.46
071 N asogastric  T ube 1 22-Jan -02 24-Jan-02 R 16.30
071 O xygen  F ace  M ask 1 2 2 -Jan-02 23-Jan-02 R 50.00
071 U rina ry  C a the te r 1 2 2 -Jan-02 24-Jan -02 R 23.46
072 U rina ry  C a th e te r 1 23-Jan -02 24 -Jan -02 R 23.46
073 C hest tubes 1 24-Jan -02 29-Jan -02 R 87.52
073 N asogastric  T ube 1 24-Jan -02 25-Jan -02 R 16.30
073 N asogastric  T ube 1 30-Jan -02 31-Jan-02 R 16.30
073 N asogas tric  T ube 1 08-Feb-02 10-Feb-02 R 16.30
073 P acked R ed ce lls 2 23-Jan -02 24-Jan-02 R 1,050.00
073 U rinary  C a the te r 1 23 -Jan -02 25-Jan-02 R 23.46
073 U rinary  C a the te r 1 08 -F eb-02 11-Feb-02 R 23.46
074 U rinary  C a the te r 1 31-Jan-02 31-Jan-02 R 23.46
075 N asogastric  tube 1 18-Feb-02 20-F eb-02 R 16.30
075 U rina ry  C a the te r 1 18-Feb-02 20-F eb-02 R 23.46
078 Fresh frozen  p lasm a 2 26 -F eb -02 26-F eb-02 R 1,560.00
078 P acked  R ed ce lls 2 26 -F eb-02 26-F eb-02 R 1,050.00
079 N asogastric  T ube 1 23-F eb-02 25-Feb-02 R 16.30
079 O xygen  F ace  m ask 1 25 -F eb-02 25-F eb-02 R 50.00
079 U rinary  ca th e te r 1 24 -F eb -02 25-Feb-02 R 23.46
081 U rinary  C a th e te r 1 27 -F eb-02 28-F eb-02 R 23.46
084 N asogastric  T ube 1 20-M ar-02 21 -M ar-02 R 16.30
084 U rina ry  C a the te r 1 13-M ar-02 14-M ar-02 R 23.46
084 U rina ry  C a the te r 1 20 -M ar-02 24-M ar-02 R 23.46
085 O xygen  F ace  M ask 1 18-M ar-02 18-M ar-02 R 50.00
085 U rina ry  C a the te r 1 18-M ar-02 18-M ar-02 R 23.46
088 U rina ry  C a the te r 1 03 -A pr-02 04-A pr-02 R 23.46
090 N asogas tric  Tube 1 2 1 -A p r-02 22 -A pr-02 R 16.30
090 U rinary  C a th e te r 1 20 -A pr-02 22-A pr-02 R 23.46
091 C hest T ubes 1 15-M ay-02 O ngo ing R 87.52
091 D ia lis is  C a the te r 1 16-M ay-02 O ngo ing R 1,649.31
091 F resh F rozen P lasm a 4 15-M ay-02 15-M ay-02 R 3,120.00










091 N asogastric  T ube 1 01 -M ay-02 03-M ay-02 R 16.30
091 N asogastric  T ube 1 10-M ay-02 O ngo ing R 16.30
091 P acked  R ed ce lls 2 15-M ay-02 15-M ay-02 R 1,050.00
091 P acked  R ed ce lls 4 17-M ay-02 17-M ay-02 R 1,050.00
091 U rinary  C a the te r 1 01 -M ay-02 03-M ay-02 R 23.46
091 U rinary  C a the te r 1 10-M ay-02 O ngo ing R 23.46
093 O xygen  F ace  M ask 1 12-M ay-02 12-M ay-02 R 50.00
093 U rina ry  C a the te r 1 12-M ay-02 13-M ay-02 R 23.46
095 N asogastric  T ube 1 06-JUI-02 08-Ju l-02 R 16.30
095 O xygen  F ace  M ask 1 20-Jun-02 20-Jun -02 R 50.00
095 U rina ry  C a the te r 1 20 -Jun -02 21-Jun -02 R 23.46
097 U rina ry  C a the te r 1 25 -Ju l-02 26 -Ju l-02 R 23.46
100 U rina ry  C a the te r 1 02 -M ay-02 03-M ay-02 R 23.46
100 U rina ry  C a th e te r 1 04 -M ay-02 08-M ay-02 R 23.46











001 Central Venous Catheter 16-Feb-01 23-Feb-01 R 871.13
002 Nasogastric Tube 20-Feb-01 21-Feb-01 R 16.30
002 Urinary Catheter 19-Feb-01 21-Feb-01 R 23.46
006 Arterial Catheter 04-Apr-01 10-Apr-01 R 303.18
006 Chest Tube Left & right 26-Mar-01 01-Apr-01 R 87.52
006 Nasal C-pap 04-Apr-01 10-Apr-01 R 765.36
006 Nasogastric Tube 26-Apr-01 26-Apr-01 R 16.30
006 Nasogastric Tube 03-Apr-01 10-Apr-01 R 16.30
006 Oxygen Face Mask 26-Mar-01 23-Apr-01 R 50.00
006 Oxygen Face Mask 10-Apr-01 16-Apr-01 R 50.00
006 Urinary Catheter 26-Apr-01 26-Apr-01 R 23.46
008 Arterial Catheter 29-Mar-01 17-Apr-01 R 303.18
008 Central Venous Catheter 29-Mar-01 17-Apr-01 R 971.13
008 Nasogastric Tube 29-Mar-01 17-Apr-01 R 16.30
008 Oxygen Face Mask 31-Mar-01 17-Apr-01 R 50.00
008 Oxygen Face Mask 29-Mar-01 31-Mar-01 R 50.00
008 Urinary catheter 29-Mar-01 17-Apr-01 R 23.46
011 Urinary Catheter 11-Apr-01 12-Apr-01 R 23.46
012 Nasogastric Tube 15-Apr-01 15-Apr-01 R 16.30
012 Urinary catheter 15-Apr-01 15-Apr-01 R 23.46
013 Nasogastric Tube 01-May-01 02-May-01 R 16.30
013 Urinary catheter 30-Apr-01 03-May-01 R 23.46
015 Urinary Catheter 09-May-01 10-May-01 R 23.46
017 NA NA NA R 0.00
020 Nasogastric Tube 22-May-01 23-May-01 R 16.30
020 Urinary catheter 22-May-01 23-May-01 R 23.46
023 Urinary Catheter 11-Jun-01 12-Jun-01 R 23.46
024 Nasogastric Tube 19-Jun-01 20-Jun-01 R 16.30
024 Oxygen Face Mask 19-Jun-01 24-Jun-01 R 50.00
024 Urinary Catheter 19-Jun-01 20-Jun-01 R 23.46
026 Chest Tube Left & right 30-Jun-01 06-Jun-01 R 84.52
026 Nasogastric tube 20-Jun-01 01-Jul-01 R 16.30
026 Urinary Catheter 30-Jun-01 02-Jul-01 R 23.46
027 Nasogastric Tube 02-Aug-01 03-Aug-01 R 16.30
027 Urinary Catheter 02-Aug-01 03-Aug-01 R 23.46
029 Nasogastric Tube 09-Aug-01 11-Aug-01 R 16.30
029 Nasogastric Tube 15-Aug-01 18-Aug-01 R 16.30
029 Urinary Catheter 09-Aug-01 11-Aug-01 R 23.46
032 Urinary Catheter 23-Aug-01 24-Aug-01 R 23.46
033 Oxygen Face Mask 10-Aug-01 10-Aug-01 R 50.00
033 Urinary Catheter 10-Aug-01 11-Aug-01 R 23.46
034 Urinary Catheter 12-Aug-01 14-Aug-01 R 23.46
035 Urinary Catheter 13-Aug-01 18-Aug-01 R 23.46
037 NA NA NA R 0.00
039 Urinary Catheter 01-Oct-01 02-Oct-01 R 23.46
043 NA NA NA R 0.00
046 Central Venous Catheter 23-Oct-01 NA R 871.13
046 Fresh frozen plasma 3 23-Oct-01 25-Oct-01 R 2,340.00
046 Nasogastric tube 23-Oct-01 01-Nov-01 R 16.30
046 Oxygen Face Mask 29-Oct-01 03-Nov-01 R 50.00
046 Urinary catheter 22-Oct-01 01-Nov-01 R 23.46
048 Chest Tube Left & right 02-Nov-01 13-Nov-01 R 87.52
048 Nasogastric Tube 29-Oct-01 31-Oct-01 R 16.30
048 Oxygen Face Mask 02-Nov-01 22-Nov-01 R 50.00
048 Urinary Catheter 29-Oct-01 31-Oct-01 R 23.46
050 Urinary Catheter 08-Nov-01 09-Nov-01 R 23.46
052 Urinary Catheter 17-Nov-01 17-Nov-01 R 23.46
053 Nasogastric Tube 19-Nov-OI 20-Nov-01 R 16.30
053 Urinary Catheter 19-Nov-01 20-Nov-01 R 23.46
056 NA NA NA R 0.00
056 NA NA NA R 0.00
057 Urinary Catheter 03-Dec-01 04-Dec-01 R 23.46
057 Urinary Catheter 03-Dec-01 04-Dec-01 R 23.46











058 Urinary Catheter 09-Dec-01 10-Dec-01 R 23.46
063 Nasogastric Tube 17-Dec-01 18-Dec-01 R 16.30
063 Urinary Catheter 16-Dec-01 18-Dec-01 R 23.46
064 Chest Tube Left 18-Dec-01 20-Dec-01 R 43.76
064 Chest Tube Right 18-Dec-01 21-Dec-01 R 43.76
064 Nasogastric tube 18-Dec-01 19-Dec-01 R 16.30
064 Oxygen Face Mask 18-Dec-01 20-Dec-01 R 50.00
064 Urinary catheter 18-Dec-01 19-Dec-01 R 23.46
065 Urinary Catheter 02-Jan-02 03-Jan-02 R 23.46
067 Urinary Catheter 05-Jan-02 06-Jan-02 R 23.46
069 Oxygen Face Mask 14-Jan-02 16-Jan-02 R 50.00
069 Urinary Catheter 12-Jan-02 14-Jan-02 R 23.46
070 Nasogastric tube 14-Jan-02 15-Jan-02 R 16.30
070 Oxygen Face Mask 15-Jan-02 18-Jan-02 R 50.00
070 Oxygen Face Mask 14-Jan-02 15-Jan-02 R 50.00
070 Urinary catheter 14-Jan-02 15-Jan-02 R 23.46
076 Nasogastric tube 19-Feb-02 20-Feb-02 R 16.30
076 Urinary Catheter 19-Feb-02 20-Feb-02 R 23.46
077 Oxygen Face Mask 20-Feb-02 20-Feb-02 R 50.00
077 Urinary catheter 20-Feb-02 21-Feb-02 R 23.46
080 Urinary catheter 24-Feb-02 25-Feb-02 R 23.46
082 NA NA NA R 0.00
083 Oxygen Face Mask 10-Mar-02 11-Mar-02 R 50.00
086 Urinary Catheter 18-Mar-02 19-Mar-02 R 23.46
087 Urinary Catheter 30-Mar-02 31-Mar-02 R 23.46
089 NA NA NA R 0.00
092 Arterial Catheter 08-May-02 13-May-02 R 303.18
092 Nasogastric Tube 08-May-02 11-May-02 R 16.30
092 Urinary Catheter 09-May-02 10-May-02 R 23.46
094 Nasogastric Tube 09-Jun-02 11-Jun-02 R 16.30
094 Oxygen Face Mask 09-Jun-02 10-Jun-02 R 50.00
094 Urinary Catheter 09-Jun-02 10-Jun-02 R 23.46
096 NA NA NA R 0.00
098 Oxygen Face Mask 11-Aug-02 12-Aug-02 R 50.00
098 Urinary Catheter 10-Aug-02 12-Aug-02 R 23.46
099 Arterial Catheter 11-Aug-02 12-Aug-02 R 303.18
099 Central Venous Catheter 11-Aug-02 12-Aug-02 R 871.13
099 Urinary Catheter 11-Aug-02 12-Aug-02 R 23.46
ITOTAL | R 10,377.36
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ADVERSE EVENTS / TREATMENT GROUP A / PPP
ADVERSE EVENT START DATE STOP DATE
003 W o u n d  In fection 01-M ar-01 08-M ar-01
014 Incom p le te  sm a ll bow el obs truc tion 17-M ay-01 28 M a y 01
V o m itin g 05-Jun-01 05-Jun-01
018 H aem op tys is 18-M ay-01 18-M ay-01
036 W o u n g  S epsis 18-Aug-01 30-Aug-01
042 S ubph re n ic  abscess 25-O ct-01 28-O ct-01
V ig ina l cand idas is 06-N ov-01 08-N ov-01
049 H eadache 04-N ov-01 04-N ov-01
055 A bd o m e n  and  th ig h  U rtica ria 22-N ov-01 26-N ov-01
068 A d u lt resp ira to ry  d is tress  synd rom e 12-Jan-02 18-Jan-02
079 E n te rocu ta neous  F is tu la 07 -M ar-02 18-M ar-02
M u ltip le  o rgan dys fu n c tio n  synd rom e 14-M ay-02 O ngo ing




ADVERSE EVENTS / TREATMENT GROUP B / PPP
ADVERSE EVENT START DATE STOP DATE
001 A b d o m in a l Pain 17-M ar-01 19-M ar-01
013 O titis  E x te rna 22-M ay-01 ongo ing
029 G astril S tas is 13-Aug-01 17-Aug-01
056 P artia l D eh iscence - A p p e n d e ltm y  w ound 08-D ec-01 04-Jan -02
T h ru m b o p le b itis 30-N ov-01 01 -Dec-01
070 P eriana l abscess 17-Jan-02 17-Jan-02
087 D ia rrheoa 19-A pr-02 2 1 -A pr-02
B ronch itis 19-A pr-02 24-A pr-02
W o u n d  A bscess 22 -A pr-02 24 -A pr-02
089 C en tra l V enuos  C e the te r 17-A pr-02 23 -A pr-02
N asogas tric  T ube 17-A pr-02 22-A pr-02
U rina ry  A th e te r 17-A pr-02 22 -A pr-02
O xygen  F acem ask 17-A pr-02 22 -A pr-02









UNITS ROUTE START DATE STOP DATE COST
CONSUM­
ABLES
003 Gentamvcin 160 mg IV 22-Feb-01 22-Feb-01 R 255.98 R 0.92
003 Flaavl 500 mg IV 22-Feb-01 22-Feb-01 R 33.20 R 0.92
004 NA NA NA NA NA NA R 0.00 R 0.00
007 NA NA NA NA NA NA R 0.00 R 0.00
009 NA NA NA NA NA NA R 0.00 R 0.00
010 Zinacef 1.5 9 IV 08-Apr-01 08-Apr-01 R 82.51 R 0.92
010 Flagyl 500 mg IV 08-Apr-01 08-Apr-01 R 33.20 R 0.92
014 Kefzol 2 g IV 06-May-01 06-Mav-01 R 247.84 R 0.92
018 NA NA NA NA NA NA R 0.00 R 0.00
019 Augmentin 1.2 g IV 16-Mav-01 16-May-01 R 53.28 R 0.92
022 Zinacef 1.5 g IV 30-May-01 30-May-01 R 82.51 R 0.92
022 Flagyl 500 mg IV 30-May-01 30-May-01 R 33.20 R 0.92
025 Zinacef 1.5 mg IV 20-Jun-01 20-Jun-01 R 82.51 R 0.92
025 Flagyl 500 mg IV 20-Jun-01 20-Jun-01 R 33.20 R 0.92
028 Augmentin 2.4 g IV 03-Aug-01 03-Auq-01 R 106.56 R 0.92
028 Flagyl 1000 mg IV 03-Aug-01 03-Aug-01 R 66.40 R 0.92
030 NA NA NA NA NA NA R 0.00 R 0.00
031 Kefzol 1 g IV 23-Aug-01 23-Aug-01 R 123.92 R 0.92
036 NA NA NA NA NA NA R 0.00 R 0.00
038 NA NA NA NA NA NA R 0.00 R 0.00
042 Augmentin 1.2 g IV 18-Oct-01 18-Oct-O1 R 53.28 R 0.92
042 Flagyl 500 mg IV 18-Oct-O1 18-Oct-O1 R 33.20 R 0.92
042 Penicillin G 1 mu IV 19-Oct-01 19-Oct-O1 R 29.94 R 0.92
042 Gentamycin 240 mg IV 19-Oct-O1 19-Oct-01 R 383.97 R 0.92
042 Gentamycin 240 mg IV 28-Oct-01 04-NOV-01 R 3,071.76 R 0.92
042 Flagyl 400-1200 mg PO 28-Oct-01 01-Nov-01 R 49.65 R 0.00
042 Penicillin G 4-16 mu IV 29-Oct-01 04-NOV-01 R 209.58 R 0.92
042 Ciprobay 250-500 mg PO 10-NOV-01 15-Nov-OI R 164.22 R 0.00
042 Penicillin G 12-16 12-16 PO 06-NOV-01 07-Nov-01 R 59.88 R 0.00
042 Gentamycin 240 mg IV 06-Nov-01 07-Nov-01 R 767.94 R 0.92
042 Penicillin G 4-12 mu IV 09-Nov-OI 10-NOV-01 R 59.88 R 0.92
042 Gentamycin 240 mg IV 09-Nov-01 09-Nov-01 R 383.97 R 0.92
042 Flagyl 400-1200 mg PO 03-NOV-01 15-Nov-OI R 129.09 R 0.00
044 Zinacef 750 mg IV 20-Nov-01 21-NOV-01 R 94.90 R 0.92
044 Flagyl 500 mg IV 20-NOV-01 20-NOV-01 R 33.20 R 0.92
045 NA NA NA NA NA NA R 0.00 R 0.00
049 Augmentin 1.2 g IV 04-Nov-01 04-NOV-01 R 53.28 R 0.92
051 Augmentin 1.2 g IV 11-NOV-01 11-Nov-01 R 53.28 R 0.92
051 Mandokef 1 g IV 11-Nov-01 11-Nov-01 R 119.31 R 0.92
054 NA NA NA NA NA NA R 0.00 R 0.00
055 Augmentin 1.2 g IV 20-NOV-01 20-Nov-01 R 53.28 R 0.92
059 Zinacef 1.5 g IV 09-Dec-01 09-Dec-01 R 82.51 R 0.92
059 Flagyl 1000 mg IV 09-Dec-01 09-Dec-01 R 66.40 R 0.92
059 Kefzol 1 g IV 09-Dec-01 09-Dec-01 R 123.92 R 0.92
060 Kefzol 1 g IV 12-Dec-01 12-Dec-01 R 123.92 R 0.92
060 Augmentin 1.2 g IV 11-Dec-01 12-Dec-01 R 106.56 R 0.92
061 Zinacef 1.5 g IV 15-Dec-01 15-Dec-01 R 82.51 R 0.92
061 Flagyl 1000 mg IV 15-Dec-01 15-Dec-01 R 66.40 R 0.92
061 Kefzol 1 g IV 15-Dec-01 15-Dec-01 R 123.92 R 0.92
062 NA NA NA NA NA NA R 0.00 R 0.00
066 Flagyl 500 mg IV 05-Jan-02 05-Jan-02 R 33.20 R 0.92
068 Amoxil 750 mg PO 07-Jan-02 10-Jan-02 R 26.52 R 0.00
071 Flagyl 1000 mg IV 22-Jan-02 22-Jan-02 R 66.40 R 0.92
071 Gentamycin 240 mg IV 22-Jan-02 22-Jan-02 R 383.97 R 0.92
071 Penicillin G 2 mu IV 22-Jan-02 22-Jan-02 R 29.94 R 0.92
072 NA NA NA NA NA NA R 0.00 R 0.00
074 NA NA NA NA NA NA R 0.00 R 0.00
075 Augmentin 2.4 g IV 18-Feb-02 18-Feb-02 R 106.56 R 0.92
075 Flagyl 1000 mg IV 18-Feb-02 18-Feb-02 R 66.40 R 0.92
079 Zinacef 1.5 mg IV 23-Feb-02 23-Feb-02 R 82.51 R 0.92
079 Flagyl 4 g IV 23-Feb-02 23-Feb-02 R 132.80 R 0.92
079 Cefuroxime 4.5 g IV 24-Feb-02 24-Feb-02 R 247.53 R 0.92
079 Flagyl 500 mg IV 24-Feb-02 24-Feb-02 R 33.20 R 0.92
081 Augmentin 1.2 g IV 26-Feb-02 27-Feb-02 R 106.56 R 0.92
081 Flagyl 500 mg IV 26-Feb-02 27-Feb-02 R 66.40 R 0.92
081 Augmentin 1.2 g IV 13-Mar-02 13-Mar-02 R 53.28 R 0.92
081 Augmentin 1.2-3.6 g IV 22-Mar-02 28-Mar-02 R 1,118.88 R 0.92
088 Augmentin 1.2 g IV 03-Apr-02 03-Apr-02 R 53.28 R 0.92
090 Zinacef 1.5-3 mg IV 20-Apr-02 21-Apr-02 R 330.04 R 0.92
090 Flagyl 500-1000 mg IV 20-Apr-02 21-Apr-02 R 132.80 R 0.92
091 Augmentin 1.2-3.6 g IV 29-Apr-02 30-Apr-02 R 310.68 R 0.92
091 Flagyl 500-1500 mg IV 29-Apr-02 30-Apr-02 R 199.20 R 0.92
091 Gentamycin 240 mg IV 09-May-02 13-May-02 R 1,919.85 R 0.92
091 Tazocin 4.5-18 g IV 09-May-02 15-May-02 R 8,591.80 R 0.92
091 Amikacin 1 g IV 14-May-02 14-May-02 R 1,359.00 R 0.92
091 Amikacin 1 g IV 17-May-02 17-May-02 R 1,359.00 R 0.92
091 Tienam 1.5-2 g IV 15-May-02 17-May-02 R 1,716.72 R 0.92
091 Fluconazole 200 mg IV 15-May-02 17-May-02 R 495.42 R 0.92
091 Amfoteracin B 50 mg IV 17-May-02 17-May-02 R 215.46 R 0.92
093 Augmentin 3.6 g IV 12-May-02 12-May-02 R 159.84 R 0.92
093 Flagyl 1500 mg IV 12-May-02 l2-May-02 R 99.60 R 0.92








DOSAGE UNITS ROUTE START DATE STOP DATE COST
CONSUM­
ABLES
097 Augmentin 1.2 mg IV 25-JUI-02 25-JUI-02 R 53.28 R 0.92
097 Flagyl 500 mg IV 25-JUI-02 25-JUI-02 R 33.20 R 0.92
100 Augmentin 2.4 9 IV 02-May-02 02-May-02 R 106.56 R 0.92
100 Flagyl 1000 mg IV 02-May-02 02-May-02 R 66.40 R 0.92




CONCOM ITANT ANITMICROBIAL MEDICATION / TR EA TM EN T GROUP B / PPP
IN HOSPITAL 
MEDICATION nntarp I UNITSDOSAGE 1 ROUTE
START
DATE STOP DATE COST
C O N S U M ­
A B L E S
001 Amikacin 500 mg IV 14-Feb-01 14-Feb-01 R 679.50 R 0.92
001 Claforan 1 9 IV 14-Feb-01 14-Feb-01 R 143.15 R 0.92
002 NA NA NA NA NA NA R 0.00 R 0.00
011 NA NA NA NA NA NA R 0.00 R 0.00
012 NA NA NA NA NA NA R 0.00 R 0.00
013 Zinacef 1.5 mg IV 30-Apr-01 30-Apr-01 R 82.51 R 0.92
013 Flagyl 500 mg IV 30-Apr-01 30-Apr-01 R 33.20 R 0.92
015 NA NA NA NA NA NA R 0.00 R 0.00
017 Augmentin 1.2 9 IV 15-May-01 15-May-01 R 53.28 R 0.92
020 Augmentin 1.2 g IV 22-May-01 22-May-01 R 53.28 R 0.92
023 Pennicillin G 4 mu IV 10-Jun-01 10-Jun-01 R 29.46 R 0.92
023 Gentamycin 240 mg IV 10-Jun-01 10-Jun-01 R 383.97 R 0.92
023 Flagyl 1 g PR 10-Jun-01 10-Jun-01 R 66.40 R 0.00
024 Augmentin 1.2 g IV 19-Jun-01 19-Jun-01 R 53.28 R 0.92
024 Flagyl 500 mg IV 19-Jun-01 19-Jun-01 R 33.20 R 0.92
026 Ampicillin 1 g IV 30-Jul-01 30-Jul-01 R 23.65 R 0.92
027 Zinacef 1.5 g IV 02-Aug-01 02-Aug-01 R 82.51 R 0.92
027 Flagyl 1000 mg IV 02-Aug-01 01-Aug-01 R 132.80 R 0.92
029 Flagyl 500 mg IV 09-Aug-01 09-Aug-01 R 33.20 R 0.92
029 Augmentin 1.2 g IV 09-Aug-01 09-Aug-01 R 53.28 R 0.92
032 NA NA NA NA NA NA R 0.00 R 0.00
033 Zinacef 1.5 g IV 10-Sep-01 10-Sep-01 R 82.51 R 0.92
033 Flagyl 1500 mg IV 10-Sep-01 10-Sep-01 R 99.60 R 0.92
033 Augmentin 1.2 g IV 10-Sep-01 10-Sep-01 R 53.28 R 0.92
033 Kefzol 1 g PO 10-Sep-01 10-Sep-01 R 123.92 R 0.00
034 Zinacef 1.5 g IV 12-Sep-01 12-Sep-01 R 82.51 R 0.92
034 Flagyl 500 mg IV 12-Sep-01 12-Sep-01 R 33.20 R 0.92
035 Zinacef 750 mg IV 12-Sep-01 12-Sep-01 R 41.26 R 0.92
035 Flagyl 500 mg IV 12-Sep-01 12-Sep-01 R 33.20 R 0.92
037 Zinacef 750 mg IV 27-Oct-01 27-Oct-01 R41.26 R 0.92
037 Flagyl 500 mg IV 27-Oct-01 27-Oct-01 R 33.20 R 0.92
037 Augmentin 1.2 g IV 27-Oct-01 27-Oct-01 R 53.28 R 0.92
039 NA NA NA NA NA NA R 0.00 R 0.00
041 Zinacef 1.5 g IV 10-Oct-01 10-Oct-01 R 82.51 R 0.92
041 Flagyl 1000 mg IV 10-Oct-01 10-Oct-01 R 66.40 R 0.92
043 NA NA NA NA NA NA R 0.00 R 0.00
046 Augmentin 1.2 g IV 23-Oct-01 23-Oct-01 R 53.28 R 0.92
046 Cefepime 2-4 g IV 29-Oct-01 04-NOV-01 R 1,575.00 R 0.92
046 Gentamycin 240 mg IV 29-Oct-01 03-NOV-01 R 2,303.82 R 0.92
046 Mandokef 1 g IV 22-Oct-01 22-Oct-01 R 119.31 R 0.92
050 Augmentin 1.2 g IV 07-Nov-01 07-Nov-01 R 53.28 R 0.92
053 NA NA NA NA NA NA R 0.00 R 0.00
056 Augmentin 1.2 g IV 27-Nov-01 27-Nov-OI R 53.28 R 0.92
056 Flagyl 500 mg IV 27-Nov-01 27-Nov-01 R 33.20 R 0.92
057 Kefeol 1 g IV 03-Dec-01 03-Dec-01 R 123.92 R 0.92
057 Flagyl 500 mg IV 03-Dec-01 03-Dec-01 R 33.20 R 0.92
058 NA NA NA NA NA NA R 0.00 R 0.00
063 Zinacef 1.5 g IV 16-Dec-01 16-Dec-01 R 82.51 R 0.92
063 Flagyl 500 mg IV 16-Dec-01 16-Dec-01 R 33.20 R 0.92
063 Kefzol 1 g IV 17-Dec-01 17-Dec-01 R 123.92 R 0.92
064 Kefeol 1 g IV 17-Dec-01 17-Dec-01 R 123.92 R 0.92
065 NA NA NA NA NA NA R 0.00 R 0.00
069 Zinacef 1.5 g IV 12-Jan-02 12-Jan-02 R 82.51 R 0.92
039 Flagyl 500 mg IV 12-Jan-02 12-Jan-02 R 33.20 R 0.92
070 Augmentin 1.2 g IV 14-Jan-02 14-Jan-02 R 53.28 R 0.92
076 Ampicillin 1 g IV 19-Feb-02 19-Feb-02 R 23.65 R 0.92
076 Gentamycin 240 mg IV 19-Feb-02 19-Feb-02 R 383.97 R 0.92
076 Flagyl 1000 mg IV 19-Feb-02 19-Feb-02 R 66.40 R 0.92
076 Kefzol 1 g IV 19-Feb-02 19-Feb-02 R 123.92 R 0.92
082 Augmentin 1.2 g IV 07-Mar-02 07-Mar-02 R 53.28 R 0.92
083 Kefeol 1 g IV 10-Mar-02 10-Mar-02 R 1,323.23 R 0.92
083 Flagyl 500 mg IV 10-Mar-02 10-Mar-02 R 33.20 R 0.92
083 Augmentin 3.6 mg PO 25-Mar-02 29-Mar-02 R 799.20 R 0.00
086 Zinacef 1.5-3.0 g IV 17-Mar-02 18-Mar-02 R 330.04 R 0.92
086 Flagyl 500-1000 mg IV 17-Mar-02 18-Mar-02 R 132.80 R 0.92
087 Augmentin 1.2 g IV 29-Mar-02 30-Mar-02 R 106.56 R 0.92
087 Augmentin 1.2-4.8 g IV 22-Apr-02 24-Apr-02 R 639.36 R 0.92
089 Augmentin 1.2 g IV 17-Apr-02 17-Apr-02 R 53.28 R 0.92
089 Betadine 1 applic TOP 18-Apr-02 18-Apr-02 R 45.37 R 0.00
092 Augmentin 1.2 g IV 08-May-02 08-May-02 R 53.28 R 0.92
092 Flagyl 500 mg IV 08-May-02 08-May-02 R 33.20 R 0.92
094 Augmentin 1.2 g IV 08-Jun-02 09-Jun-02 R 106.56 R 0.92










DATE STOP DATE COST
C O N S U M ­
A B L E S
096 Augmentin 1.2 g IV 09-Jul-02 09-Jul-02 R 53.28 R 0.92
096 Flagyl 500 mg IV 09-Jul-02 09-Jul-02 R 33.20 R 0.92
098 Kefzol 1 g IV 11-Aug-02 11-Aug-02 R 123.92 R 0.92
098 Flagyl 500 mg IV 11-Aug-02 11-Aug-02 R 33.20 R 0.92
099 Zinacef 1.5 g IV 11-Aug-02 11-Aug-02 R 82.51 R 0.92
099 Flagyl 500 mg IV 11-Aug-02 11-Aug-02 R 33.20 R 0.92
099 Amoxicillin 1500 mg PO 04-Sep-02 09-Sep-02 R 89.46 R 0.00











STA R T DATE STOP D ATE C O S T
0 0 3 P e th e d in e 1 5 0 - 3 0 0 m g IM R  5 3 .4 0 2 3 -F e b -0 1 27 -F e b -0 1 R 119.92
M a xa lo n 10 m g IM R 2 1 .3 6 2 3 -F e b -0 1 24 -F e b -0 1 R 6.88
D o lo ro l F o rte 1 0 1 6 -2 0 3 2 m g PO R  0 .00 2 7 -F e b -0 1 0 1 -M a r-0 1 R 11.28
D o lo ro l F o rte 1016 m g PO R 0 .0 0 08 -M a r-0 1 12 -M ar-01 R 9.40
0 0 4 M o rp h in e 2 0 -3 0 m g IM R  5 3 .4 0 2 3 -F e b -0 1 2 7 -F e b -0 1 R 106.31
D o lo ro l F o rte 20 3 2 m g PO R 0 .00 26 -F e b -0 1 26 -F e b -0 1 R 3.76
D o x y fe n e 2 ta b s P O R  0 .00 2 8 -F e b -0 1 2 8 -F e b -0 1 R 7.19
0 0 7 M o rp h in e 10-30 m g IM R 53 .40 2 6 -M a r-0 1 3 0 -M a r-0 1 R 106.31
0 0 9 M o rp h in e 2 0 -4 0 m g IM R  4 2 .7 2 0 7 -A p r-0 1 10 -A pr-01 R 113.40
0 1 0 M o rp h in e 10-20 m g IM R 4 2 .7 2 0 9 -A p r-0 1 12 -A pr-01 R 56.70
B e ro te c 1 .25 -3 .75 m g IN H R  0 .00 11-A p r-0 1 13 -A pr-01 R 50.35
A tro v e n t 0 .5 -1 .5 m g IN H R 0 .0 0 11-A p r-0 1 13 -A pr-01 R 95.75
0 1 4 M o rp h in e 10-20 m g IM R  4 2 .7 2 07 -M a y-0 1 10-M ay-01 R 56.70
D o lo ro l F o rte 1 0 1 6 -20 32 m g PO R 0 .00 0 9 -M ay-01 12-M ay-01 R 15.04
P e th e d in e 0 -50 m g IM R  6 4 .0 8 2 1 -M a y-0 1 26 -M a y-0 1 R 44.30
0 1 8 M o rp h in e 10-30 m g IM R  7 4 .7 6 15 -M ay-01 21 -M a y-0 1 R 148.83
P e th e d in e 50 m g IM R  3 2 .0 4 15 -M ay-01 17-M ay-01 R 22.14
T e ta n u s  to xo id 0 .5 m l IM R  3 .56 13 -M ay-01 13-M ay-01 R 35.68
N im b e x 8 m g IV R 19 .39 1 5 -M ay-01 1 5 -M ay-01 R 198.78
N e o s tig m in e 2 .5 m g IV R  0 .92 15 -M ay-01 15-M ay-01 R 6.54
R o b in u l 0 .6 m g IV R 0 .92 1 5 -M ay-01 15-M ay-01 R 220.59
0 1 9 M o rp h in e 2 0 -3 0 m g IV R  19 .39 17 -M ay-01 18-M ay-01 R 42.52
D o lo ro l F o rte 1 0 1 6 -2 0 3 2 m g PO R 0 .00 19 -M ay-01 22 -M ay-01 R 15.04
0 2 2 V e n to lin 5 -25 m g IN H R  0 .00 30 -M a y-0 1 0 3 -Jun -01 R 76.61
A tro v e n t 0 .2 5 -1 .2 5 m g IN H R 0 .00 3 0 -M ay-01 03 -Jun -01 R 132.98
M o rp h in e 10-40 m g IM R  5 3 .4 0 30 -M a y-0 1 03 -Jun -01 R 141.75
V a liu m 10 m g PO R  0 .00 03 -Jun -01 03 -Jun -01 R 11.72
V a liu m 20 m g IM R 3 .56 0 3 -Jun -01 0 3 -Jun -01 R 23.45











STA R T D ATE STOP D ATE C O ST
P e th e d in e 75 m g IM R  3 .56 30 -M a y-0 1 3 0 -M ay-01 R 14.03
T e ta n u s  to x o id 0 .5 m l IM R  3 .5 6 30 -M a y-0 1 30 -M ay-01 R 35.68
0 2 5 M o rp h in e 2 0 -4 0 m g IV R  19 .39 2 0 -Jun -01 2 5 -Ju n -0 1 R 170.10
M a xa lo n 10 m g IM R 3 .56 2 1 -Jun -01 21-Jun -01 R 6.99
M a x a lo n 10 m g IM R  3 .56 2 3 -Jun -01 2 3 -Ju n -0 1 R 6.88
0 2 8 M o rp h in e 10 m g IM R  3 2 .0 4 0 3 -A ug -01 0 5 -A ug -01 R 21.27
S te m e til 12.5 m g IM R  3 .56 0 5 -A u g -0 1 0 5 -A ug -01 R 9.19
B ru fe n 1200 m g PO R  0 .0 0 0 7 -A ug -01 16 -A ug-01 R 31.19
D o lo ro l F o rte 2032 m g P O R  0 .0 0 0 7 -A u g -0 1 12-A ug-01 R 22.56
0 3 0 P e th e d in e 75 m g IM R  3 .56 15 -A ug-01 15-A u g -0 1 R 14.03
M o rp h in e 10-20 m g IM R 3 .56 15 -A ug-01 15-A ug-01 R 14.18
S te m e til 12.5 m g IM R  3 .56 17 -A ug-01 17-A ug-01 R 9.19
H e p a rin 10000 iu S C R 6 4 .0 8 15-A ug-01 2 0 -A u g -0 1 R 83.88
T a g a m e t 4 0 0 -8 0 0 m g IV R  19 .39 15 -A ug -01 2 0 -A u g -0 1 R 88.92
L o s e c 20 m g PO R 0 .00 2 1 -A u g -0 1 c o n tin u in g R 393.77
031 M o rp h in e 10-30 m g IM R  5 3 .4 0 2 3 -A u g -0 1 2 7 -A ug -01 R 106.35
S te m e til 12.5 m g IM R  3 .56 2 4 -A u g -0 1 2 4 -A u g -0 1 R 9.19
L a m ic tin 4 0 0 g P O R  0 .0 0 2 3 -A u g -0 1 3 0 -A ug -01 R 103.84
0 3 6 S te m e til 25 m g IM R  3 .56 14 -S ep-01 14 -S ep -01 R 18.38
M o rp h in e 10-50 m g IM R 8 5 .4 4 14 -S ep-01 2 1 -S ep -01 R 283.60
L a s ix 5 -10 m g IV R  19 .39 15 -S ep -01 18 -S ep-01 R 22.36
L o s e c 200 m g PO R  0 .00 17 -S ep-01 18-Oct-O1 R 449.92
Iso rd il 0 .5 m g S L R  0 .00 17 -S ep -01 2 6 -S ep -01 R 7.18
A m y try p tilin e 25 m g PO R 0 .00 13 -S ep-01 2 6 -S e p -0 1 R 15.49
S te m e til 12.5 m g IM R  2 1 .3 6 2 2 -S e p -0 1 2 3 -S e p -0 1 R 18.38
0 3 8 M o rp h in e 10-30 m g IM R 2 1 .3 6 28 -O c t-0 1 2 9 -O c t-0 1 R 42.54
0 4 2 M o rp h in e 10-20 m g IM R  7 4 .7 6 19-O ct-O 1 25 -O ct-01 R 99.26
B e ro te c 1 .2 5 -3 .7 5 m g IN H R 0 .00 19-O ct-O 1 10-N ov-01 R 385.71











STA R T D ATE STOP D ATE C O ST
L a s ix 2 0 -4 0 m g PO R  0 .00 23 -O c t-0 1 16 -N ov-01 R 95.29
M a xa lo n 10 m g IM R  3 .56 27 -O c t-0 1 27 -O c t-01 R 6.88
D o lo ro l F o rte 1016 m g PO R  0 .00 29 -O c t-0 1 29 -O c t-01 R 1.88
P e th e d in e 5 0 -1 0 0 m g IM R 4 2 .7 2 27 -O c t-0 1 30 -O c t-01 R 31.98
H e p a rin 5 0 0 0 -2 0 0 0 0 iu S C R 7 4 .7 6 3 1 -O ct-01 0 6 -N o v -0 1 R 195.72
Iso rd il 5 m g S L R 0 .0 0 30 -O c t-01 30 -O c t-01 R 0.72
C a n e s ta n  C re a m U N K U N K P V R 0 .00 0 6 -N o v -0 1 0 8 -N o v -O I R 167.22
M a xa lo n 10-20 m g IM R  4 2 .7 2 31 -O c t-01 0 3 -N o v -0 1 R 55.01
D o lo ro l F o rte 1016 m g P O R  0 .00 31 -O c t-01 3 1 -O ct-01 R 1.88
D o lo ro l F o rte 1 0 1 6 -40 64 m g P O R  0 .00 0 3 -N o v -0 1 15 -N ov-01 R 97.76
M o rp h in e 20 m g S C R  3 2 .0 4 28 -O c t-0 1 30 -O c t-01 R 42.54
M o rp h in e 10-40 m g IM R  117 .48 0 1 -N o v -0 1 11 -N ov-01 R 311.96
M a xa lo n 10 m g IM R  2 1 .3 6 0 5 -N o v -0 1 0 6 -N o v -0 1 R 6.88
M a xa lo n 2 0 -3 0 m g PO R 0 .00 0 9 -N o v -0 1 1 0 -N ov-01 R 9.54
M a xa lo n 20 m g PO R 0 .0 0 12 -N ov-01 1 3 -N ov-01 R 6.36
M a xa lo n 10 m g PO R 0 .0 0 15 -N ov-01 15-N ov-01 R 1.59
S e n o k o t 4 ta b s PO R 0 .0 0 13 -N ov-01 13-N ov-01 R 1.76
0 4 4 M o rp h in e 15-60 m g IM R 5 3 .4 0 2 1 -N o v -0 1 2 5 -N o v -0 1 R 212.70
0 4 5 M o rp h in e 2 0 -3 0 m g IV R 19 .39 2 1 -O ct-01 23 -O c t-0 1 R 63.81
D o lo ro l F o rte 3048 m g PO R 0 .00 24 -O c t-01 2 5  O c t 01 R 11.28
0 4 9 A m ilo re t ic 55 m g PO R 0 .00 0 4 -N o v -0 1 0 8 -N o v -0 1 R 33.50
P re m a rin 0 .625 m g PO R 0 .00 0 4 -N o v -0 1 0 8 -N o v -0 1 R 71.81
D o lo ro l F o rte 203 2 m g PO R  0 .00 0 7 -N o v -O I 0 7 -N o v -0 1 R 3.76
051 B e ro te c 2 .5 -7 .5 m g IN H R  0 .00 12 -N ov-01 19 -N o v-O I R 179.01
A tro v e n t 0 .7 5 -2 .2 5 m g IN H R  0 .00 12 -N ov-01 19 -N ov-01 R 382.99
L o s e c 20 m g P O R  0 .00 16 -N ov-01 co n tin u in g R 393.77
D o lo ro l fo r te 1 0 1 6 -30 48 m g P O R  0 .00 17 -N ov-01 2 0 -N o v -0 1 R 22.56
M o rp h in e 10-20 m g IM R  4 2 .7 2 12 -N ov-01 15 -N ov-01 R 56.72











STA R T DATE STOP DATE C O S T
M o rp h in e 10 m g IM R 3 2 .0 4 19 -N ov-01 2 1 -N o v -0 1 R 21.27
0 5 5 P e th e d in e 1 50 -200 m g IM R 3 2 .0 4 2 0 -N o v -0 1 2 2 -N o v -0 1 R 47.97
T a g a m e t 4 0 0 -1 2 0 0 m g P O R 0 .00 2 0 -N o v -0 1 2 2 -N o v -0 1 R 66.66
L o s e c 20 m g P O R  0 .00 2 2 -N o v -0 1 c o n tin u in g R 393.77
P h e n a rg a n 10-30 m g P O R  0 .0 0 2 2 -N o v -0 1 2 6 -N o v -0 1 R 7.10
D o lo ro l F o rte 1016 m g PO R  0 .0 0 2 4 -N o v -0 1 2 6 -N o v -0 1 R 5.64
M o rp h in e 10-40 m g IM R 3 2 .0 4 10-D ec-01 12-D ec-01 R 85.08
S te m e til 12.5 m g IM R 3 .56 1 4 -D ec-01 1 4 -D ec-01 R 9.19
V a liu m 10-20 m g PO R 0 .00 11-D e c -0 1 13 -D ec-01 R 70.35
0 5 9 M o rp h in e 10-40 m g IM R 3 2 .0 4 10 -D ec-01 12-D ec-01 R 85.08
S te m e til 12.5 m g IM R  3 .56 14-D ec-01 14-D ec-01 R 9.19
V a liu m 10-20 m g P O R  0 .00 11-D e c -0 1 13-D ec-01 R 70.35
D o lo ro l F o rte 1016 m g P O R  0 .0 0 14-D ec-01 1 4 -D ec-01 R 1.88
0 6 0 P e th e d in e 1 0 0 -300 m g IM R 7 4 .7 6 1 0 -D ec-01 1 6 -D ec-01 R 167.89
A tro v e n t 0 .25-1 m g IN H R 0 .0 0 11-D ec-01 16 -D ec-01 R 127.66
B e ro te c 1 .25 -5 m g IN H R 0 .00 11-D e c -0 1 16 -D ec-01 R 134.26
061 M o rp h in e 2 0 -3 0 m g IM R  5 3 .4 0 15 -D ec-01 19-D ec-01 R 106.35
B e ro te c 1 .25 -5 m g IN H R  0 .00 17-D ec-01 2 1 -D ec-01 R 111.88
A tro v e n t 0 .25-1 m g IN H R  0 .00 17-D ec-01 2 1 -D ec-01 R 106.38
D u lc o la x 10 m g P R R  0 .00 2 1 -D e c -0 1 2 1 -D ec-01 R 4.14
D o lo ro l 3 9 P O R 0 .0 0 2 1 -D ec-01 2 1 -D ec-01 R 2.76
0 6 2 M o rp h in e 10-50 m g IM R 3 2 .0 4 17-D ec-01 1 9 -D ec-01 R 106.35
S e re p a x 10 m g PO R 0 .0 0 1 9 -D ec-01 2 0 -D ec-01 R 1.42
P a n a d o 1 0 0 0 -2 0 0 0 m g PO R 0 .00 2 0 -D e c -0 1 2 1 -D ec-01 R 4.28
0 6 6 M o rp h in e 20 m g IM R 3 .56 0 6 -J a n -0 2 0 6 -J a n -0 2 R 14.18
D o lo ro l F o rte 1 0 1 6 -20 32 m g PO R  0 .00 0 6 -Ja n -0 2 0 9 -J a n -0 2 R 15.04
0 6 8 M o rp h in e 10-30 m g IM R  2 1 .3 6 11-J a n -0 2 1 2 -Ja n -0 2 R 42.54
M o rp h in e 10-50 m g IV R  19 .39 12-J a n -0 2 1 7 -Ja n -0 2 R 212.70











S TA R T DATE STOP D ATE C O S T
H e p a rin 5 0 0 0 -1 5 0 0 0 iu S C R 96 .12 12 -J a n -0 2 2 0 -J a n -0 2 R 188.73
U ls a n ic 4 g P O R 0 .00 1 2 -J a n -0 2 1 8 -Ja n -0 2 R 74.44
B e ro te c 1 .2 5 -7 .5 m g IN H R  0 .00 15 -J a n -0 2 2 1 -J a n -0 2 R 234.95
A tro v e n t 0 .2 5 -3 m g IN H R 0 .00 15 -J a n -0 2 2 1 -J a n -0 2 R 446.82
P a n a d o 30 m l P O R  0 .0 0 19 -J a n -0 2 19-J a n -0 2 R 17.64
M o rp h in e 10 -20 m g IM R 2 1 .3 6 18 -J a n -0 2 19 -J a n -0 2 R 28.36
D o rm ic u m 9 m g IV R 0 .92 1 2 -Ja n -0 2 1 2 -Ja n -0 2 R 53.63
L a s ix 5 -1 0 m g IV R  0 .92 1 5 -Ja n -0 2 1 6 -Ja n -0 2 R 11.18
D o lo ro l F o rte 2 0 3 2 -4 0 6 4 m g P O R 0 .00 2 1 -J a n -0 2 2 3 -J a n -0 2 R 22.56
071 M o rp h in e 10 -30 m g IM R 32 .04 2 2 -J a n -0 2 2 4 -J a n -0 2 R 63.81
D o lo ro l F o rte 1 0 1 6 -2 0 3 2 m g P O R 0 .00 2 5 -J a n -0 2 2 9 -J a n -0 2 R 18.80
B e ro te c 3 .7 5 -6 .2 5 m g IN H R 0 .00 2 3 -J a n -0 2 2 8 -J a n -0 2 R 167.82
A tro v e n t 1 .5 -2 .5 m g IN H R  0 .0 0 2 3 -J a n -0 2 2 8 -J a n -0 2 R 319.15
T a g a m e t 800 m g IV R 19 .39 2 4 -J a n -0 2 2 5 -J a n -0 2 R 29.64
L o s e c 20 m g P O R 0 .00 2 5 -J a n -0 2 co n tin u in g R 393.77
N im b e x 12 m g IV R  0 .92 2 2 -J a n -0 2 2 2 -J a n -0 2 R 298.17
P h e n y le p h rin e 2 5 0 m g IV R 0 .92 2 2 -J a n -0 2 2 2 -J a n -0 2 R 993.58
N e o s tig m in e 0 .5 m g IV R 0 .92 2 2 -J a n -0 2 2 2 -J a n -0 2 R 3.09
R o b in u l 2 .5 m g IV R 0 .92 2 2 -J a n -0 2 2 2 -J a n -0 2 R 882.36
072 M o rp h in e 2 0 -3 0 m g IM R 2 1 .3 6 2 3 -J a n -0 2 2 4 -J a n -0 2 R 42.54
D o lo ro l F o rte 1 0 1 6 -2 0 3 2 m g P O R  0 .0 0 2 5 -J a n -0 2 1 0 -F e b -0 2 R 63.92
074 M o rp h in e 10 -30 m g IM R  4 2 .7 2 2 9 -J a n -0 2 0 1 -F e b -0 2 R 85.08
V o lta re n 7 5 -1 5 0 m g IM R 2 1 .3 6 3 0 -J a n -0 2 3 1 -J a n -0 2 R 31.42
M a xa lo n 10 m g IM R 3 .56 3 0 -J a n -0 2 3 0 -J a n -0 2 R 6.88
D o lo ro l 3 g P O R 0 .00 0 3 -F e b -0 2 0 6 -F e b -0 2 R 10.96
075 P e th e d in e 3 5 0 m g IM R 3 .5 6 18 -F e b -0 2 18 -F e b -0 2 R 31.37
M o rp h in e 10-30 m g IM R 5 3 .4 0 1 8 -F e b -0 2 2 2 -F e b -0 2 R 106.35
T a g a m e t 8 0 0 -1 2 0 0 m g IM R  53 .40 18 -F e b -0 2 2 2 -F e b -0 2 R 111.15











STA R T D ATE STOP D ATE C O ST
D o lo ro l F o rte 1 0 1 6 -20 32 m g P O R 0 .00 2 5 -F e b -0 2 0 3 -M a r-0 2 R 26.32
0 7 9 M o rp h in e 30 m g IM R  3 .56 2 4 -F e b -0 2 2 4 -F e b -0 2 R 21.27
M o rp h in e 20 m g IM R 3 .56 2 6 -F e b -0 2 2 6 -F e b -0 2 R 14.18
L a s ix 2 0 -4 0 m g IV R  19 .39 2 4 -F e b -0 2 2 5 -F e b -0 2 R 44.72
D o lo ro l F o rte 1 0 1 6 -4 0 6 4 m g P O R 0 .00 0 8 -M a r-0 2 2 3 -M a r-0 2 R 45.12
081 M o rp h in e 10-20 m g IM R  4 2 .7 2 2 7 -F e b -0 2 0 2 -M a r-0 2 R 56.72
B e ro te c 1 .25 -5 m g IM R 7 4 .7 6 2 6 -F e b -0 2 0 4 -M a r-0 2 R 156.63
V e n to lin 200 ug IN H R  0 .00 1990 o n g o in g R 46.26
D o lo ro l F o rte 1 0 1 6 -2 0 3 2 m g PO R 0 .00 0 5 -M a r-0 2 1 2 -M a r-0 2 R 30.08
B ru fe n 200 m g P O R  0 .00 0 5 -M a r-0 2 1 2 -M a r-0 2 R 4.16
M o rp h in e 10-40 m g IM R 138 .84 1 3 -M a r-0 2 2 5 -M a r-0 2 R 368.68
S te m e til 12.5 m g IM R 2 1 .3 6 1 5 -M a r-0 2 1 6 -M a r-0 2 R 18.38
S te m e til 12 .5 m g IM R  3 .5 6 2 0 -M a r-0 2 2 0 -M a r-0 2 R 9.19
B e ro te c 3 .7 6 -5 m g IN H R  0 .00 1 4 -M a r-0 2 1 9 -M a r-0 2 R 134.26
A tro v e n t 1 .5 -2 m g IN H R  0 .0 0 1 4 -M a r-0 2 1 9 -M a r-0 2 R 255.32
M a x a lo n 10 m g IM R 3 .56 2 0 -M a r-0 2 2 0 -M a r-0 2 R 6.88
H e p a rin 5 0 0 0 -1 0 0 0 0 iu S C R  7 4 .7 6 2 0 -M a r-0 2 2 6 -M a r-0 2 R 97.86
P e th e d in e 100 m g IM R 3 .56 2 0 -M a r-0 2 2 0 -M a r-0 2 R 7.99
M o rp h in e 4 0 m g IV R  19 .39 2 0 -M a r-0 2 2 0 -M a r-0 2 R 28.36
M a xa lo n 10 m g IV R 0 .92 2 0 -M a r-0 2 2 0 -M a r-0 2 R 6.99
N e o s tig m in e 2 .5 m g IV R  0 .92 2 0 -M a r-0 2 2 0 -M a r-0 2 R 6.54
R o b in u l 0 .8 m g IV R 0 .92 2 0 -M a r-0 2 2 0 -M a r-0 2 R 294.12
H e p a rin 50 0 0 iu SC R  3 .56 2 0 -M a r-0 2 2 0 -M a r-0 2 R 6.99
D o lo ro l F o rte 1016 m g PO R 0 .00 2 6 -M a r-0 2 3 0 -M a r-0 3 R 9.40
0 8 8 P e th e d in e 5 0 -1 0 0 m g IV R  19 .39 0 3 -A p r-0 2 0 5 -A p r-0 2 R 23.98
D o lo ro l F o rte 1016 m g PO R  0 .00 0 7 -A p r-0 2 11-A p r-0 2 R 9.40
0 9 0 M o rp h in e 2 0 -3 0 m g IM R  2 1 .3 6 2 1 -A p r-0 2 2 2 -A p r-0 2 R 42.54
D o lo ro l F o rte 1 0 1 6 -3 0 4 8 m g PO R  0 .0 0 2 3 -A p r-0 2 0 2 -M a y-0 2 R 56.40











STA R T D ATE STOP D ATE C O S T
091 M o rp h in e 10-20 m g IM R 5 3 .4 0 0 1 -M a y -0 2 0 5 -M a y-0 2 R 70.90
H e p a rin 5 0 0 0 -1 0 0 0 0 iu S C R  6 4 .0 8 1 2 -M a y-0 2 1 7 -M a y -0 2 R 83.88
L o se c 20 m g P O R 0 .0 0 0 3 -M a y -0 2 0 9 -M a y -0 2 R 112.50
L o se c 20 m g PO R  0 .00 11-M a y -0 2 17 -M a y -0 2 R 98.44
S e re p a x 10 m g P O R 0 .00 0 5 -M a y -0 2 0 7 -M a y -0 2 R 2.12
S e re p a x 10 m g PO R  0 .00 0 9 -M a y -0 2 1 4 -M a y -0 2 R 4.25
B e ro te c 1 .25 -7 .5 m g IN H R 0 .00 0 6 -M a y -0 2 1 7 -M a y -0 2 R 402.77
A tro v e n t 0 .2 5 -1 .2 5 m g IN H R  0 .00 0 6 -M a y -0 2 1 7 -M a y -0 2 R 319.15
D o lo ro l F o rte 1 0 1 6 -3 0 4 8 m g PO R 0 .0 0 0 7 -M a y -0 2 0 9 -M a y -0 2 R 16.92
L a s ix 10-20 m g P O R  0 .00 0 9 -M a y -0 2 11-M a y -0 2 R 7.84
P a n a d o 3 0 -1 2 0 m l PO R 0 .00 1 0 -M a y -0 2 1 7 -M a y -0 2 R 17.64
D u ra te a rs 0 2 -Ja n d ro p s EY E R  0 .00 1 6 -M a y -0 2 1 7 -M a y -0 2 R 46.16
A d re n a lin e 2 0 -5 0 m g IV R  19 .39 1 0 -M a y -0 2 1 2 -M a y -0 2 R 683.66
A d re n a lin e 4 0 -1 0 0 m g IV R  0 .92 1 4 -M a y -0 2 1 8 -M a y -0 2 R 2,278.86
M o rp h in e 2 -2 0 m g IV R  0 .92 0 9 -M a y -0 2 1 6 -M a y -0 2 R 113.44
D o rm ic u m 4 m g IV R  0 .92 0 9 -M a y -0 2 0 9 -M a y-0 2 R 26.81
D o rm ic u m 2 -5 0 m g IV R  0 .92 1 3 -M a y -0 2 1 4 -M a y -0 2 R 328.50
D o b u tre x 2 0 0 m g IV R 0 .92 1 7 -M a y -0 2 1 7 -M a y -0 2 R 384.17
P e n ie le fe r in e 10-40 m g IV R  0 .92 1 7 -M a y -0 2 1 8 -M a y -0 2  . R 397.43
L a s ix 4 0 -5 0 0 m g IV R 0 .92 1 4 -M a y -0 2 1 7 -M a y -0 2 R 351.23
P ro p o fo l 12 m l IV R  0 .92 1 4 -M a y -0 2 1 4 -M a y -0 2 R 174.43
A c e b u to lo l 1 m g IV R 0 .92 1 7 -M a y -0 2 1 7 -M a y -0 2 R 47.30
S o lu -c o rte f 100 m g IV R  0 .92 1 7 -M a y -0 2 1 7 -M a y -0 2 R 31.82
P a vu lo n 12.5 m g IV R 0 .92 1 7 -M a y-0 2 1 7 -M a y -0 2 R 92.07
A c tra p id IV R  0 .92 17-M  a y -0 2 1 7 -M a y-0 2 R 233.41
L o ra z e p a n 2 m g IV R  0 .92 11-M a y -0 2 11-M a y -0 2 R 2.40
U ls a n ic 1 9 PO R 0 .00 0 9 -M a y -0 2 11-M a y -0 2 R 7.98
U ls a n ic 1 g P O R  0 .00 1 5 -M a y -0 2 17-M  a y -0 2 R 7.98











S TA R T D ATE STOP D ATE C O S T
D o lo ro l F o rte 20 3 2 m g P O R  0 .00 1 4 -M a y-0 2 1 4 -M a y -0 2 R 3.76
V o lta re n 75 m g IM R  10 .68 1 3 -M a y-0 2 1 3 -M a y-0 2 R 7.85
P e th e d in e 100 m g IM R  2 1 .3 6 11-M a y -0 2 1 2 -M a y -0 2 R 15.99
0 9 5 M o rp h in e 10 -40 m g IM R 5 3 .4 0 2 0 -J u n -0 2 2 4 -J u n -0 2 R 141.80
S te m e til 25 m g IM R 7 .12 2 2 -J u n -0 2 2 2 -J u n -0 2 R 18.38
S te m e til 12.5 m g IM R  3 .56 2 4 -J u n -0 2 2 4 -J u n -0 2 R 9.19
M a x a lo n 10 m g P O R 0 .00 2 2 -J u n -0 2 2 2 -J u n -0 2 R 1.59
M a x a lo n 10 m g PO R 0 .00 2 4 -J u n -0 2 2 4 -J u n -0 2 R 1.59
D o lo ro l F o rte 1 0 1 6 -4 0 6 4 m g PO R  0 .00 2 5 -J u n -0 2 3 0 -Ju n -0 2 R 45.12
P e th e d in e 50 m g IM R  3 2 .0 4 0 7 -J u l-0 2 0 9 -Ju l-0 2 R 22.15
D o lo ro l F o rte 1 0 1 6 -4 0 6 4 m g PO R 0 .00 1 0 -Ju l-0 2 1 2 -Ju l-0 2 R 10.82
0 9 7 T a g a m e t 2 0 0 -8 0 0 m g IV R 19 .39 2 5 -J u l-0 2 2 9 -J u l-0 2 R 74.10
M o rp h in e 30 -4 0 m g IV R  0 .92 2 5 -J u l-0 2 2 6 -J u l-0 2 R 56.72
100 D o lo ro l F o rte 1 0 1 6 -30 48 m g IV R  19 .39 0 4 -M a y -0 2 0 5 -M a y -0 2 R 11.28
D o lo ro l F o rte 1 0 1 6 -20 32 m g IV R 0 .92 0 9 -M a y -0 2 1 2 -M a y -0 2 R 15.04
H e p a rin 5 0 0 0 -1 0 0 0 0 iu S C R 106 .80 0 2 -M a y -0 2 11-M a y -0 2 R 139.80
B e ro te c 1 .2 5 -6 .2 5 m g IN H R  0 .00 0 4 -M a y -0 2 1 2 -M a y -0 2 R 251.73
A tro v e n t 0 .5 -2 .5 m g IN H R 0 .00 0 4 -M a y -0 2 1 2 -M a y -0 2 R 478.73
M o rp h in e 10-40 m g IM R 7 2 .4 5 0 2 -M a y -0 2 0 8 -M a y -0 2 R 198.52
| TO TA L  I R 3,171.14 R 24,479.11




CONCOMITANT MEDICATION / TREATMENT GROUP B / PPP




START DATE STOP DATE COST
001 M axa lon 10 mg IV R 19.39 17-Feb-01 21-Feb-01 R 6.88
S erva trin 37.5 mg PO R 0.00 unk ongo ing R 54.40
D orm icum 7.5 mg IV R 0.92 16-Feb-01 16-Feb-01 R 40.22
B ayer A sp irin 2 g PO R 0.00 16-M ar-01 18-M ar-01 R 25.99
A kine ton 4 g PO R 0.00 10-M ar-01 ongo ing R 128.79
M orph ine 10 m g IM R 96.12 16-Feb-01 24-Feb-01 R 63.81
002 M orph ine 10-40 m g IM R 53.40 20-Feb-01 24-Feb-01 R 141.80
D oloro l 2000 m g PO R 0.00 23-Feb-01 23-Feb-01 R 0.91
011 M orph ine 10-30 mg IM R 42.72 11-Apr-01 14-Apr-01 R 113.44
D oloro l Forte 1016-2032 mg PO R 0.00 18-Apr-01 19-Apr-01 R 7.51
012 P eth id ine 75-200 m g IM R 32.04 15-Apr-01 17-Apr-01 R 47.97
Panado 1-3 g PO R 0.00 16-Apr-01 19-Apr-01 R 12.83
013 B ero tec 2 .5 -3 .75 m g INH R 0.00 01-M ay-01 07-M ay-01 R 117.47
A troven t 0 .5-0 .75 m g INH R 0.00 01-M ay-01 07-M ay-01 R 111.70
V a lium 10 m g PO R 0.00 04-M ay-01 05-M ay-01 R 23.45
T h iam ine 100 m g IM R 42.72 04-M ay-01 07-M ay-01 R 82.66
M orph ine 20-40 m g IM R 21.36 01-M ay-01 02-M ay-01 R 56.72
F lam azine 1 app lic TO P R 0.00 02-M ay-01 09-M ay-01 R 89.90
015 Peth id ine 150-200 mg IM R 64.08 09-M ay-01 14-May-01 R 95.94
017 P eth id ine 75 m g IM R 10.68 15-M ay-01 15-May-01 R 14.03
S tem etil 12.5 m g IM R 7.12 16-M ay-01 17-M ay-01 R 18.38
M orph ine 10-30 m g IM R 42.72 15-M ay-01 18-M ay-01 R 85.08
D olo ro l Forte 1016 m g PO R 0.00 16-M ay-01 20-M ay-01 R 9.40
Brufen 600 m g PO R 0.00 20-M ay-01 27-M ay-01 R 16.02
D oloro l Forte 3048 m g PO R 0.00 21 -M ay-01 27-M ay-01 R 39.48
020 M orph ine 10-30 mg IM R 64.08 22-M ay-01 27-M ay-01 R 127.62
M orph ine 10 m g IV R 19.39 27-M ay-01 27-M ay-01 R 7.09
P eth id ine 50-100 m g IV R 0.92 20-M ay-01 2 1 -M ay-01 R 15.99
T e ta n u s  Toxo id 0.5 m l IM R 3.56 20-M ay-01 20-M ay-01 R 35.68
D oloro l Forte 1016 m g PO R 0.00 21 -M ay-01 21 -M ay-01 R 1.88




CONCOMITANT MEDICATION / TREATMENT GROUP B / PPP




START DATE STOP DATE COST
H eparin 4000 iu SC R 32.04 11-Jun-01 13-Jun-01 R 16.80
P eth id ine 50 mg IM R 3.56 10-Jun-01 10-Jun-01 R 7.38
024 H eparin 5000-10000 iu SC R 32.04 19-Jun-01 21-Jun-01 R 41.94
M orph ine 10-30 mg IM R 74.76 19-Jun-01 25-Jun-01 R 148.89
S tem etil 12.5 mg IM R 3.56 23-Jun-01 23-Jun-01 R 9.19
D olo ro l Forte 1016 mg PO R 0.00 25-Jun-01 25-Jun-01 R 1.88
B ero tec 1.25 mg INH R 0.00 23-Jun-01 25-Jun-01 R 16.78
A tro ve n t 0.25 mg INH R 0.00 23-Jun-01 25-Jun-01 R 15.96
026 M orph ine 20-50 mg IM R 53.40 01 -Jul-01 05-Jul-01 R 212.70
P eth id ine 75 mg IM R 3.56 30-Jul-01 30-Jul-01 R 14.03
027 M orph ine 10 mg IM R 53.40 02 -Aug-01 06-Aug-01 R 42.54
S tem etil 12.5 mg IM R 3.56 06-Aug-01 06-Aug-01 R 9.19
T ag a m e t 800-600 mg IV R 19.39 03-Aug-01 06-Aug-01 R 49.32
Losec 20 mg PO R 0.00 06-Aug-01 06-Aug-01 R 14.06
029 M orph ine 10-30 mg IM R 53.40 10-Aug-01 14-Aug-01 R 106.35
S tem etil 12.5 mg IV R 19.39 12-Aug-01 18-Aug-01 R 64.33
H eparin 5000-10000 iu SC R 74.76 10-Aug-01 16-Aug-01 R 97.86
032 P eth id ine 75-400 mg IM R 85.44 23-Aug-01 30-Aug-01 R 255.83
S tem etil 12.5-25 mg IM R 7.12 26-Aug-01 27-Aug-01 R 36.76
Losec 20 mg PO R 0.00 27-Aug-01 con tinue ing R 393.77
033 T h iam ine 200 mg PO R 0.00 13-Sep-01 14-Sep-01 R 0.90
V itC 1000 mg PO R 0.00 13-Sep-01 14-Sep-01 R 0.81
M orph ine 30-60 mg IM R 42 .72 10-Sep-01 13-Sep-01 R 170.16
S tem etil 12.5 mg IM R 3.56 10-Sep-01 10-Sep-01 R 9.19
D oloro l 1-3 9 PO R 0.00 14-Sep-01 15-Sep-01 R 5.52
T e ta n u s  Toxo id 0.5 ml SC R 3.56 09-Sep-01 09-Sep-01 R 5.68
034 M orph ine 10-40 mg IM R 32.04 12-Sep-01 14-Sep-01 R 85.08
035 M orph ine 10-30 mg IM R 64.08 13-Sep-01 18-Sep-01 R 127.62
Z es to re tic 1 tab le ts PO R 0.00 N A N A R 123.82
B ero tec 1.25-3.75 mg INH R 0.00 14-Sep-01 24-Sep-01 R 184.60










START DATE STOP DATE COST
H eparin 5000-15000 iu SC R 85.44 13-Sep-01 20-Sep-01 R 167.76
F lee t Enem a 1 bottle PR R 0.00 18-Sep-01 20-Sep-01 R 15.05
Disprin 150 mg PO R 0.00 19-Sep-01 26-Sep-01 R 1.12
D oxyfene 2-4 tab le ts PO R 0.00 19-Sep-01 21-Sep-01 R 43.08
M axalon 20 mg PO R 0.00 18-Sep-01 20-Sep-01 R 3.18
037 M orph ine 30 mg IM R 3.56 27-Sep-01 27-Sep-01 R 21.27
D olo ro l Forte 1016-2032 mg PO R 0.00 01-O ct-01 03-O ct-01 R 5.64
M orph ine 10 mg IM R 3.56 29-O ct-01 29-O ct-01 R 7.09
039 M orph ine 30 mg IM R 32.04 01 -O ct-01 03-O ct-01 R 63.81
S tem etil 12.5 mg IM R 3.56 02-O ct-01 02-O ct-01 R 9.19
041 P eth id ine 150-200 mg IM R 53.40 10-O ct-01 14-Oct-O1 R 79.95
H eparin 5000-15000 iu SC R 74.76 12-Oct-O1 18-Oct-O1 R 125.82
D oxyfene 4 caps PO R 0.00 18-O ct-01 22-O ct-01 R 71.80
D olo ro l Forte 1016-3048 mg PO R 0.00 18-Oct-O1 30-O ct-01 R 73.32
043 M orph ine 10-30 mg IM R 64.08 19-Oct-O1 24-O ct-01 R 127.62
046 H eparin 10000-15000 iu SC R 117.48 24-O ct-01 03-N ov-01 R 230.67
U lsan ic 1-4 9 PO R 0.00 25-O ct-01 01 -Nov-01 R 85.07
M axalon 10-30 mg IM R 32.04 28-O ct-01 30-O ct-01 R 61.89
V olta ren 150 mg IM R 21.36 29-O ct-01 30-O ct-01 R 31.42
S erapax 20 mg PO R 0.00 29-O ct-01 30-O ct-01 R 2.83
V olta ren 75 mg IM R 3.56 03-N ov-01 03-N ov-01 R 7.85
C anesten  C ream 1-3 NA PV R 0.00 01-Nov-01 05-N ov-01 R 167.22
M axalon 10 mg IM R 3.56 02-N ov-01 02-NOV-01 R 6.99
M orph ine 5-70 mg IV R 19.39 23-O ct-01 31-O ct-01 R 446.67
M orph ine 10-30 mg IM R 32.04 31 -O ct-01 02-Nov-01 R 63.81
D orm icum 100-140 mg IV R 0.92 23-O ct-01 25-O ct-01 R 1,478.26
050 M axa lon 10 m g IM R 3.56 09-N ov-01 09-N ov-01 R 6.88
Indocid 100-300 m g PR R 0.00 08-N ov-01 11-Nov-01 R 147.59
M orph ine 7.5-30 m g IM R 21.36 08-N ov-01 09-N ov-01 R 42.54
D olo ro l Forte 1016 mg PO R 0.00 10-Nov-01 12-Nov-01 R 5.64




CONCOMITANT MEDICATION / TREATMENT GROUP B / PPP





053 M orph ine 20 m g IM R 3.56 19-Nov-01 19-Nov-01 R 14.18
D oloro l Forte 1016-2032 mg PO R 0.00 2 1 -Nov-01 23-N ov-01 R 11.28
056 V o lta ren 75 m g IM R 32.04 27-N ov-01 29-N ov-01 R 23.56
D oloro l Forte 3048 mg PO R 0.00 01-D ec-01 18-Dec-01 R 101.52
Brufen 600 m g PO R 0.00 01 -D ec-01 08-D ec-01 R 16.02
058 M orph ine 20-30 mg IM R 32.04 09-D ec-01 10-Dec-01 R 42.54
S tem etil 12.5-25 mg IM R 32.04 11-D ec-01 13-Dec-01 R 55.14
D olo ro l Forte 1016 mg PO R 0.00 10-Dec-01 11-D ec-01 R 3.76
D oloro l Forte 1016 mg PO R 0.00 15-Dec-01 15-Dec-01 R 1.88
056 V o lta ren 75 mg IM R 32.04 27-N ov-O I 29-N ov-01 R 23.56
057 M orph ine 10-30 mg IM R 32.04 03-D ec-01 05-D ec-01 R 63.81
058 M orph ine 20-30 mg IV R 0.92 09-D ec-01 10-D ec-02 R 42.54
S tem etil 12.5-25 mg IM R 32.04 11-D ec-01 13-Dec-01 R 55.14
D oloro l Forte 1016 mg PO R 0.00 10-Dec-01 11-D ec-01 R 3.76
063 M orph ine 20-40 m g IM R 53.40 17-Dec-01 21 -D ec-01 R 141.80
V olta ren 75 mg IM R 74.76 17-Dec-01 23-D ec-01 R 54.98
M orph ine 10 mg IM R 3.56 23-D ec-01 23-D ec-01 R 7.09
064 D o lo ro l Forte 2032 mg PO R 0.00 2 1 -D ec-01 2 1 -Dec-01 R 3.76
M orph ine 10-40 mg IM R 53.40 17-Dec-01 21 -D ec-01 R 141.80
065 M orph ine 30-40 mg IM R 53.40 02-Jan -02 06-Jan-02 R 170.16
D olo ro l Forte 2032-3048 mg PO R 0.00 07-Jan-02 11-Jan -02 R 28.20
069 M orph ine 10-30 mg IM R 42.72 13-Jan-02 16-Jan-02 R 85.08
M axalon 10-20 mg IM R 21.36 13-Jan-02 14-Jan-02 R 27.51
B ero tec 1.25-5 mg INH R 0.00 14-Jan-02 18-Jan-02 R 111.88
A troven t 0.25-1 mg INH R 0.00 14-Jan-02 18-Jan-02 R 106.38
070 P eth id ine 125-200 mg IM R 21.36 14-Jan-02 15-Jan-02 R 31.98
D oloro l Forte 1016 mg PO R 0.00 18-Jan-02 18-Jan-02 R 1.88
H eparin 5000-10000 iu SC R 42.72 15-Jan -02 18-Jan-02 R 55.92
T ag a m e t 400-1200 mg IV R 19.39 15-Jan-02 18-Jan-02 R 200.07
M orph ine 20 mg IM R 3.56 15-Jan-02 15-Jan-02 R 14.18




CONCOMITANT MEDICATION / TREATMENT GROUP B / PPP





START DATE STOP DATE COST
A troven t 0.5-2 mg INH R 0.00 16-Jan-02 18-Jan-02 R 127.66
M orph ine 10 mg IM R 3.56 18-Jan-02 18-Jan-02 R 7.09
Losec 20 mg PO R 0.00 19-Jan-02 continu ing R 393.77
Theophylin 400 mg PO R 0.00 19-Jan-02 02-Feb-02 R 45.85
076 Peth id ine 50 mg IM R 21.36 19-Feb-02 20-Feb-02 R 14.77
M axalon 10 mg IV R 0.92 20 -F eb-02 20-Feb-02 R 6.88
M orph ine 10 mg IM R 3.56 2 1 -Feb-02 21 -Feb-02 R 7.09
B uscopan 20-60 mg IM R 32.04 20 -F eb-02 22-Feb-02 R 141.73
D oloro l Forte 1016-3048 mg PO R 0.00 24-Feb-02 29 Feb 02 R 33.84
B uscopan 20 mg IM R 21.36 25-Feb-02 26-Feb-02 R 31.50
082 P eth id ine 50 mg IV R 0.92 07-M ar-02 07-M ar-02 R 7.38
P eth id ine 200 mg IM R 21.36 07-M ar-02 08-M ar-02 R 31.98
D oloro l Forte 1016-3048 mg PO R 0.00 07-M ar-02 11-M ar-02 R 28.20
D oloro l Forte 1016-3048 mg PO R 0.00 11-M ar-02 15-M ar-02 R 28.20
083 M orph ine 7.5-20 mg IM R 42.72 10-M ar-02 13-M ar-02 R 56.72
S tem etil 12.5 mg IM R 3.56 11-M ar-02 11-M ar-02 R 9.19
D oloro l Forte 1016-3048 mg PO R 0.00 13-M ar-02 15-M ar-02 R 16.92
D olo ro l Forte 1046-2032 mg PO R 0.00 17-M ar-02 18-M ar-02 R 7.52
D olo ro l Forte 1016 mg PO R 0.00 22 -M ar-02 22-M ar-02 R 1.88
D oloro l Forte 1016 mg PO R 0.00 25 -M ar-02 29-M ar-02 R 9.40
P eth id ine 50 mg IM R 3.56 17-M ar-02 17-M ar-02 R 7.38
086 M orph ine 30 mg IM R 32.04 17-M ar-02 19-M ar-02 R 63.81
D oloro l Forte 1016-2032 mg PO R 0.00 20-M ar-02 23-M ar-02 R 15.04
087 M orph ine 10 mg IM R 3.56 30-M ar-02 30-M ar-02 R 7.09
D oloro l Forte 4064 mg PO R 0.00 03-A pr-02 08-A pr-02 R 45.12
B ero tec 1.25-2.5 mg INH R 0.00 23-A pr-02 24 -A pr-02 R 22.38
A troven t 0.5-1 mg INH R 0.00 23 -A pr-02 24 -A pr-02 R 42.55
B uscopan 20 mg IM R 3.56 19 -A pr-02 19-A pr-02 R 15.75
089 M orph ine 10-30 mg IM R 53.40 17-Apr-02 21 -A pr-02 R 106.35
B ero tec 1.25-5 mg INH R 0.00 20-A pr-02 22 -A pr-02 R 67.13




CONCOMITANT MEDICATION / TREATMENT GROUP B / PPP
IN HOSPITAL MEDICATION DAILY
DOSAGE UNITS ROUTE
CONSUM­
ABLES START DATE STOP DATE COST
D oloro l Forte 1016 mg PO R 0.00 25-A pr-02 29 -A pr-02 R 9.40
092 P eth id ine 75-300 mg IM R 64.08 08-M ay-02 13-M ay-02 R 143.91
D oloro l Forte 1016-3048 mg PO R 0.00 14-M ay-02 21 -M ay-02 R 45.12
094 M orph ine 10-40 mg IM R 64.08 09-Jun-02 14-Jun-02 R 170.16
H eparin 5000-15000 iu SC R 74.76 09-Jun -02 15-Jun-02 R 146.79
Losec 20 mg PO R 0.00 14-Jun-02 con tinu ing R 393.77
D oloro l Forte 1016-2032 mg PO R 0.00 15-Jun-02 28-Jun-02 R 48.88
096 P eth id ine 75-150 mg IM R 53.40 08-Ju l-02 12-Ju l-02 R 76.89
D oloro l Forte 3048-4064 mg PO R 0.00 12-Ju l-02 19-Ju l-02 R 60.16
B ero tec 2 .5-3 .75 mg INH R 0.00 09-Ju l-02 11 -Ju l-02 R 50.35
A troven t 1-1.5 mg INH R 0.00 09-Ju l-02 11 -Ju l-02 R 95.75
098 M orph ine 30-40 mg IM R 42.72 10 -A ug-02 13-A ug-02 R 113.44
D F118 30-90 mg PO R 0.00 13-A ug-02 13-A ug-02 R 9.11
S tem etil 12.5 mg IM R 3.56 11-A ug-02 11-A ug-02 R 9.19
D oloro l Forte 3048 mg PO R 0.00 17-Aug-02 27-A ug-02 R 62.04
Fybogel 3.5 9 PO R 0.00 22-A ug-02 O ngoing R 69.10
S eneko t 15 mg PO R 0.00 02-A ug-02 16-S ep-02 R 41.44
A ntabuse  im p lan t unk unk SC R 3.56 Ju ly  2002 O ngo ing R 4.14
D ulco lax 10 mg PR R 0.00 18 -A ug-02 18-A ug-02 R 170.16
099 M orph ine 10-40 mg IM R 64.08 11-A ug-02 16-Aug-02 R 9.19
S tem etil 12.5 mg IM R 3.56 12-Aug-02 12-Aug-02 R 104.85
H eparin 10000-15000 iu SC R 53.40 12 -A ug-02 16-Aug-02 R 134.26
B ero tec 1.25-5 mg INH R 0.00 13-A ug-02 18-A ug-02 R 255.32
A troven t 0.5-2 mg INH R 0.00 13-A ug-02 18-A ug-02 R 8.01
Brufen 600 mg PO R 0.00 04-S ep-02 07-S ep-02 R 15.99
P eth id ine 50-100 mg IM R 21.36 11-S ep-02 12-Sep-02 R 15.99
I TOTAL | R 3,051.74 R 13,157.51







U K A rn lV / U A I A /  1 KfcAinflci'l 1 U K U U r  A  /M n





003 11-Dec-65 37 1 1
004 03-Nov-38 64 1 1
007 14-Dec-79 23 1 1
009 12-Feb-75 27 1 1
010 15-Aug-82 20 1 1
014 26-Apr-62 40 1 1
018 13-Apr-80 22 1 1
019 14-Feb-40 62 1 1
022 06-Feb-52 50 1 1
025 01-Jan-38 64 1 1
028 17-Dec-65 37 1 1
030 12-Feb-60 42 1 1
031 16-Aug-80 22 1 1
036 13-Mar-33 69 1 1
038 28-Jan-81 21 1 1
042 05-Mar-67 35 1 1
044 01-Nov-78 24 1 1
045 20-Nov-81 21 1 1
049 07-Jul-30 72 1 1
051 27-NOV-71 31 1 1
054 11-Oct-74 28 1 1
055 07-Aug-55 45 1 1
059 29-Jul-64 38 1 1
060 29-Jan-60 42 1 1
061 21-Dec-80 22 1 1
062 18-Jul-62 40 1 1
066 14-Jul-57 45 1 1
068 16-Apr-72 30 1 1
071 17-Sep-50 51 1 1
072 12-Jun-75 25 1 1
074 6-Sep-76 26 1 1
075 21-May-59 43 1 1
079 1-Jan-60 41 1 1
081 18-Mar-59 43 1 1
084 30-Nov-65 35 1 1
088 8-Jul-74 28 1 1
090 16-Apr-66 34 1 1




DEMOGRAPHIC DATA / TREATMENT GROUP A / PPP
D ATE OF 
BIRTH
AGE
GENDER NATURE OF sURGEry---------------------------------------------------------------------




093 28-Aug-52 50 1 1
095 3-Nov-78 24 1 1
097 6-Jun-74 28 1 1
100 12-Oct-52 50 1 1








GENDER NATURE OF SURGERY




001 12-Jul-30 71 1 1
002 03-Jul-78 24 1 1
011 15-May-58 44 1 1
012 07-Jan-77 25 1 1
013 28-Dec-58 44 1 1
015 01-Aug-64 38 1 1
017 11-Nov-82 30 1 1
020 15-Jul-70 32 1 1
023 31-Dec-54 48 1 1
024 31-Mar-52 50 1 1
026 24-Mar-72 30 1 1
027 15-Nov-68 34 1 1
029 08-Oct-63 39 1 1
032 30-Apr-59 43 1 1
033 29-Sep-68 34 1 1
034 192/12/16 40 1 1
035 05-Mar-23 79 1 1
037 21-Sep-79 23 1 1
039 15-Feb-65 37 1 1
041 27-Jan-63 39 1 1
043 13-Mar-83 19 1 1
046 02-Mar-81 21 1 1
050 02-Mar-74 28 1 1
053 21-Jul-59 43 1 1
056 14-Oct-73 29 1 1
057 19-Dec-81 21 1 1
058 28-Jul-53 49 1 1
063 1-Jan-81 21 1 1
064 21-Jan-81 21 1 1
065 24-Oct-68 34 1 1
069 23-Mar-74 28 1 1
070 28-Jan-62 40 1 1
076 31-Jul-79 22 1 1
082 1-Jan-76 25 1 1
083 5-Apr-57 45 1 1
086 8-Apr-51 51 1 1
087 26-Jul-68 34 1 1 1
089 4-Aug-78 23 1 1








GENDER NATURE OF SURGERY




094 6-Apr-46 56 1 1
096 5-Jan-72 30 1 1
098 23-Sep-64 38 1 1
099 3-Apr-68 34 1 1
j : I 23 I 2 r 0 I 0 I




HOSPITALISATION / TREATMENT GROUP A / PPP
DATE















TO TA L COST
003 20-Feb-01 08-M ar-01 0 R 0 .00 17 R 12 ,461 .00 R 12,461.00
004 22-Feb-01 01 -M ar-01 0 R 0.00 8 R 5 ,864 .00 R 5,864.00
28-M ar-01 02-Apr-01 0 R 0 .00 3 R 2 ,199 .0 0 R 2,199.00
007 26-M ar-01 05-Apr-01 0 R 0 .00 11 R 8 ,063 .00 R 8,063.00
009 07-Apr-01 12-Apr-01 0 R 0 .00 6 R 4 ,398 .00 R 4,398.00
010 09-Apr-01 10-Apr-01 0 R 0 .00 6 R 4 ,398 .0 0 R 4,398.00
014 06-M ay-01 14-M ay-01 0 R 0.00 9 R 6 ,597 .00 R 6,597.00
2 1 -M ay-01 28-M ay-01 0 R 0 .00 8 R 5 ,864 .00 R 5,864.00
018 15-M ay-01 22-M ay-01 0 R 0.00 8 R 5 ,864 .00 R 5,864.00
019 15-M ay-01 24-M ay-01 0 R 0.00 8 R 5 ,864 .00 R 5,864.00
022 30-M ay-01 03-Jun-01 0 R 0 .00 5 R 3 ,665 .00 R 3,665.00
025 19-Jun-01 28-Jun-01 0 R 0 .00 10 R 7 ,330 .00 R 7,330.00
028 03-Aug-01 07-Aug-01 0 R 0 .00 5 R 3 ,665 .00 R 3,665.00
030 14-Aug-01 2 1 -Aug-01 0 R 0 .00 8 R 5 ,864 .00 R 5,864.00
031 23-Aug-01 30-Aug-01 0 R 0.00 8 R 5 ,864 .00 R 5,864.00
036 13-Sep-01 26-Sep-01 0 R 0 .00 14 R 10,262 .00 R 10,262.00
038 28-Sep-01 01 -O ct-01 0 R 0.00 4 R 2 ,932 .0 0 R 2,932.00
042 18-Oct-O1 20-N ov-01 0 R 0 .00 34 R 24 ,922 .00 R 24,922.00
044 20-O ct-01 26 O c t 017 0 R 0 .00 7 R 5 ,131 .00 R 5,131.00
045 20-O ct-01 26-O ct-01 0 R 0.00 7 R 5 ,131 .00 R 5,131.00
049 04-N ov-01 08-N ov-01 0 R 0 .00 5 R 3 ,665 .00 R 3,665.00
051 11-N ov-01 2 1 -Nov-01 0 R 0.00 11 R 8 ,063 .00 R 8,063.00
054 18-Nov-01 24-N ov-01 0 R 0 .00 7 R 5 ,131 .00 R 5,131.00
055 19-Nov-01 26-N ov-01 0 R 0 .00 8 R 5 ,864 .00 R 5,864.00
05-D ec-01 05-Dec-01 0 R 0.00 1 R 733 .00 R 733.00
059 09-D ec-01 14-Dec-01 0 R 0 .00 6 R 4 ,398 .00 R 4,398.00
060 10-Dec-01 17-Dec-01 0 R 0.00 8 R 5 ,864 .00 R 5,864.00
061 15-Dec-01 21 -Dec-01 0 R 0.00 7 R 5 ,131 .00 R 5,131.00
062 16-Dec-01 2 1 -Dec-01 0 R 0 .00 6 R 4 ,398 .0 0 R 4,398.00
066 04-Jan-02 10-Jan-02 0 R 0.00 7 R 5 ,131 .00 R 5,131.00
068 10-Jan-02 11-Jan-02 0 R 0 .00 2 R 1 ,466.00 R 1,466.00




HOSPITALISATION / TREATMENT GROUP A / PPP
DATE















TO TA L COST
18-Jan-02 2 1 -Jan-02 0 R 0.00 4 R 2 ,932 .0 0 R 2,932.00
071 22-Jan -02 29-Jan-02 0 R 0.00 8 R 5 ,864 .00 R 5,864.00
072 22-Jan-02 28-Jan -02 0 R 0 .00 7 R 5 ,131 .00 R 5.131.00
074 29-Jan -02 04-Feb-02 0 R 0.00 7 R 5 ,131 .00 R 5,131.00
075 17-Feb-02 26 -F eb-02 0 R 0 .00 10 R 7 ,330 .00 R 7,330.00
079 23-F eb-02 03-M ar-02 0 R 0.00 9 R 6 ,597 .00 R 6,597.00
081 26-F eb-02 05-M ar-02 0 R 0 .00 8 R 5 ,864 .00 R 5,864.00
084 12-M ar-02 26 -M ar-02 0 R 0 .00 14 R 10,262 .00 R 10,262.00
088 02-A pr-02 07 -A pr-02 0 R 0 .00 6 R 4 ,398 .0 0 R 4,398.00
090 20-A p r-02 25 -A pr-02 0 R 0.00 6 R 4 ,398 .0 0 R 4,398.00
091 29-A pr-02 08 -M ay-02 0 R 0 .00 10 R 7 ,330 .00 R 7,330.00
09-M  ay-02 18-M ay-03 10 R 30 ,179 .00 0 R 0 .00 R 30,179.00
093 11-M ay-02 16-M ay-02 0 R 0.00 6 R 4 ,398 .00 R 4,398.00
095 20-Jun-02 25-Jun -02 0 R 0 .00 6 R 4 ,398 .0 0 R 4,398.00
06-Ju l-02 10-Ju l-02 0 R 0.00 5 R 3 ,665 .00 R 3,665.00
097 24-Ju l-02 30-Ju l-02 0 R 0 .00 7 R 5 ,131 .00 R 5,131.00
100 02-M ay-02 12-M ay-02 0 R 0.00 11 R 8 ,063 .00 R 8,063.00




HOSPITALISATION / TREATMENT GROUP B / PPP
DATE















TO TA L COST
001 30-Jan-01 27-Feb-01 0 R 0.00 29 R 21 ,257 .00 R 21 ,257 .00
18-M ar-01 20-M ar-01 0 R 0.00 3 R 2 ,199 .00 R 2 ,199 .00
002 20-Feb-01 24-Feb-01 0 R 0.00 5 R 3 ,665 .00 R 3 ,665 .00
011 10-Apr-01 19-Apr-01 0 R 0 .00 10 R 7 ,330 .00 R 7 ,330 .00
012 14-Apr-01 19-Apr-01 0 R 0 .00 6 R 4 ,398 .00 R 4 ,398 .0 0
013 30-Apr-01 09-M ay-01 0 R 0 .00 10 R 7 ,330 .00 R 7 ,330 .00
015 08-M ay-01 16-M ay-01 0 R 0 .00 9 R 6 ,597 .00 R 6 ,597 .0 0
017 14-M ay-01 20-M ay-01 0 R 0 .00 7 R 5 ,131 .00 R 5 ,131 .00
020 20-M ay-01 29-M ay-01 0 R 0 .00 10 R 7 ,330.00 R 7 ,330 .00
023 10-Jun-01 15-Jun-01 0 R 0 .00 6 R 4 ,398 .00 R 4 ,398 .0 0
024 19-Jun-01 27-Jun-01 0 R 0 .00 9 R 6 ,597 .00 R 6 ,597 .00
026 30-Jun-01 07-Jul-01 0 R 0 .00 8 R 5 ,864 .00 R 5 ,864 .00
027 02-Aug-01 08-A ug-08 0 R  0 .00 8 R  5 ,864 .00 R 5 ,864 .00
029 09-Aug-01 20-Aug-01 0 R 0 .00 12 R 8 ,796 .00 R 8 ,796 .00
032 23-Aug-01 30-Aug-01 0 R 0.00 8 R 5 ,864 .00 R 5 ,864 .00
033 09-Sep-01 15-Sep-01 0 R 0.00 7 R 5 ,131 .00 R 5 ,131 .00
034 12-Sep-01 18-Sep-01 0 R 0.00 7 R 5 ,131 .00 R 5 ,131 .00
035 12-Sep-01 26 -S ep-02 0 R 0 .00 15 R 10,995.00 R 10,995 .00
037 26-Sep-01 01 -O ct-01 0 R 0 .00 6 R 4 ,398 .00 R 4 ,398 .0 0
039 30-Sep-01 07-O ct-01 0 R 0 .00 8 R 5 ,864 .00 R 5 ,864 .00
041 10-O ct-01 23-O ct-01 0 R 0 .00 14 R 10,262 .00 R 10 ,262 .00
043 18-Oct-O1 24-O ct-01 0 R 0 .00 3 R 2 ,199 .00 R 2 ,199 .00
046 23-O ct-01 30-O ct-01 8 R 24 ,143 .20 0 R 0 .00 R 24 ,143 .20
31-O ct-01 06-N ov-01 0 R 0.00 7 R 5 ,131 .00 R 5 ,131 .00
050 07-N ov-01 12-Nov-01 0 R 0 .00 12 R 8 ,796 .00 R 8 ,796 .00
053 18-Nov-01 24-N ov-01 0 R 0.00 7 R 5 ,131 .00 R 5 ,131 .00
056 26-N ov-01 01 -Dec-01 0 R 0.00 6 R 4 ,398 .00 R 4 ,398 .00
057 02-Dec-01 09-Dec-01 0 R 0.00 8 R 5 ,864 .00 R 5 ,864 .00
058 08-Dec-01 15-Dec-01 0 R 0.00 8 R 5 ,864 .00 R 5 ,864 .00
063 16-Dec-01 26-D ec-01 0 R 0.00 11 R 8 ,063 .00 R 8 ,063 .00
064 17-Dec-01 22-D ec-01 0 R 0.00 6 R 4 ,398 .00 R 4 ,398 .00
Appendix D 5.2



















TO TA L COST
065 02-Jan-01 07-Jan-02 0 R 0.00 6 R 4 ,398 .00 R 4 ,398 .00
069 12-Jan-02 18-Jan-02 0 R 0 .00 7 R 5 ,131 .00 R 5 ,131 .00
070 14-Jan-02 19-Jan-02 0 R 0 .00 6 R 4 ,398 .00 R 4 ,398 .0 0
076 18-Feb-02 26-F eb-02 0 R 0 .00 9 R 6 ,597 .00 R 6 ,597 .00
082 06-M ar-02 11-M ar-02 0 R 0.00 6 R 4 ,398 .00 R 4 ,398 .00
083 09-M ar-02 15-M ar-02 0 R 0 .00 7 R 5 ,131 .00 R 5 ,131 .00
16-M ar-02 25-M ar-02 0 R 0.00 10 R 7 ,330 .00 R 7 ,330 .00
086 17-M ar-02 23 -M ar-02 0 R 0 .00 7 R 5 ,131 .00 R 5 ,131 .00
087 29-M ar-02 03-A pr-02 0 R 0.00 6 R 4 ,398 .00 R 4 ,398 .00
22-A pr-02 24-A pr-02 0 R 0.00 3 R 2 ,199 .00 R 2 ,199 .00
089 16-A pr-02 25 -A pr-02 0 R 0 .00 9 R 6 ,597 .00 R 6 ,597 .0 0
092 08-M ay-02 14-M ay-02 0 R 0.00 7 R 5 ,131 .00 R 5 ,131 .00
094 08-Jun-02 15-Jun-02 0 R 0 .00 8 R 5 ,864 .00 R 5 ,864 .00
096 08-Ju l-02 14-Ju l-02 0 R 0.00 7 R 5 ,131 .00 R 5 ,131 .00
098 10-Aug-02 19-A ug-02 0 R 0 .00 10 R 7 ,330 .00 R 7 ,330 .00
099 10-A ug-02 18-A ug-02 0 R 0 .00 9 R 6 ,597 .00 R 6 ,597 .0 0




PROFESSIONAL FEE / TREATMENT GROUP A / PPP
Initial Visit Hospital Visit Final Visit TO TA L COST
003 R 841 .20 R 2 ,383 .40 R 210 .30 R 3,434.90
004 R 841 .20 R 1 ,121.60 R 210 .30 R 2,173.10
R 841 .20 R 420 .60 R 210 .30 R 1,472.10
007 R 841 .20 R 1 ,542.20 R 210 .30 R 2,593.70
009 R 841 .20 R 841 .20 R 210 .30 R 1,892.70
010 R 841.20 R 841 .20 R 210 .30 R 1,892.70
014 R 841.20 R 1 ,261.80 R 210 .30 R 2,313.30
R 841.20 R 1,121.60 R 210 .30 R 2,173.10
018 R 841.20 R 1,121.60 R 210 .30 R 2,173.10
019 R 841.20 R 1,121.60 R 210 .30 R 2,173.10
022 R 841.20 R 701 .00 R 210 .30 R 1,752.50
025 R 841.20 R 1,402.00 R 210 .30 R 2,453.50
028 R 841.20 R 701 .00 R 210 .30 R 1,752.50
030 R 841.20 R 1,121.60 R 210 .30 R 2,173.10
031 R 841.20 R 1,121.60 R 210 .30 R 2,173.10
036 R 841 .20 R 1,962.80 R 210 .30 R 3,014.30
038 R 841 .20 R 560 .80 R 210 .30 R 1,612.30
042 R 841 .20 R 4 ,766 .8 0 R 210 .30 R 5,818.30
044 R 841 .20 R 981 .40 R 210 .30 R 2,032.90
045 R 841 .20 R 981 .40 R 210 .30 R 2,032.90
049 R 841 .20 R 701 .00 R 210 .30 R 1,752.50
051 R 841 .20 R 1 ,542.20 R 210 .30 R 2,593.70
054 R 841 .20 R 981 .40 R 210 .30 R 2,032.90
055 R 841 .20 R 1 ,121.60 R 210 .30 R 2,173.10
R 841 .20 R 140.20 R 210 .30 R 1,191.70
059 R 841 .20 R 841 .20 R 210 .30 R 1,892.70
060 R 841.20 R 1 ,121.60 R 210 .30 R 2,173.10
061 R 841.20 R 981.40 R 210 .30 R 2,032.90
062 R 841.20 R 841 .20 R 210 .30 R 1,892.70
066 R 841.20 R 981 .40 R 210 .30 R 2,032.90
068 R 841.20 R 280 .40 R 210 .30 R 1,331.90
R 841 .20 R 0 .00 R 210 .30 R 1,051.50
R 841 .20 R 560 .80 R 210 .30 R 1,612.30
071 R 841 .20 R 1 ,121.60 R 210 .30 R 2,173.10
072 R 841 .20 R 981.40 R 210 .30 R 2,032.90
074 R 841.20 R 981.40 R 210 .30 R 2,032.90
075 R 841.20 R 1 ,402.00 R 210 .30 R 2,453.50
079 R 841.20 R 1 ,261.80 R 210 .30 R 2,313.30
R 841 .20 R 0 .00 R 210 .30 R 1,051.50
081 R 841 .20 R 1 ,121.60 R 210 .30 R 2,173.10
084 R 841 .20 R 1 ,962.80 R 210 .30 R 3,014.30
R 841.20 R 0.00 R 210 .30 R 1,051.50
R 841.20 R 0.00 R 210 .30 R 1,051.50
R 841.20 R 0 .00 R 210 .30 R 1,051.50
R 841 .20 R 0 .00 R 210 .30 R 1,051.50
R 841 .20 R 0 .00 R 210 .30 R 1,051.50
R 841.20 R 0.00 R 210 .30 R 1,051.50
R 841.20 R 0.00 R 210 .30 R 1,051.50
R 841.20 R 0.00 R 210 .30 R 1,051.50
R 841 .20 R 0 .00 R 210 .30 R 1,051.50
R 841.20 R 0 .00 R 210 .30 R 1,051.50
081 R 841.20 R 1 ,121.60 R 210 .30 R 2,173.10
084 R 841.20 R 1,962.80 R 210 .30 R 3,014.30
088 R 841 .20 R 841 .20 R 210 .30 R 1,892.70
090 R 841 .20 R 841 .20 R 210 .30 R 1,892.70
091 R 841.20 R 1 ,402.00 R 210 .30 R 2,453.50
R 841.20 R 1 ,402.00 R 210 .30 R 2,453.50




PROFESSIONAL FEE / TREATMENT GROUP A / PPP
Initial Visit Hospital Visit Final Visit TO TA L COST
095 R 841 .20 R 841 .20 R 210 .30 R 1,892.70
R 841 .20 R 701 .00 R 210 .30 R 1,752.50
097 R 841 .20 R 981 .40 R 210 .30 R 2,032.90
100 R 841 .20 R 1 ,542.20 R 210 .30 R 2,593.70




PROFESSIONAL FEE / TREATMENT GROUP B / PPP
Initial Visit Hospital Visit Final Visit TO TA L COST
001 R 841.20 R 4 ,0 6 5 .8 0 R 210.30 R 5 ,117.30
R 841.20 R 420 .60 R 210 .30 R 1 ,472.10
002 R 841 .20 R 701 .00 R 210 .30 R 1,752.50
011 R 841.20 R 1 ,402.00 R 210 .30 R 2 ,453.50
012 R 841.20 R 841 .20 R 210 .30 R 1,892.70
013 R 841 .20 R 1 ,402.00 R 210 .30 R 2 ,453 .50
015 R 841 .20 R 1 ,261.80 R 210 .30 R 2 ,313 .30
017 R 841.20 R 981 .40 R 210 .30 R 2 ,032 .90
020 R 841.20 R 1 ,402.00 R 210 .30 R 2 ,453 .50
023 R 841.20 R 841 .20 R 210 .30 R 1,892.70
024 R 841.20 R 1 ,261.80 R 210 .30 R 2 ,313 .30
026 R 841 .20 R 1 ,121 .60 R 210 .30 R 2 ,173 .10
027 R 841 .20 R 1 ,121.60 R 210 .30 R 2 ,173 .10
029 R 841.20 R 1 ,682.40 R 210 .30 R 2 ,733 .90
032 R 841.20 R 1 ,121.60 i R 210 .30 R 2 ,173 .10
033 R 841 .20 R 981.40 R 210 .30 R 2 ,032 .90
034 R 841 .20 R 981 .40 R 210 .30 R 2 ,032 .90
035 R 841.20 R 2 ,103 .0 0 R 210 .30 R 3 ,154.50
037 R 841.20 R 841 .20 R 210 .30 R 1,892.70
039 R 841 .20 R 1 ,121.60 R 210 .30 R 2 ,173 .10
041 R 841.20 R 1 ,962.80 R 210 .30 R 3 ,014.30
043 R 841 .20 R 420 .60 R 210.30 R 1,472.10
046 R 841 .20 R 1 ,121.60 R 210 .30 R 2 ,173 .10
R 841 .20 R 981 .40 R 210 .30 R 2 ,032 .90
050 R 841.20 R 1,682.40 R 210 .30 R 2 ,733 .90
053 R 841.20 R 981 .40 R 210 .30 R 2 ,032 .90
056 R 841 .20 R 841 .20 R 210.30 R 1,892.70
057 R 841.20 R 1,121.60 R 210 .30 R 2 ,173.10
058 R 841.20 R 1 ,121.60 R 210 .30 R 2 ,173.10
063 R 841.20 R 1 ,542 .20 R 210 .30 R 2 ,593 .70
064 R 841 .20 R 841 .20 R 210 .30 R 1,892.70
065 R 841.20 R 841.20 R 210 .30 R 1,892.70
069 R 841.20 R 981 .40 R 210.30 R 2 ,032 .90
070 R 841.20 R 841 .20 R 210 .30 R 1,892.70
076 R 841.20 R 1 ,261.80 R 210 .30 R 2 ,313 .30
082 R 841.20 R 841.20 R 210 .30 R 1,892.70
083 R 841.20 R 981 .40 R 210 .30 R 2 ,032 .90
R 841 .20 R 1 ,402.00 R 210 .30 R 2 ,453 .50
086 R 841.20 R 981.40 R 210 .30 R 2 ,032 .90
087 R 841.20 R 841 .20 R 210.30 R 1,892.70
R 841.20 R 420 .60 R 210 .30 R 1,472.10
089 R 841.20 R 1,261.80 R 210.30 R 2 ,313 .30
092 R 841.20 R 981.40 R 210 .30 R 2 ,032.90
094 R 841.20 R 1 ,121 .60 R 210.30 R 2 ,173 .10
096 R 841 .20 R 981.40 R 210 .30 R 2 ,032.90
098 R 841.20 R 1,402.00 R 210.30 R 2 ,453 .50
099 R 841.20 R 1 ,261.80 R 210.30 R 2 ,313.30










toOXIFLOXACIN IV MOXIFLOXACIN TABLcTS























003 23-Feb-02 01-Mar-01 7 R 1,603.00 NA NA 0 0 R 0.00 R 1.603.00 Cure R 109.04
004 23-Feb-01 28-Feb-0l 6 R 1,374.00 NA NA 0 0 R 0.00 R 1,374.00 Cure R 109.04
007 26-Mar-01 30-Mar-01 5 R 1,145.00 NA NA 0 0 R 0.00 R 1,145.00 Cure R 109.04
009 07-Apr-01 10-Apr-01 4 R 916.00 11-Apr-01 11-Apr-01 1 0 R 30.54 R 946.54 Cure R 109.04
010 09-Apr-01 13-Apr-01 5 R 1,145.00 NA NA 0 0 R 0.00 R 1.145.00 Cure R 109.04
014 07-Mav-01 09-May-01 3 R 687.00 10-Mav-01 12-May-01 3 0 R 91.62 R 778.62 Cure R 109.04
018 15-Mav-01 19-May-01 5 R 1,145.00 20-May-01 22-May-01 3 0 R 91.62 R 1.236.62 Cure R 109.04
019 16-May-01 22-May-01 7 R 1,603.00 23-May-01 24-May-01 2 0 R 61.08 R 1.664.08 Cure R 109.04
022 30-May-01 03-Jun-01 5 R 1,145.00 NA NA 0 0 R 0.00 R 1.145.00 Cure R 109.04
025 20-Jun-01 25-Jun-01 6 R 1,374.00 NA NA 0 0 R 0.00 R 1.374.00 Cure R 109.04
028 04-Aug-01 06-Aug-01 3 R 687.00 07-Aug-01 08-Aug-01 2 0 R 61.08 R 748.08 Cure R 109.04
030 15-Aug-01 20-Aug-01 6 R 1,374.00 NA NA 0 0 R 0.00 R 1,374.00 Cure R 109.04
031 23-Auq-OI 28-Aug-01 5 R 1,145.00 29-Aug-01 30-Aug-01 2 0 R 61.08 R 1.206.08 Cure R 109.04
036 14-Sep-01 18-Sep-01 5 R 1,145.00 19-Sep-01 20-Sep-01 1 0 R 30.54 R 1,175.54 Cure R 109.04
038 28-Sep-01 30-Sep-01 3 R 687.00 01-Oct-01 04-Oct-01 4 0 R 122.16 R 809.16 Cure R 109.04
042 19-Oct-O1 24-Oct-01 6 R 1,374.00 24-Oct-01 28-Ocl-OI 5 0 R 152.70 R 1,526.70 Failure R 109.04
044 21-Oct-01 24-Oct-01 4 R 916.00 25-Oct-01 26-Oct-01 2 0 R 61.08 R 977.08 Cure R 109.04
045 21-Oct-01 25-Oct-01 5 R 1,145.00 26-Oct-01 26-Oct-01 1 0 R 30.54 R 1,175.54 Cure R 109.04
049 04-NOV-01 06-NOV-01 3 R 687.00 07-Nov-01 07-NOV-01 1 0 R 30.54 R 717.54 Cure R 109.04
051 12-NOV-01 16-NOV-01 5 R 1,145.00 17-NOV-01 21-Nov-01 5 0 R 152.70 R 1.297.70 Cure R 109.04
054 19-Nov-01 22-NOV-01 4 R 916.00 23-NOV-01 24-NOV-01 2 0 R 61.08 R 977.08 Cure R 109.04
055 20-NOV-01 22-NOV-01 3 R 687.00 23-NOV-01 25-NOV-01 3 0 R 91.62 R 778.62 Cure R 109.04
059 09-Dec-01 12-Dec-01 4 R 916.00 13-Dec-01 14-Dec-01 2 0 R 61.08 R 977.08 Cure R 109.04
060 12-Dec-01 15-Dec-01 4 R 916.00 16-Dec-01 16-Dec-01 1 0 R 30.54 R 946.54 Cure R 109.04
061 15-Dec-01 19-Dec-01 5 R 1,145.00 20-Dec-01 21-Dec-01 2 0 R 61.08 R 1.206.08 Cure R 109.04
062 16-Dec-01 20-Dec-01 5 R 1,145.00 21-Dec-01 21-Dec-01 1 0 R 30.54 R 1.175.54 Cure R 109.04
066 05-Jan-02 07-Jan-02 3 R 687.00 08-Jan-02 10-Jan-02 3 0 R 91.62 R 778.62 Cure R 109.04
068 11-Jan-02 18-Jan-02 8 R 1,832.00 19-Jan-02 20-Jan-02 2 0 R 61.08 R 1,893.08 Cure R 109.04
071 22-Jan-02 28-Jan-02 7 R 1,603.00 NA NA 0 0 R 0.00 R 1,603.00 Cure R 109.04
072 23-Jan-02 26-Jan-02 4 R 916.00 27-Jan-02 28-Jan-02 2 0 R 61.08 R 977.08 Cure R 109.04
074 30-Jan-02 01-Feb-02 3 R 687.00 02-Feb-02 03-Feb-02 2 0 R 61.08 R 748.08 Cure R 109.04
075 18-Feb-02 24-Feb-02 7 R 1,603.00 NA NA 0 0 R 0.00 R 1.603.00 Cure R 109.04
079 24-Feb-02 26-Feb-02 3 R 687.00 27-Feb-02 01-Mar-02 3 0 R 91.62 R 778.62 Cure R 109.04
081 27-Feb-02 04-Mar-02 6 R 1,374.00 NA NA 0 0 R 0.00 R 1,374.00 Cure R 109.04
084 13-Mar-02 18-Mar-02 6 R 1,374.00 NA NA 0 0 R 0.00 R 1.374.00 Indeterminate R 109.04
088 03-Apr-02 05-Apr-02 3 R 687.00 06-Apr-02 07-Apr-02 2 0 R 61.08 R 748.08 Cure R 109.04
090 21-Apr-02 23-Apr-02 3 R 687.00 24-Apr-02 25-Apr-02 2 0 R 61.08 R 748.08 Cure R 109.04
091 01-May-02 07-May-02 7 R 1,603.00 NA NA 0 0 R 0.00 R 1.603.00 Failure R 109.04
093 12-May-02 14-May-02 3 R 687.00 15-May-02 16-May-02 2 0 R 61.08 R 748.08 Cure R 109.04
095 20-Jun-02 23-Jun-02 4 R 916.00 24-Jun-02 25-Jun-02 2 0 R 61.08 R 977.08 Cure R 109.04
097 25-JUI-02 28-JUI-02 4 R 916.00 29-JUI-02 30-JUI-02 2 0 R 61.08 R 977.08 Cure R 109.04
100 02-May-02 09-May-02 8 R 1,832.00 NA NA 0 0 R 0.00 R 1,832.00 Cure R 109.04
I 1 R1.985.i4T R 48,243.14| R 4,579.68
ITO TA L COST |  R  52,822.82
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001 16-Feb-01 23-Feb-01 8 R 2.5S7.34 16-Feb-01 18-Feb-01 6 R 199.18 NA N A 0 0 R 0.00 R 2.756.52 C ure R 109.04
0 0 2 20-F e b -0 1 24-Fet>-01 5 R 1.598.34 20-Feb-01 23-Feb-01 9 R 298.77 NA NA 0 0 R 0.00 R 1.897.11 Cure R 109.04
011 14-A dt-01 15-ADT-01 5 R 1.598.34 14-Apr-01 16-Apr-O ! 15 R 497.95 16-AW -01 19-Adt-OI 9 0 R 99.94 R 2.196.23 Cure R 109.04
0 1 2 15-Aor-01 18-Aor-01 4 R 1.278.57 15-Apr-O I 18-ADT-01 10 R 331.97 18-Aor-01 20 -A dt-OI 6 0 R 66.63 R 1.677.26 Cure R 109.04
0 1 3 0 1 -M a v-0 1 0 7-M av-01 7 R 2.237.67 01-M av-01 07-M av-01 21 R 697.13 NA NA 0 0 R 0.00 R 2.934.8Q C ure R 109.04
0 1 5 0 9 -M a y-0 1 1 4-M av-01 6 R 1.918.00 09-M av-01 14-M av-01 15 R 497.95 14-M av-01 16-M av-01 5 0 R 55.52 R 2.471.48 Cure R 109.04
0 1 7 1 5 -M a v-0 1 2 0-M av-01 6 R 1.918.00 15-M av-01 2 0-M av-01 14 R 464.76 NA NA 0 0 R 0.00 R 2.382.76 Cure R 109.04
0 2 0 2 2-M av-01 2 7 -M a v-0 1 6 R 1.918.00 27-M av-01 28-M av-01 4 R 132.79 27-M av-01 2 8-M av-01 4 0 R 44.42 R 2.095.21 Cure R 109.04
0 2 3 11-Jun-01 13-Jun-01 3 R 959.00 11-Jun-01 13-Jun-01 6 R 199.18 13-Jun-01 14-Jun-01 5 0 R 55.52 R 1.213.70 C ure R 109.04
0 2 4 19-Jun-01 2 5-Jun -01 7 R 2.237.67 19-Jun-01 26-Jun-01 19 R 630.74 NA NA 0 0 R 0.00 R 2.868.41 C ure R 109.04
0 2 6 30-Jun -01 05-Ju l-01 6 R 1.918.00 0 1-JuK M 06-JuF01 15 R 497.95 06-Ju l-O I 07-Juf-01 4 0 R 44.42 R 2.460.37 Cure R 109.04
0 2 7 02-Aug-01 06-AUO-01 5 R 1.598.34 02-Auo-01 06-Auo-01 11 R 365.16 NA N A 0 0 R 0.00 R 1.963.50 Cure R 109.04
0 2 9 10-AUQ-01 17-AUQ-01 8 R 2.557.34 10-Aug-01 17-Aug-01 21 R 697.13 NA NA 0 0 R 0.00 R 3.254.47 Cure R 109.04
0 3 2 23-A ua-01 2 8 -Aug-01 6 R 1.918.00 23-A ua-O I 25-Aua-01 7 R 232.38 29-AUQ-01 30-AUO-01 3 0 R 33.31 R 2.183.70 C ure R 109.04
0 3 3 1 0 -S ep-01 15-S ep-01 4 R 1.278.67 10-Seo-01 13-SeD-01 9 R 298.77 14-Sep-01 15-Sep-01 4 0 R 44.42 R 1.621.86 Cure R 109.04
0 3 4 12-S ep-01 15-S eo-01 4 R 1.278.67 13-Seo-01 16-S eo-02 8 R 265.57 16-Sep-01 18-S ep-01 6 0 R 66.63 R 1.610.87 C ure R 109.04
0 3 5 13-A uo-O I 17-AUQ-01 5 R 1.598.34 NA NA 0 R 0.00 18-Auo-01 20-Auo-O I 3 0 R 33.31 R 1.631.65 Cure R 109.04
0 3 7 2 7 -S ep-01 30-S ep-01 4 R 1.278.67 27-SeD-01 3O-SeD-01 11 R 365.16 01-Sep-Q1 01-S eo-O I 1 0 R 11.10 R 1.654.94 Cure R 109.04
0 3 9 0 1-O ct-01 O1-Oct-O1 4 R 1.278.67 0 1 -O ct-01 05-O ct-01 12 R 398.36 05-O ct-01 06 -O ct-01 5 0 R 55.52 R 1.732.55 C ure R 109.04
041 10-O ct-01 16-Oct-O1 7 R 2.237.67 11-O ct-01 16 O c  01 18 R 597.54 17-O ct-01 19-OC1-01 5 0 R 55.52 R 2.890.74 Cure R 109.04
0 4 3 19-Oct-O1 2 3-O ct-01 5 R 1.598.34 19-Oct-O1 23-O ct-01 10 R 331.97 23-O ct-01 26 -O ct-01 4 0 R 44.42 R 1.974.72 Cure R 109.04
0 4 6 23 -O ct-0 1 29 -O c t-0 1 7 R 2.237.67 24-O ct-01 29 -O ct-01 17 R 564.35 NA NA 0 0 R 0.00 R 2.802.02 Failu re R 109.04
0 5 0 08-NOV-01 12-N o v-01 5 R 1.598.34 08-N ov-01 11-N ov-01 11 R 365.16 NA NA 0 0 R 0.00 R 1.963.50 Cure R 109.04
0 5 3 19-N ov-01 22-NOV-01 4 R 1.278.67 19-N ov-O I 22-NOV-01 9 R 298.77 23-NOV-01 23-NOV-01 1 0 R 11.10 R 1.688.55 Cure R 109.04
0 5 6 27-N ov-01 2 9 -N o  v-01 3 R 959.00 27-N o  v-01 30-NOV-01 9 R 298.77 30-N ov-O I 0 1 -D ec-01 4 0 R 44.42 R 1.302.19 Cure R 109.04
0 5 7 0 3 -O ec-01 0 7 -D ec-01 5 R 1.598.34 03-D ec-01 07-D ec-01 12 R 398.36 NA NA 0 0 R 0.00 R 1.996.70 Cure R 109.04
0 5 8 0 9 -D ec-01 14-D ec-01 6 R 1.918.00 09-D ec-01 14-D ec-01 16 R 531.15 NA NA 0 0 R 0.00 R 2.449.15 Cure R 109.04
0 6 3 17-D ec-01 2 5 -D ec-01 9 R 2.877.01 17-D ec-01 25-D ec-01 22 R 730.33 NA NA 0 0 R 0.00 R 3.607.34 C ure R 109.04
0 6 4 18-D ec-01 2 0 -D ec-01 3 R 959.00 18-D ec-01 2 1 -D ec-01 8 R 265.57 2 1 -D ec-01 22-D ec-01 3 0 R 33.31 R 1.257.89 Cure R 109.04
0 6 5 0 2 -J a n -0 2 0 5 -Ja n -0 2 4 R 1.278.67 N /A W A 0 R 0.00 0 6-Jan -02 07 -Ja n -0 2 3 0 R 33.31 R 1.311.98 Cure R 109.04
0 6 9 1 3 -Ja n -0 2 16 -Ja n -0 2 4 R 1.276.67 13-Jan -02 17 -Jan -02 11 R 365.16 17-Jan -02 18 -Ja n -0 2 5 0 R 55.52 R 1.699.36 C ure R 109.04
0 7 0 14-Ja n -0 2 18 -Ja n -0 2 5 R 1.598.34 14- Jan -02 l8 -J a n -0 2 12 R 398.36 18-Jan -02 1 9-Jan -02 4 0 R 44.42 R 2.041.12 C ure R 109.04
0 7 6 1 9 -F e b -0 2 2 2 -F e b -0 2 4 R 1.278.67 19-Feb-02 2 2 -F e b -0 2 10 R 331.97 22-F e b -0 2 26 -F e b -0 2 11 0 R 122.15 R 1.732.79 C ure R 109.04
0 8 2 0 7 -M a r-0 2 0 9 -M a r-0 2 3 R 959.00 0 7 -M a r-0 2 09 -M a r-0 2 9 R 298.77 10-M ar-02 11 -M ar-02 4 0 R 44.42 R 1.302.19 Cure R 109.04
0 8 3 1 0 -M a r-0 2 1 4 -M a r-0 2 5 R 1.598.34 10 -M ar-02 14 -M ar-02 12 R 398.36 14-M ar-02 15 -M ar-02 4 0 R 44.42 R 2.041.12 C ure R 109.04
0 8 6 1 8 -M a r-0 2 2 0 -M a r-0 2 3 R 959.00 18-M ar-02 2 1 -M a r-0 2 9 R 298.77 21 -M a r-0 2 23 -M a r-0 2 6 0 R 66.63 R 1.324.40 C ure R 109.04
0 8 7 2 9 -M a r-0 2 02 -A dt-02 4 R 1.278.67 30-M ar-02 02-ADT-02 9 R 298.77 02-A pr-02 0 2 -A pr-02 0 R 11.10 R 1.588.55 C ure R 109.04
0 8 9 16-A or-02 2 5 -A o r-0 2 6 R 1.918.00 17-A pr-02 23-AOT-02 16 R 531.15 23-A pr-02 2 5 -A pr-02 6 0 R 66.63 R 2.515.78 Cure R 109.04
0 9 2 0 9 -M a v -0 2 12 -M a v -0 2 4 R 1.278.67 0 9 -M a v-0 2 1 3 -M av-02 12 R 398.36 1 3-M av-02 1 4 -M av-02 3 0 R 33.31 R 1.710.34 C ure R 109.04
0 9 4 0 9 -Ju n -0 2 13 -Ju n -0 2 5 R 1.598.34 09-Jun -02 13-Jun-02 12 R 398.36 13-Jun-02 15-Jun -02 6 0 R 66.63 R 2.063.32 C ure R 109.04
0 9 6 09-Ju (-02 11 -Ju l-02 3 R 959.00 09-Ju l-02 12-JuF02 8 R 265.57 12-Ju l-02 14-Ju l-02 6 0 R 66.63 R 1.291.20 C ure R 109.04
0 9 8 11-A ua-02 15-A ua-02 5 R 1.598.34 11-A ua-02 16-Aug-02 15 R 497.95 NA NA 0 0 R 0.00 R 2.096.29 C ure R 109.04
0 9 9 11 -A ug-02 15-A ug-02 5 R 1.598.34 11 -Aua-02 16-A uq-02 14 R 464.76 16-Auo-02 18-A ua-02 5 0 R 55.52 R 2.118.61 C ure R 109.04
TOTALS | I 217 I R 69.367.83 | ^ _ _ 4 9 0 _ _ _ | _ _ J ? J 6 13 9 9 j2 ] I 138 I  0 I R 1,510.191 R 87,277.241 _ _ R 4 jM « i72i




THERAPEUTIC ADJUNCTIONS / TREATMENT GROUP A / PPP
THERAPEUTIC
ADJUNCTIONS
UNITS STARTDATE STOP DATE COST
003 U rinary  C a the te r 1 22-Feb-01 23-Feb-01 R 23.46
N asogastric  T ube 1 22-Feb-01 23-Feb-01 R 16.30
004 U rinary  C a the te r 1 23-Feb-01 25-Feb-01 R 23.46
N asogastric  T ube 1 23-Feb-01 25-Feb-01 R 16.30
007 U rinary  C a the te r 1 26-M ar-01 04-Apr-01 R 23.46
009 U rinary  C a the te r 1 06-Apr-01 08-Arp-01 R 23.46
C hest P hys io the rapy 1 07-Apr-01 09-Apr-01 R 409.95
N asogastric  T ube 1 06-Apr-01 07-Apr-01 R 16.30
010 U rinary  C a the te r 1 08-Apr-01 09-Apr-01 R 23.46
N asogastric  T ube 1 09-Apr-01 09-Apr-01 R 16.30
C hest P hys io therapy 1 10-Apr-01 12-Apr-01 R 409.95
014 U rina ry  C a the te r 1 06-M ay-01 07-M  ay-01 R 23.46
N asogastric  T ube 1 06-M ay-01 07-M av-01 R 16.30
018 U rinary  C a the te r 1 15-M ay-01 17-M ay-01 R 23.46
019 N asogastric  T ube 1 16-M ay-01 18-M ay-01 R 16.30
U rinary  ca the te r 1 16-M ay-01 18-M ay-01 R 23.46
O xygen  Face M ask 11 16-M ay-01 17-M ay-01 R 50.00
022 NA 0 NA NA R 0.00
025 N asogastric  T ube 1 19-Jun-01 21-Jun-01 R 16.30
U rinary  C a the te r 1 20-Jun-01 21-Jun-01 R 23.46
028 U rinary  C a the te r 1 03-Aug-01 04-Aug-01 R 23.46
030 U rinary  C a the te r 1 14-Aug-01 16-Aug-01 R 23.46
N asogastric  T ube 1 14-Aug-01 17-Aug-01 R 16.30
031 U rina ry  C a the te r 1 23-Aug-01 24-Aug-01 R 23.46
036 U rinary  C a the te r 1 13-Aug-01 16-Aug-01 R 23.46
N asogastric  T ube 1 13-Aug-01 17-Aug-01 R 16.30
O xyg e n  F ace  M ask 1 14-Aug-01 16-Aug-01 R 50.00
038 NA 1 NA NA R 0.00
042 N asogas tric  T ube 1 19-Oct-O1 22-O ct-01 R 16.30
U rinary  C a the te r 1 19-Oct-O1 22-O ct-01 R 23.46
U rinary  C a the te r 1 28-O ct-01 03-N ov-01 R 23.46
P acked  R ed ce lls 2 19-Oct-O1 19-Oct-O1 R 1,050.00
044 N asogastric  T ube 1 21 -N ov-01 22-N ov-O I R 16.30
U rinary  ca th e te r 1 21 -N ov-01 22-N ov-O I R 23.46
045 U rinary  C a the te r 1 2 1 -N ov-01 22-N ov-01 R 23.46
049 NA 0 NA NA R 0.00
051 U rina ry  C a the te r 1 11-N ov-01 13-Nov-01 R 23.46
C entra l V enous  C a the te r 1 12-N ov-01 13-Nov-01 871.13
O xygen  F ace  M ask 1 12-N ov-01 12-Nov-01 R 50.00
N asogastric  T ube 1 11-N ov-01 14-Nov-01 R 16.30
054 U rinary  C a the te r 1 19-Nov-01 20-N ov-01 R 23.46
N asogastric  T ube 1 19-N ov-01 22-N ov-01 R 16.30
P acked R ed ce lls 4 19-N ov-01 19-N ov-O I R 2,100.00
055 U rina ry  C a the te r 1 20-N ov-01 21-N ov-01 R 23.46
N asogastric  T ube 1 20-N ov-01 20-N ov-01 R 16.30
059 O xygen  F ace  M ask 1 09-D ec-01 10-Dec-01 R 50.00
U rinary  C a the te r 1 09-D ec-01 10-Dec-01 R 23.46
060 U rina ry  C a the te r 1 12-Dec-01 12-Dec-01 R 23.46
N asogastric  T ube 1 12-Dec-01 12-Dec-01 R 16.30
061 U rina ry  C a the te r 1 15-Dec-01 17-Dec-01 R 23.46
N asogastric  T ube 1 15-Dec-01 16-Dec-01 R 16.30
O xygen  F ace  M ask 1 15-Dec-01 16-Dec-01 R 50.00
C hest T ubes 1 15-Dec-01 18-Dec-01 R 87.52
062 U rinary  C a the te r 1 16-Dec-01 18-Dec-01 R 23.46










066 NA 0 NA NA R 0.00
068 U rinary  C a the te r 1 11-Jan-02 19-Jan-02 R 23.46
N asogastric  tube 1 11-Jan-02 16-Jan-02 R 16.30
O xygen  F ace  M ask 1 12-Jan-02 16-Jan-02 R 50.00
O xygen  Face m ask 1 12-Jan-02 12-Jan-02 R 50.00
O xygen  F ace  m ask 1 16-Jan-02 19-Jan-02 R 50.00
071 N asogastric  T ube 1 22 -Jan -02 24-Jan -02 R 16.30
U rina ry  C a the te r 1 22-Jan -02 24 -Jan -02 R 23.46
O xygen  F ace  M ask 1 22 -Jan -02 23-Jan-02 R 50.00
072 U rina ry  C a the te r 1 23-Jan -02 24-Jan -02 R 23.46
074 U rinary  C a the te r 1 31 -Jan-02 31-Jan-02 R 23.46
075 U rinary  C a the te r 1 18 -Feb-02 20-F eb-02 R 23.46
N asogastric  tube 1 18-Feb-02 20-F eb-02 R 16.30
079 O xygen  F ace  m ask 1 25 -F eb-02 25-F eb-02 R 50.00
N asogastric  T ube 1 23 -F eb-02 25-Feb-02 R 16.30
U rinary  ca th e te r 1 24 -F eb-02 25-F eb-02 R 23.46
081 U rinary  C a the te r 1 27 -F eb-02 28-Feb-02 R 23.46
084 U rina ry  C a the te r 1 13-M ar-02 14-M ar-02 R 23.46
N asogastric  T ube 1 20 -M ar-02 21 -M ar-02 R 16.30
U rinary  C a th e te r 1 20 -M ar-02 24 -M ar-02 R 23.46
088 U rina ry  C a the te r 1 03 -A pr-02 04-A pr-02 R 23.46
090 U rinary  C a th e te r 1 20-A pr-02 22 -A pr-02 R 23.46
N asogastric  T ube 1 2 1 -A pr-02 22-A pr-02 R 16.30
091 U rinary  C a th e te r 1 01-M ay-02 03-M ay-02 R 23.46
N asogastric  T ube 1 01-M ay-02 03-M ay-02 R 16.30
C hest T ubes 1 15-M ay-02 O ngo ing R 87.52
D ia lis is  C a the te r 1 16-M ay-02 O ngo ing R 1,649.31
Fresh F rozen  P lasm a 4 15-M ay-02 15-M ay-02 R 3,120.00
P acked  Red ce lls 2 15-M ay-02 15-M ay-02 R 1,050.00
Fresh F rozen  P lasm a 2 16-M ay-02 16-M ay-02 R 1,560.00
P acked  Red ce lls 1 17-M ay-02 17-M ay-02 R 1,050.00
U rina ry  C a the te r 1 10-M ay-02 O ngo ing R 23.46
N asogastric  T ube 1 10-M ay-02 O ngo ing R 16.30
093 U rinary  C a th e te r 1 12-M ay-02 13-M ay-02 R 23.46
O xygen  F ace  M ask 1 12-M ay-02 12-M ay-02 R 50.00
095 U rinary  C a th e te r 1 20 -Jun -02 21-Jun -02 R 23.46
N asogastric  T ube 1 06-Ju l-02 08-Ju l-02 R 16.30
O xyg e n  F ace  M ask 1 20-Jun -02 20 -Jun -02 R 50.00
097 U rina ry  C a the te r 1 25 -Ju l-02 26 -Ju l-02 R 23.46
100 U rinary  C a the te r 1 02 -M ay-02 03-M ay-02 R 23.46
U rinary  C a the te r 1 04 -M ay-02 08-M ay-02 R 23.46




THERAPEUTIC ADJUNCTIONS / TREATMENT GROUP B / PPP
THERAPEUTIC
ADJUNCTIONS
UNITS START DATE STOP DATE COST
001 Central Venous Catheter 16-Feb-01 23-Feb-01 R 871.13
002 Nasogastric Tube 20-Feb-01 21-Feb-01 R 16.30
002 Urinary Catheter 19-Feb-01 21-Feb-01 R 23.46
011 Urinary Catheter 11-Apr-01 12-Apr-01 R 23.46
012 Nasogastric Tube 15-Apr-01 15-Apr-01 R 16.30
012 Urinary catheter 15-Apr-01 15-Apr-01 R 23.46
013 Urinary catheter 30-Apr-01 03-May-01 R 23.46
013 Nasogastric Tube 01-May-01 02-May-01 R 16.30
015 Urinary Catheter 09-May-01 10-May-01 R 23.46
017 NA NA NA R 0.00
020 Urinary catheter 22-May-01 23-May-01 R 23.46
020 Nasogastric Tube 22-May-01 23-May-01 R 16.30
023 Urinary Catheter 11-Jun-01 12-Jun-01 R 23.46
024 Nasogastric Tube 19-Jun-01 20-Jun-01 R 16.30
024 Urinary Catheter 19-Jun-01 20-Jun-01 R 23.46
024 Oxygen Face Mask 19-Jun-01 24-Jun-01 R 50.00
026 Nasogastric tube 20-Jun-01 01 -Jul-01 R 16.30
026 Urinary Catheter 30-Jun-01 02-Jul-01 R 23.46
026 Chest Tube Left & right 30-Jun-01 06-Jun-01 R 84.52
027 Urinary Catheter 02-Aug-01 03-Aug-01 R 23.46
027 Nasogastric Tube 02-Aug-01 03-Aug-01 R 16.30
029 Nasogastric Tube 09-Aug-01 11-Aug-01 R 16.30
029 Urinary Catheter 09-Aug-01 11-Aug-01 R 23.46
029 Nasogastric Tube 15-Aug-01 18-Aug-01 R 16.30
032 Urinary Catheter 23-Aug-01 24-Aug-01 R 23.46
033 Urinary Catheter 10-Aug-01 11-Aug-01 R 23.46
033 Oxygen Face Mask 10-Aug-01 10-Aug-01 R 50.00
034 Urinary Catheter 12-Aug-01 14-Aug-01 R 23.46
035 Urinary Catheter 13-Aug-01 18-Aug-01 R 23.46
037 NA NA NA R 0.00
039 Urinary Catheter 01-Oct-01 02-Oct-01 R 23.46
041 NA NA NA R 0.00
043 NA NA NA R 0.00
046 Central Venous Catheter 23-Oct-01 NA R 871.13
046 Fresh frozen plasma 3 23-Oct-01 25-Oct-01 R 2,340.00
046 Nasogastric tube 23-Oct-01 01-Nov-01 R 16.30
046 Urinary catheter 22-Oct-01 01-Nov-01 R 23.46
046 Oxygen Face Mask 29-Oct-01 03-Nov-01 R 50.00
050 Urinary Catheter 08-Nov-01 09-Nov-01 R 23.46
053 Urinary Catheter 19-Nov-01 20-Nov-01 R 23.46
053 Nasogastric Tube 19-Nov-01 20-Nov-01 R 16.30
056 NA NA NA R 0.00
057 Urinary Catheter 03-Dec-01 04-Dec-01 R 23.46
058 Urinary Catheter 09-Dec-01 10-Dec-01 R 23.46
056 NA NA NA R 0.00
057 Urinary Catheter 03-Dec-01 04-Dec-01 R 23.46
058 Urinary Catheter 09-Dec-01 10-Dec-01 R 23.46
063 Nasogastric Tube 17-Dec-01 18-Dec-01 R 16.30
064 Urinary Catheter 16-Dec-01 18-Dec-01 R 23.46
064 Urinary catheter 18-Dec-01 19-Dec-01 R 23.46
064 Nasogastric tube 18-Dec-01 19-Dec-01 R 16.30
064 Chest Tube Left 18-Dec-01 20-Dec-01 R 43.76
064 Oxygen Face Mask 18-Dec-01 20-Dec-01 R 50.00
064 Chest T  ube Right 18-Dec-01 21-Dec-01 R 43.76
065 Urinary Catheter 02-Jan-02 03-Jan-02 R 23.46
069 Urinary Catheter 12-Jan-02 14-Jan-02 R 23.46
069 Oxygen Face Mask 14-Jan-02 16-Jan-02 R 50.00
070 Nasogastric tube 14-Jan-02 15-Jan-02 R 16.30
070 Oxygen Face Mask 15-Jan-02 18-Jan-02 R 50.00
070 Oxygen Face Mask 14-Jan-02 15-Jan-02 R 50.00
070 Urinary catheter 14-Jan-02 15-Jan-02 R 23.46
076 Nasogastric tube 19-Feb-02 20-Feb-02 R 16.30




THERAPEUTIC ADJUNCTIONS / TREATMENT GROUP B / PPP
THERAPEUTIC
ADJUNCTIONS UNITS
START DATE STOP DATE COST
082 NA NA NA R 0.00
083 Oxygen Face Mask 10-Mar-02 11-Mar-02 R 50.00
086 Urinary Catheter 18-Mar-02 19-Mar-02 R 23.46
087 Urinary Catheter 30-Mar-02 31-Mar-02 R 23.46
089 NA NA NA R 0.00
092 Arterial Catheter 08-May-02 13-May-02 R 303.18
092 Nasogastric Tube 08-May-02 11-May-02 R 16.30
092 Urinary Catheter 09-May-02 10-May-02 R 23.46
094 Urinary Catheter 09-Jun-02 10-Jun-02 R 23.46
094 Nasogastric Tube 09-Jun-02 11-Jun-02 R 16.30
094 Oxygen Face Mask 09-Jun-02 10-Jun-02 R 50.00
096 NA NA NA R 0.00
098 Urinary Catheter 10-Aug-02 12-Aug-02 R 23.46
098 Oxygen Face Mask 11-Aug-02 12-Aug-02 R 50.00
099 Urinary Catheter 11-Aug-02 12-Aug-02 R 23.46
099 Arterial Catheter 11-Aug-02 12-Aug-02 R 303.18
099 Central Venous Catheter 11-Aug-02 12-Aug-02 R 871.13
ITOTAL ~| R 7,329.99
